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 Sex differences in plasma docosahexaenoic acid (DHA) status during adulthood have 
been documented previously, and recent studies suggest the effects of DHA supplementation on 
human cognition are different in females compared with males during infancy, adolescence, and 
early adulthood. Differences in estradiol concentration are believed to be the predominant factor 
in sexual dimorphisms in DHA status when DHA is not supplemented. This suggests that sexual 
dimorphisms begin during adolescence when fed diets not supplemented with DHA, but this has 
not been examined comprehensively. Therefore, this thesis examined: 1) DHA status in rat 
maternal, fetal and pup tissues with and without dietary DHA supplementation during 
pregnancy; 2) the onset of sex differences in the fatty acid composition of plasma, heart, brain 
and liver from birth to adulthood in rats fed chow diets; and 3) the impact of DHA 
supplementation during the perinatal period on spatial memory in female and male adolescent 
pups, and possible relationships to brain lipidomic profiles. Results from these studies show that 
maternal DHA status decreased significantly during the postpartum period when DHA was not 
provided in the diet and suggest that DHA could be mobilized from maternal adipose and 
possibly maternal heart and liver for milk production. Furthermore, results show that sex 
differences in tissue polyunsaturated fatty acids (PUFA) began at 6 weeks of age. In the spatial 
memory experiment, DHA supplementation significantly increased latency times during the final 
learning session of Morris Water Maze (MWM) testing and reduced arachidonic acid (ARA) and 
n-6 docosapentaenoic acid (DPA) containing phospholipid species in the hippocampus of both 
males and females. Understanding the effects of DHA supplementation during the perinatal and 
adolescent periods on the PUFA composition of maternal and pup tissues, and how these effects 
interact with sexual dimorphisms is critical to understanding dietary requirements of DHA 
throughout pregnancy and childhood. Additionally, MWM testing and lipidomic analyses 
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indicate that DHA supplementation may interact with long chain n-6 PUFA metabolism that may 
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1 General Introduction 
Docosahexaenoic acid (DHA) is essential to the development and maintenance of the 
central nervous system, and supports learning and spatial memory performance throughout life 
[1,2]. The ability of DHA to support learning and spatial memory performance has been linked 
to neurogenesis and synaptogenesis [3], particularly in the hippocampus, a brain region 
associated with spatial memory [4]. Recent human trials have reported a sex x diet interaction in 
young adults supplemented with DHA, where supplementation improved episodic memory in 
females, and working memory reaction time in males [5], but the mechanism behind this 
interaction has not been fully explained. Animal models could provide further insight into the 
mechanisms behind this. Animal models show rats with adequate dietary DHA intakes have 
shorter latency times during spatial memory testing as compared with n-3 PUFA deficient rats, 
but this research has been largely limited to male rats [6–10]. Additionally, MUFAs, which are 
higher in the typical Western diet than regular chow diets used in most studies have been shown 
to reduce PUFA metabolism [11]. Examining an animal model that incorporates females and 
Western diets could provide further insight into the mechanism behind a sex x diet interaction in 
young adults supplemented with DHA. 
Sex differences in the interaction between DHA and brain function could be occurring 
directly through the effect of estradiol on the brain [12,13] or indirectly via the ability of 
estradiol to increase circulating levels of DHA [14,15], which could then affect brain 
concentrations [16]. DHA is incorporated at higher levels in the hippocampi of female control 
mice as compared with ovariectomized mice [13]. In addition, 17β-estradiol increases mRNA 
and protein expression of hepatic delta 6 desaturase (D6D), providing females with the ability to 
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synthesize DHA from shorter chain precursors more rapidly than males [14,17], particularly 
when DHA status is low [14,15,18,19]. 
The general consensus is that estrogen largely mediates sexual dimorphisms in DHA 
status. However, when sexual dimorphisms in DHA status begin, and how they relate to 
differences reported in memory and cognition at infancy [20], adolescence [21], and adulthood 
[5,22] is not fully explained. Although overall estrogen levels are low during prepubescence, 
levels in females are higher than males [23]. Female rats also begin adolescence earlier than 
males [24].  Understanding the influence of estrogen on LCPUFA synthesis and when sexual 
dimorphisms begin is important. Most DHA is accumulated in the brain between the third 
trimester and two years of age in humans, and prenatal day 7 to postnatal day 21 in rats [3]. 
Knowing how much the brain needs, at what stages of life, and how sexual dimorphisms affect 
DHA supply and demand is important for making dietary recommendations for all stages of life. 
Current recommendations for DHA intakes during pregnancy and lactation vary between 
authoritative bodies. During pregnancy, the International Society for the Study of Fatty Acids 
and Lipids (ISSFAL) recommends 200mg/d [25], and Health Canada recommends that women 
continue eating the generally recommended 150g of fish per week [26]. The Institute of 
Medicine (IOM) has general omega-3 recommendations, but no DHA recommendations specific 
to pregnancy [27]. Most Canadian women do not meet the recommended 200mg/d of DHA [28]. 
Quantifying the effect of insufficient DHA consumption during pregnancy and lactation could 
help in determining the impact insufficient consumption has on public health, and identify better 
dietary recommendations for pregnant women, and for males and females in general. 
This thesis aims to better understand sex differences in DHA metabolism from infancy to 
adulthood. This will provide insights on the impact of diet on maternal-fetal levels of DHA, 
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changes in DHA status, and fatty acid composition in males and females during development and 
adulthood, and the potential impact of sex differences and dietary DHA on spatial memory and 
lipidomic profiles. Determining what effect these sex differences may have, and how DHA status 
changes during development in males and females is critical to understanding the dietary 
requirement of DHA throughout pregnancy and childhood development, and their impact on 




2  Biochemical Foundations 
2.1 DHA status during pregnancy and perinatal uptake 
The mechanisms responsible for increasing DHA during pregnancy have not been fully 
identified, but dietary intakes and de novo synthesis could both contribute [1,29–32]. Maternal 
intakes during pregnancy can be low in North America [28], and are unlikely to match the 
amount transferred to the fetus [33] for a considerable proportion of the population. Low DHA 
intakes and status in mothers may also affect the amount of DHA supplied to the newborn during 
lactation [34,35]. The rate of DHA conversion from alpha linolenic acid (ALA) adults is 
generally less than 1% [36], and although de novo synthesis of DHA is upregulated during 
pregnancy [30], it may not be adequate to meet fetal and infant demand. Therefore, in situations 
where de novo synthesis and dietary intakes are insufficient, mobilization of maternal stores may 
be a major provider of DHA for fetuses and newborns, but mothers not consuming DHA can 
deplete them within two months of delivery [37].  
Most research examining maternal DHA mobilization is focused on the liver and adipose 
depots [31,32,38,39].  However, there are other tissues with considerable concentrations of DHA 
that could provide DHA during pregnancy and lactation. Skeletal muscle in the rat has both 
higher relative, and absolute amounts of DHA as compared with white adipose [40], and fatty 
acid levels in muscle decrease near parturition in bovine models [41]. In addition, gene 
expression for fatty acid uptake and degradation enzymes are decreased in the muscle during 
lactation in the rat [42]. The ability for skeletal muscle to mobilize fatty acids during pregnancy 
could allow mothers to provide fetuses and newborns with a minimal supply of DHA. Similarly, 
cardiac muscle in rats also has a higher concentration and percentage of DHA relative to white 
adipose [40].  Cardiac muscle also has a high fatty acid turnover rate [43] with potential 
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specificity for long chain polyunsaturated fatty acid (LCPUFA) lipolysis [44,45], but whether 
these lipids are exported for perinatal supply has not been examined. The expression of proteins 
involved in lipid uptake have been shown to decrease during lactation in skeletal muscle[42], and 
a similar mechanism could be occurring in cardiac muscle. 
Pregnancy-induced lipidemia is well documented [46]. Circulating levels of 
triacylglycerols (TAG), phospholipids (PL), and nonesterified fatty acids (NEFA) increase 
during gestation in part due to stimulation from placentally derived leptin [37]. In plasma, DHA 
increases predominantly in 16:0/DHA phosphatidylcholine (PC) [29]. This increase is due to 
repackaging of phosphatidylethanolamine (PE) to PC through the Kennedy pathway by increased 
phosphatidylethanolamine methyl transferase (PEMT) activity [29]. Generally, PE has a higher 
content of DHA than PC, but PE predominantly resides on the inner cell membrane of 
phospholipid bilayers [47]. Hepatic PEMT-derived PC appears to be preferentially partitioned to 
the fetus [48]. Converting DHA-rich hepatic PE to PC allows the DHA to be readily incorporated 
into the lipoprotein monolayers that are predominantly PC. Once in the circulation, the DHA-
rich PC is then accessible to lipases found on the microvillous membrane of the placenta, 
allowing DHA to be delivered as NEFA to the fetus by passive diffusion [33] or through protein 
mediated transport [49].  
 During lactation, circulating NEFA levels are increased by reducing fatty acid oxidation 
and increasing lipolysis in maternal adipose [50]. Adipose derived NEFA can then be sent to the 
liver for repackaging as triacylglycerol (TAG) dominant lipoproteins such as very low density 
lipoproteins (VLDL) before being sent to the mammary gland to support milk synthesis [51], 
though uptake of albumin-bound NEFA could be occurring as well [52]. Similar to lipolytic 
signalling from the placenta during pregnancy, lipoprotein lipase (LPL) activity at the mammary 
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gland is increased via increased prolactin levels [51]. The increase in LPL activity is an adaption 
to promote the incorporation of DHA into milk, as DHA from the diet is preferentially 
incorporated into plasma PL and TAG [53]. Lipids derived from intestinal absorption circulate 
primarily as chylomicrons, while those derived from hepatic synthesis or adipose tissue circulate 
primarily as VLDL[54].  
 In all, the combined provision of maternal DHA to the fetus and infant via placental 
transfer and lactation are important in ensuring adequate perinatal DHA status. Tracer studies 
have confirmed that increases in maternal dietary DHA consumption increase DHA 
concentrations in the placenta [55] and breast milk [56], but no tracer studies have yet confirmed 
to what degree each mechanism of transfer for maternal DHA to the infant is responsible for 
perinatal DHA status. De novo synthesis of DHA during the perinatal period has also been 
reported in term and preterm infants [57], but these synthesis pathways do not appear to have as 
large an impact on infant DHA status compared to adequate maternal DHA [58]. Increases in 
maternal DHA intakes are linked with increases in perinatal DHA status [58]. However, further 
research is needed to fully characterize the role of placenta, breast milk, and perinatal de novo 
synthesis on infant DHA status. 
2.2 Sex differences in DHA metabolism  
DHA levels in females are generally higher than those of males when dietary intake is 
controlled [15,59]. Females have higher biosynthesis of DHA from ALA [60]. These differences 
are believed to be primarily the result of 17β-estradiol, which increases gene expression of 
FADS2, the gene responsible for Δ6-desaturase (D6D), the rate limiting enzyme in DHA and 
ARA synthesis [17].  
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How estrogen increases D6D activity and circulating levels of DHA has not been fully 
uncovered. The three main forms of estrogens in humans are estriol, estrone, and 17β-estradiol. 
17β-estradiol is the most bioactive form in mammals, and functions through genomic and 
nongenomic mechanisms. For genomic mechanisms, 17β-estradiol binds to estrogen receptors 
(ERα and/or ERβ) to up- or downregulate gene expression, while for nongenomic mechanisms, it 
binds primarily to G protein-coupled receptor 30 (GPR30) to mediate secondary messengers 
through protein phosphorylation and calcium signalling [61]. To date, no mechanisms directly 
relating estrogen to D6D have been identified. However, genomic mechanisms explaining the 
role of 17β-estradiol in DHA synthesis have been proposed, involving the upregulation of 
desaturase, elongase, and peroxisomal enzymes through ERα-activated peroxisome proliferator-
activated receptor alpha (PPARα) upregulation [14]. 
Determining the exact lipid pools in which DHA differs between males and females 
could lead to a better understanding of the metabolic control of DHA partitioning. A recent 
review highlighted that sex differences in circulating DHA can be specified to total plasma, 
plasma PL, and red blood cell (RBC) PC fractions in humans [18,62] and rats [63]. This is in 
agreement with tracer studies showing DHA elongated from ALA leaves its synthesis pathway 
as acyl-CoA and incorporates primarily into PC, followed by CE, TAG and NEFA pools in 
women of reproductive age [59] The higher content in PC could be a result of higher circulating 
levels of 17β-estradiol, which can increase PEMT gene expression, thereby increasing their 
conversion of PE 16:0/DHA to PC 16:0/DHA [64].  
Sex differences in DHA status may be dependent on low background intakes of omega-3 
PUFA [14,65], as these sex differences have been shown to disappear with fish oil 
supplementation, and are not observed in countries with a high omega-3 intakes and blood levels 
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[18,66,67].  Most observations of higher blood DHA levels in females have been observed 
between the ages of 13-50 years old [18]. Although it is assumed that sex differences are 
associated with the higher concentration of circulating sex hormones that occur during the onset 
of puberty, this has not been clearly demonstrated.   
2.3 Established DHA biomarkers 
 For fatty acid biomarkers, various tissues can be used, but blood has significant 
advantages as it is routinely collected and stored in clinical settings. Within blood, there are 
various fractions and lipid pools that can be examined, including whole blood (that can be 
collected as dried blood spots), plasma (or serum), erythrocytes, and the buffy coat. Within 
blood, DHA is found primarily in the PL of the various blood fractions with the fatty acid 
compositions of plasma and RBC being reported the most often [67,68]. Tissue n-3 LCPUFA 
status correlates more strongly with RBC than plasma, given that RBC has a lipid bilayer and is 
composed of a more comprehensive phospholipid profile, unlike plasma, which is dominated by 
PC lipoproteins [69]. It has also been demonstrated that DHA levels in RBC are better indicators 
of dietary adherence than other n-3 LCPUFA measures in plasma, as turnover of DHA in this 
pool is slower [70]. However, the recent identification of plasma PC 16:0/DHA as the specific 
lipid responsible for most of the increase in plasma DHA during pregnancy suggests that 
lipidomic analyses has the potential to identify highly informative biomarkers not possible with 
methods that rely on the chemical isolation and derivatization of fatty acids [29]. 
While blood fatty acids can be used as biomarkers of DHA intake, the brain strongly 
retains DHA, even when blood DHA status is low [71]. Although correlations between brain and 
blood n-3 LCPUFA can be strong when n-3 PUFA deficient rats (r ≥ 0.95) are included, the 
correlations become considerably weaker when all animals are adequate in n-3 PUFA, even 
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when it is primarily obtained as ALA and not preformed DHA [69]. When examining intake 
ranges above deficiency, correlations between RBC and brain (r = 0.62) are stronger than brain 
and plasma (r=0.46) [69]. A lipidomic approach examining different brain regions may identify 
acyl specific lipid species that are highly correlated in brain and blood, and potentially serve as 
informative biomarkers in the future.  
Lipidomic data also have the potential to provide additional insights about metabolism 
when examining sex differences. Previously, the identification of increased 16:0/DHA PC in late 
pregnancy led to additional evidence that increased expression of PEMT supports maternal-fetal 
DHA transfer [29] and not just the synthesis of PC. Changes in acyl specific lipid species allows 
for systems biology approaches to identify molecular pathways with sexual dimorphism in 
response to physiological changes and diets.  However, with known sex differences in 
lipoprotein metabolism [72], lipoprotein isolation followed by lipidomic analysis, though 
currently technically challenging, needs to be considered to improve characterization of the 
plasma lipidome and our understanding of sex differences in hepatic fatty acid and lipid 
metabolism. 
2.4 Cognitive benefits of DHA 
DHA comprises between 15 and 20% of total lipids in the adult rodent brain, and is 
critical for optimal brain function [3,73]. The majority of DHA in the brain is incorporated 
within PL [16], but the effect of dietary intervention, and the PL fraction most affected by it is 
debatable. The PE and PC fractions are the most abundant phospholipids in brain [74], but these 
phospholipids and their DHA content are relatively resistant to changes in DHA intake other than 
outright n-3 PUFA deficiency [75]. However, DHA supplementation can increase DHA 
composition (%wt) of other lipid species, and possibly increase the absolute amounts of DHA 
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containing phosphatidylserine (PS) [74]. Plasmalogens, which make up an important subclass, 
and constitute approximately 20% of white matter phospholipid mass [76] may also increase in 
DHA content during dietary DHA supplementation [77,78]. DHA supplementation may also 
reduce arachidonic acid (ARA) in PC, PE, PS, and phosphatidylinositol (PI) fractions, even 
though relative amounts of DHA do not change [75]. Aging may also have a role in sex 
differences in brain, as brain DHA in lysoPC is higher in aging female as compared with male 
mice [79].  
In multi-generational studies of DHA depletion, male rodents show impaired spatial 
memory performance in Morris water maze (MWM) studies [6–10]. In vitro studies show 
neurons from the hippocampus, an area critical for spatial memory, generate more synapses in 
cell cultures with DHA included as compared with cultures without DHA [4]. This observation 
of increased neural connections could explain the shorter latency times in MWM performance of 
rats with adequate levels of DHA [6–10], as DHA may be supporting memory formation and 
increased recall speed. 
Cognitive interactions between sex and DHA intake have been reported. In 18-45 year 
old adults, DHA supplementation improved episodic memory reaction times and working 
memory accuracy in both sexes, episodic memory accuracy in females only, and working 
memory reaction times in males only [5]. DHA blood levels also correlate with cognitive test 
scores twice as strongly in girls as compared with boys, and DHA supplementation shows an 
inverse relationship with blood levels of n-6 PUFA in females only [21]. DHA supplementation 
is also linked with reducing depression in women, but not men [22]. Interestingly, in 3 year old 
Danish girls, an inverse relationship was shown between DHA in RBC and communication as 
determined by the ASQ-3 [20]. Studies examining the effects of DHA on cognition do not 
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always reach significance, and its effects remain controversial [80]. This may be partially 
explained by studies not accounting for sex differences, only measuring effects in males, or not 
accounting for age, as it is possible the effects of DHA supplementation interact with sex 
differently at different ages. Understanding the mechanisms behind why DHA supplementation 





3  Rationale, Objectives, and Hypotheses 
3.1 Rationale: 
 Sexual dimorphisms have been overlooked in science [81]. Within the last decade, 
policies have been put into place to prevent basic and preclinical research from being focused on 
males only [82,83]. A significant amount of basic research on the benefits of DHA has been 
conducted using only male specimens [6–10,84–86], despite female and male humans showing 
different circulating levels of DHA [15,59,60], different memory improvements from DHA 
supplementation [5], and sexually dimorphic cognitive differences in infants following maternal 
DHA supplementation [87]. Pregnancy models can provide insights on the effects of sex 
hormones on fatty acid and lipid metabolism and need to be examined to understand female 
biology. Plasma DHA increases approaching parturition in humans and rats [29,88], and sex 
differences in DHA are associated with higher levels of estrogen in females [17,29]. As 
Canadian women do not meet ISSFAL recommendations for DHA consumption during 
pregnancy [28], examining the effects of a high fat diet that mimics a Western fatty acid profile 
with and without DHA on the mother, fetuses, and 7d old pups could provide more insight on 
maternal adaptations to DHA supplementation and sexual dimorphisms in pup development. 
Additionally, circulating DHA levels are often reported to be greater in females relative 
to males [14,15,18]. This increased capacity is associated with circulating estrogen [14,15] and 
sex differences in the expression of genes related to PUFA synthesis [14,89]. While the onset of 
these differences has not been examined comprehensively, human studies suggest differences in 
circulating DHA begin with puberty [18], but sex-DHA status interactions on communication 
skills have been observed at 9 months of age [20]. This could be due to differences in DHA 
status occurring earlier than previously thought. Animal studies examining tissue DHA status 
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have been limited to single time points in mature rats [14,63], and when examined in growing 
rats, it has been examined under n-3 PUFA deprivation/repletion models [89]. Puberty in the rat 
begins between 40-60 days of age [90]. Examining changes in DHA status from 1 to 9 weeks of 
age could provide insight on how sexual dimorphisms in DHA occur in rats during development. 
 Finally, DHA supplementation causes sexually dimorphic memory improvements in 
young adults [5], and multigenerational studies in rats show severe DHA depletion negatively 
affects spatial memory in MWM [6,9,10]. However, this effect on spatial memory has only been 
examined in males. Spatial memory and MWM performance are highly associated with 
hippocampal function [91]. Dietary ALA supplementation increases DHA brain composition in 
females more than males [92], and DHA supplementation has been shown to improve memory 
differently in females as compared with males [5]. In the hippocampus, DHA accumulation 
occurs primarily in PL [93], and DHA uptake and PE levels in the brain are affected by estrogen, 
as estrogen treatment appears to maintain brain lipid homeostasis in aging and ovariectomized 
rodents [12]. A lipidomic analysis of the hippocampus compared with blood lipidomics may 
provide further insight on sexually dimorphic responses to DHA supplementation and identify 
novel blood biomarkers that are more informative than fatty acid based blood-brain biomarkers.  
3.2 Objectives: 
Using a rat model, the main objectives of this thesis are to: 1) assess the effect of dietary 
DHA supplementation and high fat Western diets during pregnancy on tissue DHA status of 
mothers, fetuses and pups, 2) determine the onset of sex differences in DHA status from birth to 
adulthood, and 3) determine the impact of DHA supplementation during pregnancy and lactation 
on the spatial memory of adolescent offspring.  
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 Assessing the effect of dietary DHA on maternal tissue stores involved a pregnancy 
model with total Western diets with (TWD+) and without DHA (TWD-), and a standard chow 
diet. Maternal and 7-day old pup tissues were analyzed during pregnancy and lactation. Plasma, 
RBC, heart, liver, brain, white perirenal adipose and placenta from the mothers were collected to 
determine how fetal demand for LCPUFA during pregnancy and lactation affected maternal 
tissue stores of LCPUFA. Brain, heart, and liver from 7-day old pups were also collected and 
examined for potential dietary effects and sexual dimorphisms in LCPUFA composition.  
 Upon examination of sexual dimorphisms in brain DHA concentrations of 7-day old pups 
fed TWD+, an objective of determining when sexual dimorphisms in the LCPUFA status of 
chow fed Sprague-Dawley rats was established. Plasma, heart, liver, and brain fatty acid 
compositions were examined. 
 The potential interaction between dietary DHA supplementation throughout development 
and sexual dimorphisms at 6 weeks of age was also examined. Spatial memory was then assessed 
using the Morris water maze, and lipidomic and fatty acid analyses were performed on the 
offspring to determine the lipid species of the hippocampus and erythrocytes. Correlations were 
performed to determine whether erythrocytes could be an effective biomarker for assessing the 
hippocampal lipidome.  
3.3 Hypotheses 
Study 1: The Effect of Dietary DHA on the Fatty Acid Composition of Maternal Tissues 
and 7 Day Old Pups 
1. At days 20 of pregnancy or 7 days postpartum, mothers fed TWD- and chow will have 
lower levels of DHA in their adipose, heart, and liver, as compared with mothers fed 
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TWD+. Maternal brain levels throughout pregnancy and postpartum will not change, 
regardless of diet. 
2. TWD+ pups will have greater levels of DHA in whole body, brain, heart, and liver than 
TWD- and chow. 
3. The tissue compositions of female and male fetuses and pups will be similar.  
Study 2: Sex Differences in Fatty Acid Compositions of Plasma, Liver, Brain, and Heart 
from Birth to Adulthood 
1. Plasma, heart, and liver DHA composition will be higher in females than males 
beginning at 40 days of age. 
2. Brain DHA composition (%wt) and concentration will be the same between sexes 
throughout the experiment (weeks 1 – 9). 
Study 3: Examining the Effects of Dietary DHA Supplementation on Spatial Memory and 
the Hippocampus in Female and Male Rats 
1. At week 6, DHA+ females will have shorter latency times than DHA+ males. For both 
sexes, the DHA supplemented group will have shorter latency times than controls  
2. Females will have greater hippocampal DHA levels than males in the supplemented, but 
not the control group at 7 weeks of age with the increased DHA occurring in PC and PE 
16:0/DHA and 18:0/DHA, and PS 18:0/DHA at the expense of n-6 LCPUFA. 
3. DHA levels in the RBC PE 16:0/DHA and PE 18:0/DHA will correlate with PE 




4  Common Methods 
4.1 Animals and Tissue Collection 
All animal experiments will be performed in agreement with the policies of the Canadian 
Council on Animal Care and submitted for approval by the University of Waterloo Animal Care 
Committee. In all experiments, exsanguinated blood will be collected in the presence of 
ethylenediaminetetraacetic acid (EDTA) and plasma will be isolated by centrifugation at 4°C and 
1,500 g for 10 mins. Tissues will be washed in saline (0.9% v/v), weighed, and flash-frozen in 
liquid nitrogen. After collection, samples will be stored at -80°C until analysis.  
4.2 Lipid Extraction 
Tissue samples will be pulverized, weighed, placed in an ice bath, and homogenized 
using a Kinematica PT 1200E Polytron (Kinematica Inc., Bohemia, NY) in 3mL of 2:1 
chloroform:methanol containing 50μg/mL 2,6-di-tert-butyl-4-methylphenol (butylated 
hydroxytoluene, BHT; Sigma-Aldrich, St. Louis, MO, USA) and 10μg of docosatrienoic acid 
(22:3n-3, Nu Chek Prep Inc., Elysian MN) for gas chromatography analysis, or 500pmol of 
17:0/17:0 PC for mass spectrometry analysis as internal standard. Homogenized samples will be 
left at room temperature overnight in 3mL of 2:1 chloroform:methanol for lipid extraction 
following a method modified from Folch et al. [94]. Aqueous and organic phases will be 
separated by aqueous buffer of 500μL of 0.2M sodium phosphate, and the organic phase will be 
collected. 
4.3 Gas Chromatography 
 The collected organic phase containing the extracted lipids will be dried under nitrogen 
and methylated in 1mL BF3-MeOH and 300µL of hexane for one hour at 100°C. The hexane 
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layer with fatty acid methyl esters will be collected, dried under nitrogen and reconstituted in 
65µL of hexane for analysis with a Varian 3900 gas chromatograph equipped with a DB-FFAP 
15 m x 0.1 mm injected dose x 0.1 μm film thickness polyethylene glycol capillary column (J 
and W Scientific from Agilent Technologies, Mississauga, ON) at a 100:1 split ratio. The inlet 
will be heated to 250ºC with hydrogen used as a carrier gas. A temperature program will be used 
with an initial column temperature of 150ºC with a 0.25 minute hold, followed by a 35ºC/min 
ramp to 200ºC and a 8ºC/min ramp until 245ºC will be reached and held for 15 minutes [95]. 
Fatty acid methyl esters will be measured using a flame ionization detector set at 300°C and a 




5 The Effect of Dietary DHA on the Fatty Acid Composition of Maternal Tissues and 7 
Day Old Pups 
5.1 Introduction 
Levels of DHA in plasma increase approaching parturition in both humans [88,97,98] and 
rats [29,99], likely as an adaptation to meet fetal demand during fetal brain growth. Mechanisms 
responsible for this increase have not been fully identified, but dietary intake, upregulated de 
novo synthesis and mobilization from maternal tissues are potential mechanisms [1,29–32]. 
Evidence suggests DHA is mobilized from maternal liver and adipose depots during pregnancy 
and lactation [31,32,38,39], and it is possible that DHA could also be mobilized from other 
maternal tissues, particularly those demonstrated to be rich in DHA [40]. The exact roles of these 
mechanisms, and how they interact with high fat diets typically found in Western societies could 
provide a better understanding as to how mothers meet fetal and infant DHA demand. 
The goal of this study was to investigate if DHA can be mobilized from various maternal 
tissues in addition to adipose during pregnancy and postpartum, and if this mobilization can be 
influenced by DHA supplementation and high fat diets. This was examined with a background 
rodent diet designed to emulate a typical human Western diet, including percentages of saturated 
fatty acids (SFA), monounsaturated fatty acids (MUFA) and PUFA [100].  A common rodent 
chow diet was included as an additional control. Maternal liver, brain, adipose, heart, 
erythrocytes, and plasma, as well as placenta, and fetal and pup tissues were examined 
throughout pregnancy and into the postpartum period across all diets. To my knowledge, this is 
the first study to comprehensively examine changes in the fatty acid compositions of multiple 





5.2.1 Animals and Pregnancy Model 
Seventy-two female Sprague-Dawley rats were purchased from Envigo (Mississauga, 
Ontario, Canada) and arrived at the University of Waterloo Central Animal Facility at 7 weeks of 
age. Baseline rats were not bred and fed either a fixed-formula 8640 Teklad 22/5 Rodent Diet 
(Chow), a TD.110424 total western diet with DHA (TWD+) or a total western diet without DHA 
(TWD-) (Table 1) for 7 days prior to being sacrificed (n=6 per diet). Rats assigned to the 
pregnancy groups were housed with male breeders and fed chow diets until confirmation of 
pregnancy by vaginal plug. Once pregnant, rats were immediately assigned to chow, TWD+, or 
TWD- diets (Figure 1). Daily food intakes and body weight were measured at baseline, day 15 
and 20 of pregnancy, and postpartum. Following an overnight fast, rats were sacrificed at day 15 
of pregnancy, day 20 of pregnancy, or 7 days postpartum by exsanguination after anesthesia 
using isoflurane (n=6 per group). Plasma, RBC, adipose, brain, heart, liver, fetuses, 7 day old 
pups, and pup brain, hearts, and livers were collected and analysed by gas chromatography as 
described in the general methods chapter. 
5.2.2 Statistical Analyses 
All statistical analyses were performed using SPSS release 20.0 (IBM, Chicago, IL, USA). 
The effect of diet and time was examined across maternal parameters using a two-way ANOVA 
with interactions. Differences in pup tissues across diets were examined by one-way ANOVA. 
Individual means were compared by Tukey post hoc testing after significant F-value by 




5.3.1 Maternal food intake and body weight 
Energy intakes did not differ across the diets despite the higher energy density of the 
TWD+ and TWD- as compared with chow.  Maternal energy intakes were significantly increased 
in all diets at 7 days postpartum as compared with baseline and gestation across all diets (Figure 
2). At 7 days postpartum, chow dams consumed a significantly greater mass of food than TWD+ 
and TWD- dams (47.5 ± 4.37g vs. 34.0 ± 10.0g and 32.33 ± 12.45g, respectively).  Maternal 
body weight increased from baseline throughout pregnancy with a decrease at postpartum that 
remained higher than baseline. This was in agreement with previous reports using this pregnant 
rat model [29]. Maternal and fetal body weights did not differ between diets (data not shown).  
However, the weights of 7-day old pups from TWD+ and TWD- mothers were significantly 
higher than those from chow mothers (14.16 ± 2.99g and 14.14 ± 2.63g vs 12.63 ± 1.68g 
respectively. p = 0.0001).   
5.3.2 Fatty acid composition of maternal tissues 
The TWD+ diet supported increased concentrations of DHA in most maternal tissues 
during pregnancy while the TWD- and chow diets did not, although the responses of each tissue 
were not similar (Figure 3).  In plasma, there was a significant increase in DHA at day 20 of 
pregnancy in all three diets, and the DHA concentration with TWD+ feeding was 53% and 78% 
higher than the DHA concentrations with chow and TWD- feeding, respectively (Figure 3A).  
These concentrations returned to baseline levels by 7 days postpartum in all the diets.  These 
increases reflected, in part, a general increase in total fatty acids in plasma at 20 days of 
pregnancy. However, the relative percentage of DHA was significantly higher at 20 days of 
pregnancy for the TWD+ and chow groups, but not the TWD- diet (Appendix Table 5.1, Appendix 
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Table 5.2Error! Reference source not found.). Concentrations of ARA also changed, 
increasing above baseline at 20 days of pregnancy in TWD+ and chow rats, and decreasing 
below baseline at 7 days postpartum in TWD+ rats. The TWD+ and TWD- diets also resulted in 
higher percentages of saturated and monounsaturated and lower percentages of n-6 PUFA as 
compared with plasma from the chow diet. In erythrocytes, the increase in DHA concentrations 
at day 20 was also observed in all the diets, but the increase was more gradual, very subtle in the 
chow and TWD-, and extended into postpartum for the TWD+ group (Figure 3 B).  In contrast to 
plasma, the total fatty acid concentrations of erythrocytes did not increase at day 20 of 
pregnancy. 
Liver DHA concentrations increased above baseline at day 15 and 20 in the TWD+ group 
and decreased below baseline at 7 days postpartum in the TWD- group (Figure 3C). The relative 
percentage of DHA was significantly higher at day 20 in both the chow (6.42±0.78 vs 
10.96±2.98) and TWD+ groups (7.42±0.90 vs 11.35±2.45, Appendix Table 5.3).  Liver ARA 
concentrations did not change from baseline in any of the dams. In the TWD+ and TWD- groups, 
total fatty acid concentrations significantly increased at 7 days postpartum as compared with day 
20 of pregnancy (1.7 – 1.9 fold) and were significantly higher than chow at the 7 days 
postpartum (2.5 – 2.7 fold, Appendix Table 5.3). These increases in liver total fatty acids were 
driven by very large increases in 16:0 and 18:1n-9, as percentages of n-3 and n-6 PUFA 
decreased in the TWD+ and TWD- diets. 
Adipose DHA concentrations were decreased throughout pregnancy in the TWD- group 
(Figure 3D).  The TWD+ and chow groups had similarly higher DHA concentrations in adipose 
throughout pregnancy and postpartum with an increase at day 20 of pregnancy that was above 
baseline levels.  There was a tendency for total fatty acid concentrations of adipose to increase 
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during pregnancy and then decrease postpartum across all diets with the decrease at postpartum 
in the chow diet being the largest.  In the heart, DHA concentrations increased in the TWD+ at 
day 20 of pregnancy and then returned to baseline levels (Figure 3E).  In the TWD- and chow 
groups, heart DHA concentrations did not increase at day 20 and significantly decreased at 7 
days postpartum (Figure 3E) and there was evidence of increased percentages of 22:4n-6 and 
22:5n-6 in these groups as compared with the TWD+ group (Appendix Table 5.5).  Maternal 
brain DHA concentrations in the TWD- group were significantly lower than those in the TWD+ 
group, at day 20 of pregnancy, but none of the values were different from baseline (Figure 3F) 
and the percentage of brain DHA did not differ in any of the groups (Appendix Table 5.6).    
5.3.4 Fatty acid composition of the placenta and pup whole bodies. 
Placental DHA concentrations increased in all diets from day 15 to day 20 of pregnancy 
with the increase in the TWD+ placentas being significantly greater than the other diets (Figure 
4A).  While there was a tendency for total fatty acid concentrations to also increase from day 15 
to day 20 (approximately 30-40%), the percentages of DHA at day 20 remained significantly 
higher than day 15 for all the diets with TWD+ having the greatest increase (Appendix Table 
5.7).  In the fetus, whole body DHA concentrations did not differ (Figure 4B) although the 
percentage of DHA increased in the TWD+ and chow fetuses from day 15 to day 20 (Appendix 
Table 5.8).  After birth, DHA concentrations increased in the pups relative to the fetuses in all 
the diets with a remarkable increase in the TWD+ diet (7 fold from baseline versus 3.7 fold in 
TWD- and 3.6 fold in chow, Figure 4B). After birth, total fatty acid concentrations increased 
significantly in all the pups, however, the concentrations in the TWD+ and TWD- 7-day old pup 
whole bodies were approximately 3 times the concentration of the chow-fed pups (Appendix 
Table 5.8).  
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5.3.5 Fatty acid composition of pup brain, liver and heart. 
The pups from the TWD+ group had the highest concentrations of DHA all tissues, 
although chow had a statistically similar level of DHA in the heart (Figure 5).  DHA 
concentrations in the brain and heart of TWD- group were also significantly lower than the chow 
group.  Differences in total fatty acid concentrations appear to have contributed to this 
observation as total fatty acid concentrations in the TWD- group were lower in the brain and 
heart but higher in the liver relative to the chow group (Appendix Table 5.9).  In the brain, the 
percentage of DHA was only different (1.2 times higher) in the TWD+ group, while the 
percentages of 22:5n-6 and 22:5n-3 were higher in the TWD- and chow pups as compared with 
the TWD+ pups (Appendix Table 5.9).  In both the heart and liver, there were increases in the 
percentages of 18:1n-9 with the TWD+ and TWD- feeding relative to chow.  In the heart, this 
was offset by lower percentages of 18:2n-6 and 18:3n-6 relative to chow, while in the liver, the 
TWD+ and TWD- had lower percentages of 18:0 and 20:4n-6 (Appendix Table 5.9). 
5.4 Discussion 
 Results of this study indicate that including preformed DHA can, in general, increase 
DHA status in various maternal, fetal and pup tissues even when fed a background Western style 
diet.  High fat feeding during pregnancy has been demonstrated to potentially reduce the hepatic 
DHA status of neonatal pups [101], but surprisingly, manipulating the DHA content of a Western 
style diet fed rodents during pregnancy has not been examined previously to our knowledge.  
This is despite the fact that the use of DHA supplements during pregnancy is encouraged for 
women in Western countries [102].   
An increase in DHA concentrations in maternal plasma has been observed previously 
[29,31,38,39,88,103]. This study also confirms a recent report that the DHA increase occurs 
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largely in late and not early pregnancy, where it was demonstrated that DHA was specifically 
increased into 16:0/DHA PC for incorporation into lipoproteins during pregnancy induced 
hyperlipidemia [29]. The present study demonstrates that the DHA increase in plasma during late 
pregnancy is even higher when preformed DHA is included in the diet, and that this metabolic 
adaptation to mobilize DHA to the plasma for potential fetal uptake was also evident in the 
TWD- diet, a high fat diet without preformed DHA. The increase and decrease in DHA 
concentrations and percentages in plasma during pregnancy and postpartum have been observed 
previously in rodents [29] and in humans [88,97].  This rise and fall is associated with changes in 
lipoprotein levels, but also DHA availability for incorporation into PC [29,104]. Erythrocyte 
DHA concentrations were also increased above baseline with this increase being higher and 
persisting into 7 days postpartum in the TWD+ group.  
In the other maternal tissues examined, an increase in DHA concentrations at day 20 of 
pregnancy was observed only in tissues of the TWD+ group.  Specifically, liver, adipose, heart 
and erythrocyte, but not brain DHA concentrations were all increased above baseline at day 20 
and they all returned to baseline levels at 7 days postpartum.  In the heart and liver, the chow and 
TWD- groups were generally similar with the DHA concentrations remaining at baseline levels, 
but lower than the TWD+ group throughout pregnancy.  However, at 7 days postpartum, DHA 
concentrations fell below baseline levels in both the chow and TWD- groups in the heart, and in 
the TWD- group in the liver. The decrease in heart tissue DHA in both the chow and TWD- was 
not expected, but losses of DHA in the heart could have been anticipated. Heart tissue has a high 
concentration of DHA [40] and high fatty acid turnover rate [43], with a potential specificity for 
lipolysis of LCPUFA such as DHA by phospholipase A2 enzymes [44,45] . It is not clear if the 
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decrease in DHA was caused by metabolic use of DHA by the heart or by release of DHA from 
the heart to the circulation.  Further examination is required. 
In contrast to the response in maternal liver and heart, perirenal adipose tissue DHA 
concentrations in the chow and TWD+ groups were similar, while the TWD- group was lower 
throughout pregnancy and postpartum.  The DHA content of adipose was actually increased at 
day 20 in the TWD+ and chow diets suggesting that adipose may have been taking up DHA from 
plasma, rather than providing it.  Previously it has been reported that DHA concentrations in 
periuterine adipose decrease but that perirenal adipose do not change at 18 days of pregnancy in 
rats fed low n-3 or ALA adequate diets [38].  In this study, an increase in DHA in perirenal 
adipose in the chow and TWD+ diets at day 20 but not day 15 of pregnancy was observed.  
The lower levels of DHA in the adipose of the TWD- group throughout pregnancy and 
postpartum suggest that the fetal/pup demand was not being met by the intake of dietary DHA 
and that adaptations to increase DHA biosynthesis during pregnancy [29,59,105,106] could not 
meet the demand as well.  The TWD- diet contained only 17 µg DHA/g diet (0.01% of total fat) 
while the chow diet had 226 µg DHA/g diet (0.41% of total fat). In regard to DHA biosynthesis, 
the total ALA content in the TWD- diet (3.17 mg ALA/g diet) was slightly higher than chow 
(2.63 mg ALA/g diet), but the % of ALA in total fat in the TWD- (1.8% of total fatty acids) was 
less than half of the chow diet (4.8% of total fatty acids).  Based on a previous study that 
considered the ratios of linoleic acid (LA) to ALA and the energy % of over 50 diets [107], it is 
unlikely that the DHA biosynthesis potential of the chow and TWD- diets would differ.  
However, the previous work was completed in male rats and not pregnant females, and this study 
included different levels of preformed DHA in the diets.  In addition, high MUFA intakes can 
reduce ALA metabolism [11] and absolute MUFA content in the TWD- diet was 66.9 mg 
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MUFA/g diet as compared with 13.4 mg MUFA/g diet in the chow diet.  Additionally, the 
different micronutrient composition of the chow and TWD diets could have had an effect on the 
metabolic outcomes of the pups[108]. Further research on their impact is necessary. 
Placental and whole body pup DHA concentrations from this model are consistent with 
previous reports of maternal DHA status affecting fetal and infant DHA status through both 
placental transfer [33] and lactation [109].  The TWD+ pups had both higher whole body and 
tissue specific DHA concentrations when compared to their chow or TWD- counterparts. 
However, it was interesting that the differences in whole body DHA concentrations were only 
observed in the 7-day old pups and not in the fetuses. This suggests that maternal adaptations 
during pregnancy were meeting fetal demand, but that this did not extend into postpartum 
lactation. Fetal synthesis of DHA could also be occurring, but from the current literature, it is 
difficult to quantitate DHA synthesis occurring during early infancy from that occurring in utero 
[33]. Future research is needed to quantify how much perinatal DHA is synthesized from the 
mother relative to the infant. Tissue fatty acid analyses of the pups indicate that while some of 
the increased DHA in the TWD+ group is probably excess and accumulating in depots such as 
liver and possibly adipose (not measured), diets low in DHA can result in slightly, but 
significantly lower levels in brain and heart.  Interestingly, the pup heart was the most sensitive 
to losses of DHA with the TWD- diet.  As mentioned previously, there is the potential for high 
DHA turnover in the heart [110], but it remains to be seen if this turnover is to meet the 
metabolic need for DHA by the heart itself or if some of the DHA is released to the circulation 
for uptake by other tissues.  More research understanding DHA metabolism and turnover in the 
heart is needed. The postpartum observations in this study may be unique to rodent models and 
not extrapolate to humans as rat pup brain development does not reach the same level as a term 
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human infant until 12 days postpartum [90]. In this rat model, however, it appears that while 
adaptations during pregnancy maintain maternal DHA status before birth, these adaptations 
change postpartum and may not support DHA demand by the pup via lactation.  
This study has several limitations.  While several maternal and fetal/pup tissues across 
various time points were screened to identify decreases in tissue levels as evidence of maternal 
mobilization for fetal/pup transfer, only static measures of tissue fatty acid levels were 
completed.  Also, while several maternal tissues were examined, results of decreases in DHA in 
heart indicate that maternal skeletal muscle should also be examined, and a recent study suggests 
that other adipose sites should be examined as well [38]. While the use of a background diet that 
resembled human fat intakes was novel for DHA supplementation during pregnancy, there were 
some unanticipated results that made it difficult to compare to the existing literature in the field. 
The TWD+ and TWD- resulted in significant increases in hepatic total fatty acids at postpartum, 
suggesting the development of fatty liver. The TWD+ and TWD- resulted in significant increases 
in hepatic total fatty acids at postpartum only (73.1 ± 25.4 and 77.2 ± 33.3 mg/g) that suggested 
progression towards fatty liver.  Total hepatic fatty acid concentrations of 122 mg/g and 
percentage shifts towards higher 18:1n-9 and lower 18:0 has been observed previously in rats 
with steatosis [111].This was not present during pregnancy, and was not reflected in maternal 
adipose, but it was reflected in the pup whole body total fatty acids. As only one postpartum time 
point was measured, the duration of this response and the consequences of these diets on 
maternal and pup health need to be examined in more detail.  
5.5 Conclusion 
In conclusion, this study provides further evidence that DHA is increased in plasma 
during late pregnancy across diets with different intakes of DHA and that tissues other than 
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adipose and liver may be a source of DHA during pregnancy and lactation in order to meet fetal 
and pup accretion and physiological requirements. These observations also suggest that in this 
model, maternal adaptations to meet lipid and fatty acid requirements change in the transition 
from pregnancy to lactation with the pup requirement for DHA during lactation being 
particularly detrimental to maternal tissue levels when dietary DHA levels are low. Additional 
work examining the rates of mobilization of DHA from maternal tissues, and the dietary intake 





Figure 1: Study design flowchart for pregnancy study. Female Sprague Dawley rats were fed 
either a fixed formula 8640 Teklad 22/5 Rodent Diet (Chow), a TD.110424 total western diet 
with DHA (TWD+) or a total western diet without DHA (TWD-).  Baseline rats were sacrificed 
at 9 weeks of age after one week on the diets. Rats assigned to the pregnancy groups were fed 
chow diets until confirmation of pregnancy and then immediately assigned to one of the 3 diets, 




Figure 2: Food intake across pregnancy and the postpartum period. *Significantly higher than 
intakes at other time points for all diets (main effect of time by two-way ANOVA followed by 






Figure 3: Effects of pregnancy and diet on DHA concentrations of maternal tissues. Different 
letters indicate diet differences within a timepoint, and * indicate timepoint differences from 
baseline within a diet. All differences are as determined by Tukey’s post hoc following 
significant (p<0.05) F-value by two-way ANOVA. Mean ± SD, n = 6 for each point. TWD+: 





Figure 4: Effects of pregnancy and diet on DHA concentrations of placenta and whole body 
fetuses and pups. Different letters indicate diet differences within a timepoint, and * indicate 
timepoint differences from baseline within a diet. All differences are as determined by Tukey’s 
post hoc following significant (p<0.05) F-value by two-way ANOVA. Mean ± SD, n = 6 for 
each point. TWD+: DHA-supplemented Total Western Diet, TWD-: Total Western Diet. 
 
 
Figure 5: Effects of pregnancy and diet on DHA concentrations of pup tissues. Different letters 
indicate diet differences. All differences are as determined by Tukey’s post hoc following 
significant (p<0.05) F-value by two-way ANOVA. Mean ± SD. TWD+: DHA-supplemented 




Figure 6: Effects of pregnancy and diet on DHA total lipids, phospholipids, and triacylglycerols 
in maternal heart. *Significantly different from baseline (p<0.05) as determined by two-tailed 
student’s t-test. Mean ± SEM, n = 6 for each point. TWD+: DHA-supplemented Total Western 
Diet, TWD-: Total Western Diet. 
 
 
Figure 7: Effects of maternal diet on brain DHA concentrations of male and female pups 
*Significant differences between male and female pups from mothers of the same diet (p<0.05), 
and letters indicate significant differences between diet as determined by two-tailed student’s t-
test. Mean ± SD. n=4 for TWD+ and chow. n=3 for TWD-. TWD+: DHA-supplemented Total 
Western Diet, TWD-: Total Western Diet.  
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Table 1: Macronutrient and fatty acid composition of chow, and DHA supplemented and 
unsupplemented Total Western Diets (TWD). 
Diet component Chow TWD-DHA TWD+DHA 
Macronutrient  mg/g of diet  
Protein 22.0 16.8 16.8 
Carbohydrate 40.6 54.6 54.6 
Fat 5.5 16.7 16.7 
Fatty Acid % composition 
C 16:0 13.24 ± 0.11 18.73 ± 0.08 18.81 ± 0.13 
C 18:0 3.68 ± 0.02 8.87 ± 0.01 9.16 ± 0.01 
Total SFA 18.56 ± 0.13 32.78 ± 0.05 32.74 ± 0.16 
C 16:1 0.77 ± 0.01 1.18 ± 0.01 1.14 ± 0.01 
C 18:1n-7 1.31 ± 0.01 1.49 ± 0.02 1.52 ± 0.06 
C 18:1n-9 21.82 ± 0.26 36.64 ± 0.10 36.79 ± 0.08 
Total MUFA 24.34 ± 0.23 39.90 ± 0.10 40.03 ± 0.07 
C 18:2n-6 48.51 ± 0.05 20.21 ± 0.04 20.86 ± 0.03 
C 20:4n-6 0.14 ± 0.02 0.08 ± 0.01 0.09 ± 0.01 
Total n-6 PUFA 48.82 ± 0.03 20.55 ± 0.04 21.23 ± 0.05 
C 18:3n-3 4.78 ± 0.01 1.83 ± 0.01 1.90 ± 0.01 
C 20:3n-3 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
C 20:5n-3 0.42 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 22:5n-3 0.08 ± 0.01 0.05 ± 0.01 0.03 ± 0.01 
C 22:6n-3 0.41 ± 0.02 1.21 ± 0.02 0.01 ± 0.01 
Total n-3 PUFA 5.71 ± 0.03 3.12 ± 0.01 1.98 ± 0.01 
Data is mean ± SD from triplicate analysis in our laboratory. SFA: saturated fatty acids, MUFA: 




Table 2 : Macronutrient and fatty acid composition of chow vs DHA supplemented (TWD+) and 
unsupplemented (TWD-) Total Western Diets. 
Diet component Chow TWD+ TWD- 
Energy Density (kcal/g) 3.0 4.4 4.4 
Macronutrients (g/100g)    
Protein 22.0 16.8 16.8 
Carbohydrate 40.6 54.6 54.6 
Fat 5.5 16.7 16.7 
Fatty Acid (% wt)    
C 16:0 13.24 ± 0.11 18.73 ± 0.08 18.81 ± 0.13 
C 18:0 3.68 ± 0.02 8.87 ± 0.01 9.16 ± 0.01 
Total SFA 18.56 ± 0.13 32.78 ± 0.05 32.74 ± 0.16 
C 16:1 0.77 ± 0.01 1.18 ± 0.01 1.14 ± 0.01 
C 18:1n-7 1.31 ± 0.01 1.49 ± 0.02 1.52 ± 0.06 
C 18:1n-9 21.82 ± 0.26 36.64 ± 0.10 36.79 ± 0.08 
Total MUFA 24.34 ± 0.23 39.90 ± 0.10 40.03 ± 0.07 
C 18:2n-6 48.51 ± 0.05 20.21 ± 0.04 20.86 ± 0.03 
C 20:4n-6 0.14 ± 0.02 0.08 ± 0.01 0.09 ± 0.01 
Total n-6 PUFA 48.82 ± 0.03 20.55 ± 0.04 21.23 ± 0.05 
C 18:3n-3 4.78 ± 0.01 1.83 ± 0.01 1.90 ± 0.01 
C 20:3n-3 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
C 20:5n-3 0.42 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C 22:5n-3 0.08 ± 0.01 0.05 ± 0.01 0.03 ± 0.01 
C 22:6n-3 0.41 ± 0.02 1.21 ± 0.02 0.01 ± 0.01 
Total n-3 PUFA 5.71 ± 0.03 3.12 ± 0.01 1.98 ± 0.01 
Micronutrients    
Minerals (mg/kg)    
Calcium  11000 2011 2011 
Phosphorus  9000 2757 2757 
Sodium 4000 7078 7078 
Potassium  10000 5333 5333 
Magnesium  2000 589 589 
Zinc  77.0 25.0 25.0 
Copper  24.0 2.6 2.6 
Iron  280 31.0 31.0 
Vitamins (U/kg)    
Vitamin A (IU) 15800 4300 4300 
Vitamin D3 (IU) 3000 391 391 
Vitamin E (IU) 150 24.6 24.6 
Vitamin B1 (mg) 32.0 3.5 3.5 
Vitamin B2 (mg) 9.0 4.4 4.4 
Niacin (mg) 66.0 50.6 50.6 
Vitamin B6 (mg) 14.0 3.9 3.9 
Vitamin B12 (mg) 0.06 11 11 
Folate (mg) 3.0 1.3 1.3 
Choline (mg) 2380 648 648 
Isoflavones (mg/kg) 350-650 n.d. n.d. 
Data is mean ± SD from triplicate analysis in our laboratory. SFA: saturated fatty acids, MUFA: 





Appendix Table 5.1: Fatty acid composition (weight %) of maternal plasma during pregnancy and postpartum 
Chow Baseline 15d Preg 20d Preg 7d PP 
16:0 14.54 ± 0.63a 15.99 ± 0.75a 20.31 ± 1.14b 15.73 ± 1.53a,1 
18:0 15.50 ± 1.11a 13.56 ± 1.42a 8.54 ± 0.95b 13.76 ± 1.96a 
Total SFA 33.46 ± 0.81a 31.60 ± 1.15b,1 30.01 ± 1.16b,1 31.37 ± 1.10b,1 
16:1 0.58 ± 0.14 0.67 ± 0.171 0.74 ± 0.141 0.70 ± 0.151 
18:1n-7 1.13 ± 0.06a 1.24 ± 0.03b 1.37 ± 0.06c 1.34 ± 0.09bc,1 
18:1n-9 5.73 ± 0.43a 8.81 ± 1.64b 11.28 ± 0.96b,1 10.72 ± 2.20b,1 
Total MUFA 8.10 ± 0.41a 11.31 ± 1.72b 13.73 ± 1.01b,1 13.27 ± 2.30b,1 
18:2n-6 17.96 ± 1.75a 20.78 ± 3.16ab,1 22.60 ± 1.37b,1 21.31 ± 2.29ab,1 
20:4n-6 33.82 ± 1.09a 26.79 ± 3.72b 19.05 ± 1.65c 24.16 ± 3.56b 
22:4n-6 0.22 ± 0.03a 0.36 ± 0.12a 1.31 ± 0.23b,1 0.35 ± 0.05a 
22:5n-6 0.14 ± 0.04a 0.26 ± 0.12a 1.63 ± 0.17b,1 0.65 ± 0.14c,1 
Total n-6 PUFA 52.97 ± 1.03a 49.34 ± 0.99b,1 45.72 ± 1.12c,1 48.38 ± 1.40b,1 
18:3n-3 0.48 ± 0.03a 0.73 ± 0.32a,1 1.09 ± 0.10b,1 0.48 ± 0.20a 
20:5n-3 0.58 ± 0.08 0.89 ± 0.341 0.61 ± 0.191 0.83 ± 0.151 
22:5n-3 0.42 ± 0.03a 0.63 ± 0.10a 1.50 ± 0.23b,1 0.88 ± 0.15c,1 
22:6n-3 3.16 ± 0.12a 4.25 ± 0.76a,1,2 6.28 ± 1.00b,1,2 3.24 ± 0.49a,1,2 
Total n-3 PUFA 4.65 ± 0.10a 6.53 ± 0.58b,1,2 9.49 ± 0.89c,1 5.43 ± 0.59a,1 
Total FA (µg/100µL) 235 ± 27a 187 ± 20a 584 ± 64b 233 ± 50a 
TWD+ Baseline 15d Preg 20d Preg 7d PP 
16:0 15.91 ± 0.67a 18.00 ± 0.98b 21.40 ± 0.93c 19.69 ± 1.72bc,2 
18:0 15.56 ± 0.47a 14.19 ± 0.59b 10.30 ± 0.93c 12.13 ± 1.06d 
Total SFA 34.26 ± 0.42ab 35.01 ± 0.94a,2 33.24 ± 0.75b,2 34.05 ± 1.04ab,2 
16:1 0.84 ± 0.12a 1.13 ± 0.19a,2 1.12 ± 0.25a,1,2 1.55 ± 0.27b,2 
18:1n-7 1.09 ± 0.06a 1.17 ± 0.08a 1.41 ± 0.11b 1.57 ± 0.14b,1,2 
18:1n-9 8.42 ± 0.69a 12.92 ± 1.88a 18.34 ± 2.67b,2 20.93 ± 5.16b,2 
Total MUFA 11.11 ± 0.74a 16.03 ± 2.11ab 21.26 ± 2.92bc,2 24.59 ± 5.43c,2 
18:2n-6 16.58 ± 0.69a 15.72 ± 0.62ab,2 14.25 ± 0.49b,2 16.11 ± 1.78a,2 
20:4n-6 30.28 ± 1.56a 23.59 ± 2.09b 16.64 ± 1.86c 17.30 ± 5.36c 
22:4n-6 0.17 ± 0.02a 0.18 ± 0.05a 0.48 ± 0.13b,2 0.11 ± 0.05a 
22:5n-6 0.11 ± 0.03a 0.10 ± 0.04a 0.76 ± 0.25b,2 0.07 ± 0.03a,2 
Total n-6 PUFA 47.85 ± 0.99a 40.43 ± 1.66b,2 33.04 ± 1.69c,2 34.92 ± 4.88c,2 
18:3n-3 0.40 ± 0.05ab 0.46 ± 0.08a,2 0.50 ± 0.08a,2 0.32 ± 0.05b 
20:5n-3 0.63 ± 0.10ab 0.78 ± 0.10a,1 0.40 ± 0.10c,1,2 0.60 ± 0.13b,1 
22:5n-3 0.25 ± 0.02ac 0.36 ± 0.11a 0.64 ± 0.11b,2 0.21 ± 0.05c,2 
22:6n-3 4.94 ± 0.38ac 6.14 ± 0.68a,1 9.64 ± 1.11b,1 3.73 ± 1.27c,1 
Total n-3 PUFA 6.23 ± 0.42ac 7.78 ± 0.77a,1 11.19 ± 1.03b,1 4.86 ± 1.31c,1 
Total FA (µg/100µL) 222 ± 13a 197 ± 25a 508 ± 166b 239 ± 23a 
TWD- Baseline 15d Preg 20d Preg 7d PP 
16:0 14.44 ± 1.17a 16.74 ± 0.46b 21.26 ± 0.81c 18.33 ± 2.21b,2 
18:0 16.23 ± 0.94a 14.78 ± 0.92ab 9.58 ± 0.51c 12.89 ± 2.11b 
Total SFA 33.46 ± 0.82ab 34.23 ± 0.87a,2 32.28 ± 0.90b,2 33.47 ± 0.15ab,2 
16:1 0.63 ± 0.17a 1.19 ± 0.13b,2 1.41 ± 0.18b,2 1.54 ± 0.43b,2 
18:1n-7 1.06 ± 0.05a 1.29 ± 0.09ab 1.43 ± 0.05b 1.72 ± 0.31c,2 
18:1n-9 7.73 ± 0.91a 13.09 ± 0.63b 21.17 ± 1.49c,3 22.82 ± 6.15c,2 
Total MUFA 10.14 ± 1.10a 16.39 ± 0.59b 24.37 ± 1.57c,2 26.58 ± 6.66c,2 
18:2n-6 15.51 ± 0.82 14.89 ± 1.012 14.93 ± 0.902 14.01 ± 1.182 
20:4n-6 34.22 ± 2.41a 27.09 ± 1.30b 17.27 ± 1.77c 19.46 ± 7.12c 
22:4n-6 0.22 ± 0.02a 0.24 ± 0.05a 0.68 ± 0.12b,2 0.16 ± 0.04a 
22:5n-6 0.28 ± 0.04a 0.32 ± 0.13a 2.24 ± 0.48b,3 0.34 ± 0.08a,1,2 
Total n-6 PUFA 50.99 ± 1.61a 43.50 ± 0.81b,1,2 36.43 ± 1.26c,2 35.70 ± 5.99c,2 
18:3n-3 0.36 ± 0.03a 0.47 ± 0.03b,2 0.51 ± 0.04b,2 0.23 ± 0.07c 
20:5n-3 0.41 ± 0.04a 0.39 ± 0.06a,2 0.26 ± 0.06b,2 0.24 ± 0.04b,2 
22:5n-3 0.36 ± 0.03a 0.36 ± 0.06a 0.63 ± 0.06b,2 0.30 ± 0.06a,2 
22:6n-3 3.43 ± 0.27a 3.74 ± 0.30a,2 3.96 ± 0.36a,2 1.65 ± 0.74b,2 
Total n-3 PUFA 4.57 ± 0.25a 4.98 ± 0.31ab,2 5.37 ± 0.33b,2 2.42 ± 0.71c,2 
Total FA (µg/100µL) 235 ± 27a 187 ± 20a 584 ± 64b 233 ± 50a 
Mean ± SD, n=6 for each group. Values with different alphabetical superscripts across time and different numerical superscripts 
across diet are significantly different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. SFA, saturated 
fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty acids, TWD total western diet with (+) 
or without (-) docosahexaenoic acid.  
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Appendix Table 5.2: Fatty acid composition (weight %) of maternal erythrocytes during pregnancy and postpartum 
Chow Baseline 15d Preg 20d Preg 7d PP 
16:0 23.25 ± 0.57a 22.14 ± 0.18b.1 25.10 ± 0.65c,1 24.67 ± 0.59c,1 
18:0 18.03 ± 0.38 17.96 ± 0.70 16.53 ± 1.65 16.66 ± 0.65 
24:0 1.32 ± 0.09 1.31 ± 0.101 1.30 ± 0.081 1.24 ± 0.081 
Total SFA 47.55 ± 0.65ab 48.21 ± 0.49a 47.06 ± 1.48ab,1 46.02 ± 1.13b,1 
18:1n-7 1.91 ± 0.11a 2.22 ± 0.09b 2.22 ± 0.10b 2.41 ± 0.22b 
18:1n-9 5.35 ± 0.24a 6.21 ± 0.42ab 5.97 ± 0.75ab,1 7.32 ± 1.43b,1 
24:1n-9 0.66 ± 0.05 0.64 ± 0.04 0.66 ± 0.071 0.65 ± 0.041 
Total MUFA 8.95 ± 0.26a 10.58 ± 0.82ab 9.55 ± 0.83ab 11.48 ± 2.15b 
18:2n-6 9.02 ± 0.46ab 8.28 ± 0.26a 8.82 ± 0.53a,1 9.75 ± 0.48b,1 
20:4n-6 22.70 ± 0.58a 22.47 ± 0.51ab 21.18 ± 1.10bc,1,2 20.36 ± 0.75c,1 
22:4n-6 1.81 ± 0.05a,1 1.67 ± 0.06b,1 1.64 ± 0.04bc,1 1.56 ± 0.08c,1 
22:5n-6 0.71 ± 0.03ab 0.61 ± 0.07a 0.86 ± 0.17bc,1 1.00 ± 0.17c,1 
Total n-6 PUFA 35.12 ± 0.62a 33.81 ± 0.55ab 33.26 ± 1.31b,1 33.55 ± 0.98b,1 
20:5n-3 0.22 ± 0.02a 0.27 ± 0.04b,1 0.22 ± 0.03a,1 0.28 ± 0.03b,1 
22:5n-3 1.69 ± 0.04a,1 1.59 ± 0.07ab,1 1.54 ± 0.11ab,1 1.52 ± 0.11b,1 
22:6n-3 2.42 ± 0.08a 2.75 ± 0.14a,1 3.80 ± 0.75b,1 2.70 ± 0.20a,1 
Total n-3 PUFA 4.44 ± 0.14a 4.73 ± 0.09a,1,2 5.70 ± 0.78b,1 4.63 ± 0.22a,1 
Total FA (mg/g) 2.07 ± 0.07ab 2.16 ± 0.06a 1.96 ± 0.12b,1 2.11 ± 0.13ab,1 
TWD+ Baseline 15d Preg 20d Preg 7d PP 
16:0 22.81 ± 0.63a 21.44 ± 0.55b,1,2 23.27 ± 0.88a,2 23.38 ± 1.04a,2 
18:0 18.18 ± 0.26a 18.84 ± 0.63a 16.91 ± 1.31b 15.94 ± 0.32b 
24:0 1.26 ± 0.11a 1.09 ± 0.07b,2 1.01 ± 0.06b,2 0.96 ± 0.10b,2 
Total SFA 47.08 ± 0.46a 47.77 ± 0.28a 45.16 ± 0.81b,2 44.21 ± 1.00b,2 
18:1n-7 1.83 ± 0.10a 1.96 ± 0.11ab 2.10 ± 0.18ab 2.23 ± 0.26b 
18:1n-9 6.41 ± 0.25a 7.40 ± 0.58ab 7.84 ± 0.90b,2 9.40 ± 1.29c,2 
24:1n-9 0.66 ± 0.09 0.69 ± 0.03 0.70 ± 0.081,2 0.74 ± 0.061,2 
Total MUFA 9.94 ± 0.35a 12.00 ± 0.78ab 11.60 ± 1.48ab 13.63 ± 2.08b 
18:2n-6 8.71 ± 0.45 7.82 ± 0.40 7.96 ± 0.581,2 8.62 ± 0.932 
20:4n-6 22.19 ± 0.49a 21.98 ± 0.49a 20.03 ± 0.27b,1 20.10 ± 0.79b,1 
22:4n-6 1.66 ± 0.05a,2 1.37 ± 0.03b,2 1.26 ± 0.04c,2 1.10 ± 0.08d,2 
22:5n-6 0.64 ± 0.03a 0.51 ± 0.03bc 0.54 ± 0.08b,2 0.43 ± 0.07c,2 
Total n-6 PUFA 34.05 ± 0.30a 32.50 ± 0.51b 30.51 ± 0.79c,2 31.03 ± 1.49bc,2 
20:5n-3 0.22 ± 0.03ab 0.29 ± 0.02c,2 0.21 ± 0.03a,1 0.28 ± 0.05bc,1 
22:5n-3 1.45 ± 0.05a,2 1.24 ± 0.04b,2 1.13 ± 0.04c,2 1.02 ± 0.07d,2 
22:6n-3 3.10 ± 0.19a 3.83 ± 0.19ab,2 5.36 ± 0.97c,2 4.57 ± 0.27bc,2 
Total n-3 PUFA 4.87 ± 0.20a 5.45 ± 0.17ab,1 6.78 ± 0.94c,2 5.96 ± 0.31b,2 
Total FA (mg/g) 2.09 ± 0.06a 2.25 ± 0.08bc 2.19 ± 0.07ab,2 2.34 ± 0.06c,2 
TWD- Baseline 15d Preg 20d Preg 7d PP 
16:0 22.46 ± 0.48a 20.78 ± 0.54b,2 23.36 ± 0.49c,2 23.46 ± 0.56c,1,2 
18:0 18.33 ± 0.35a 18.76 ± 0.40a 16.27 ± 0.46b 16.35 ± 1.03b 
24:0 1.26 ± 0.11a 1.14 ± 0.08ab,1,2 1.14 ± 0.07ab,1,2 1.04 ± 0.07b,2 
Total SFA 46.75 ± 0.32a 47.28 ± 0.70a 45.52 ± 0.80b,1,2 44.99 ± 0.90b,1,2 
18:1n-7 1.88 ± 0.04a 2.11 ± 0.11bc 2.06 ± 0.10ab 2.26 ± 0.19b 
18:1n-9 6.45 ± 0.33a 7.68 ± 0.58b 7.52 ± 0.37b,2 9.07 ± 0.85c,2 
24:1n-9 0.69 ± 0.05a 0.74 ± 0.06ab 0.82 ± 0.07b,2 0.82 ± 0.07b,2 
Total MUFA 10.07 ± 0.39a 12.52 ± 0.75b 11.18 ± 0.55a 13.09 ± 1.11b 
18:2n-6 8.74 ± 0.27a 7.30 ± 0.59b 7.35 ± 0.40b,2 8.32 ± 0.90a,2 
20:4n-6 22.60 ± 0.37ab 23.15 ± 0.85a 21.76 ± 0.45b,2 22.14 ± 0.73ab,2 
22:4n-6 1.72 ± 0.021,2 1.59 ± 0.091 1.70 ± 0.101 1.61 ± 0.111,2 
22:5n-6 0.71 ± 0.05a 0.61 ± 0.07a 1.19 ± 0.20b,3 1.03 ± 0.13b,1 
Total n-6 PUFA 34.63 ± 0.20a 33.39 ± 0.73bc 32.68 ± 0.25b,1 33.91 ± 0.31c,1 
20:5n-3 0.18 ± 0.02a 0.20 ± 0.02a,3 0.15 ± 0.01b,2 0.18 ± 0.03a,2 
22:5n-3 1.53 ± 0.08a,2 1.29 ± 0.06b,2 1.21 ± 0.08bc,2 1.16 ± 0.03c,2 
22:6n-3 2.58 ± 0.08a 2.77 ± 0.10a,1 3.55 ± 0.44b,1 2.40 ± 0.18a,1 
Total n-3 PUFA 4.40 ± 0.08a 4.35 ± 0.07a,2 4.99 ± 0.45b,1 3.83 ± 0.14c,1 
Total FA (mg/g) 2.11 ± 0.06a 2.22 ± 0.12ab 2.11 ± 0.09a,1 2.30 ± 0.07b,2 
Mean ± SD, n=6 for each group. Values with different alphabetical superscripts across time and different numerical superscripts 
across diet are significantly different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. SFA, saturated 
fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty acids, TWD total western diet with (+) 
or without (-) docosahexaenoic acid.  
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Appendix Table 5.3: Fatty acid composition (weight %) of maternal liver during pregnancy and postpartum 
Chow Baseline 15d Preg 20d Preg 7d PP 
16:0 17.40 ± 0.78a 16.75 ± 0.90a 20.77 ± 2.87b 16.22 ± 0.43a,1 
18:0 20.36 ± 1.54a 23.25 ± 0.99b,1 19.60 ± 1.69a,1 23.14 ± 0.89b,1 
Total SFA 39.95 ± 1.20a 42.26 ± 1.20b,1 42.50 ± 1.37b,1 41.57 ± 0.80ab,1 
16:1 0.61 ± 0.12 0.50 ± 0.24 0.42 ± 0.10 0.57 ± 0.101 
18:1n-7 1.70 ± 0.09a 1.55 ± 0.08ab 1.47 ± 0.18b 1.77 ± 0.16a 
18:1n-9 7.81 ± 2.721 6.42 ± 1.441 5.49 ± 1.161 7.54 ± 1.201 
Total MUFA 10.46 ± 2.841 8.85 ± 1.621 7.72 ± 1.391 10.25 ± 1.331 
18:2n-6 19.11 ± 1.19a 15.99 ± 2.17b 14.00 ± 2.57b 15.47 ± 0.92b,1 
20:4n-6 19.80 ± 1.93 20.97 ± 1.341 18.46 ± 2.111 19.72 ± 0.571 
Total n-6 PUFA 40.45 ± 2.69a 38.68 ± 1.37ab,1 36.53 ± 3.13b,1 38.27 ± 0.46ab,1 
18:3n-3 0.66 ± 0.11a 0.45 ± 0.18b 0.43 ± 0.10b 0.27 ± 0.04b 
20:5n-3 0.38 ± 0.07 0.38 ± 0.141 0.26 ± 0.08 0.36 ± 0.071 
22:5n-3 0.72 ± 0.19a 0.82 ± 0.13a,1 1.14 ± 0.25b,1 1.40 ± 0.15b,1 
22:6n-3 6.42 ± 0.78a 8.02 ± 1.43a,1,2 10.96 ± 2.98b,1 7.16 ± 0.54a,1 
Total n-3 PUFA 8.22 ± 0.55a,1,2 9.71 ± 1.31a,1,2 12.81 ± 3.05b,1 9.22 ± 0.56a,1 
Total (mg/g) 32.3 ± 4.6 31.7 ± 3.5 26.7 ± 5.0 28.4 ± 2.41 
TWD+ Baseline 15d Preg 20d Preg 7d PP 
16:0 18.76 ± 1.78a 19.10 ± 1.16a 21.16 ± 1.42ab 24.42 ± 3.43b,2 
18:0 17.50 ± 3.43a 18.48 ± 1.98a,2 15.24 ± 1.79a,2 9.64 ± 2.84b,2 
Total SFA 38.61 ± 2.03ab 39.52 ± 0.94a,1,2 38.06 ± 1.97ab,2 35.90 ± 1.89b,2 
16:1 0.78 ± 0.23a 0.86 ± 0.12a 0.94 ± 0.11a 2.83 ± 1.09b,2 
18:1n-7 1.66 ± 0.08 1.55 ± 0.07 1.65 ± 0.10 1.72 ± 0.31 
18:1n-9 12.73 ± 4.09a,2 15.47 ± 1.66a,2 17.27 ± 2.50a,2 31.46 ± 6.80b,2 
Total MUFA 15.47 ± 4.26a,1,2 18.24 ± 1.70a,2 20.18 ± 2.51a,2 36.30 ± 7.54b,2 
18:2n-6 18.73 ± 1.97a 15.26 ± 1.65ab 13.72 ± 3.10b 12.48 ± 2.97b,2 
20:4n-6 15.84 ± 3.52a 14.43 ± 1.72a,2 12.38 ± 1.33a,2 7.30 ± 2.98b,2 
Total n-6 PUFA 35.98 ± 3.13a 30.79 ± 0.75ab,2 28.04 ± 2.20b,2 20.89 ± 5.50c,2 
18:3n-3 0.70 ± 0.13a 0.47 ± 0.10b 0.48 ± 0.15b 0.31 ± 0.15b 
20:5n-3 0.37 ± 0.09ab 0.45 ± 0.06a,1 0.26 ± 0.11b 0.26 ± 0.13b,1,2 
22:5n-3 0.51 ± 0.14a 0.38 ± 0.06a,2 0.54 ± 0.14a,2 0.18 ± 0.09b,2 
22:6n-3 7.42 ± 0.91b 9.01 ± 0.96ab,1 11.34 ± 2.45a,1 4.48 ± 2.15c,1,2 
Total n-3 PUFA 9.04 ± 0.81b,1 10.35 ± 0.91ab,1 12.66 ± 2.30a,1 5.25 ± 2.44c,2 
Total (mg/g) 38.3 ± 8.9a 43.6 ± 6.3a 44.4 ± 8.1a 77.2 ± 33.3b,2 
TWD- Baseline 15d Preg 20d Preg 7d PP 
16:0 18.53 ± 1.19a 18.71 ± 0.90a 20.90 ± 0.66a 25.22 ± 3.07b,2 
18:0 17.51 ± 1.33a 17.20 ± 3.19a,2 16.60 ± 1.11a,1,2 9.97 ± 2.53b,2 
Total SFA 38.09 ± 0.54 38.42 ± 3.542 39.46 ± 1.212 37.13 ± 1.402 
16:1 0.83 ± 0.14a 1.04 ± 0.22a 1.07 ± 0.23a 3.24 ± 0.80b,2 
18:1n-7 1.82 ± 0.03 1.67 ± 0.05 1.64 ± 0.04 1.70 ± 0.29 
18:1n-9 14.70 ± 1.41a,2 17.44 ± 4.08a,2 16.00 ± 2.13a,2 33.58 ± 4.98b,2 
Total MUFA 17.72 ± 1.52a,2 20.47 ± 4.25a,2 19.03 ± 2.33a,2 38.80 ± 5.18b,2 
18:2n-6 17.72 ± 0.69a 15.90 ± 2.93a 11.95 ± 1.16b 9.39 ± 0.92b,2 
20:4n-6 16.74 ± 1.45a 15.42 ± 2.83a,2 15.02 ± 1.13a,1,2 8.27 ± 3.18b,2 
Total n-6 PUFA 35.95 ± 1.25a 32.87 ± 0.68ab,2 32.36 ± 1.24b,2 19.28 ± 4.20c,2 
18:3n-3 0.62 ± 0.06a 0.52 ± 0.19ab 0.35 ± 0.07b 0.16 ± 0.03c 
20:5n-3 0.26 ± 0.09a 0.23 ± 0.06ab,2 0.15 ± 0.04bc 0.10 ± 0.03c,2 
22:5n-3 0.47 ± 0.07a 0.42 ± 0.06a,2 0.68 ± 0.06b,2 0.27 ± 0.09c,2 
22:6n-3 5.58 ± 0.85a 5.76 ± 1.24a,2 6.73 ± 0.70a,2 2.30 ± 1.12b,2 
Total n-3 PUFA 6.95 ± 0.81a,2 6.97 ± 1.04a,2 7.94 ± 0.66a,2 2.83 ± 1.22b,2 
Total (mg/g) 37.6 ± 2.5a 49.3 ± 12.4a 37.5 ± 8.7a 73.1 ± 25.4b,2 
Mean ± SD, n=6 for each group. Values with different alphabetical superscripts across time and different numerical superscripts 
across diet are significantly different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. SFA, saturated 
fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty acids, TWD total western diet with (+) 
or without (-) docosahexaenoic acid.  
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Appendix Table 5.4: Fatty acid composition (weight %) of maternal adipose during pregnancy and postpartum 
Chow Baseline 15d Preg 20d Preg 7d PP 
16:0 23.17 ± 0.70 20.47 ± 2.12 21.33 ± 1.28 20.94 ± 1.24 
18:0 4.26 ± 0.31 4.88 ± 0.85 3.98 ± 0.32 4.77 ± 0.48 
Total SFA 29.53 ± 0.83 26.94 ± 2.49 26.88 ± 1.35 27.48 ± 1.30 
16:1 3.29 ± 0.46 2.42 ± 1.14 2.59 ± 0.63 2.13 ± 0.63 
18:1n-7 2.24 ± 0.11 2.22 ± 0.15 2.05 ± 0.13 2.12 ± 0.12 
18:1n-9 28.63 ± 3.56 27.29 ± 1.51 25.84 ± 0.70 27.24 ± 0.87 
Total MUFA 34.52 ± 4.02 32.28 ± 2.47 30.77 ± 1.16 31.89 ± 1.31 
18:2n-6 31.08 ± 4.15 35.38 ± 4.42 36.30 ± 1.89 35.55 ± 2.26 
20:4n-6 0.81 ± 0.22 0.79 ± 0.03 0.86 ± 0.11 0.79 ± 0.06 
22:4n-6 0.21 ± 0.06a 0.24 ± 0.03a 0.25 ± 0.02a 0.33 ± 0.04b 
22:5n-6 0.08 ± 0.02a 0.09 ± 0.02a 0.12 ± 0.02a 0.18 ± 0.04b 
Total n-6 PUFA 32.68 ± 4.48 37.01 ± 4.47 38.05 ± 2.05 37.41 ± 2.29 
18:3n-3 1.97 ± 0.26ab 2.13 ± 0.25ab 2.27 ± 0.17a 1.71 ± 0.16b 
20:5n-3 0.05 ± 0.02 0.08 ± 0.03 0.08 ± 0.02 0.04 ± 0.01 
22:5n-3 0.14 ± 0.05 0.17 ± 0.03 0.17 ± 0.03 0.19 ± 0.02 
22:6n-3 0.29 ± 0.02 0.36 ± 0.03 0.37 ± 0.06 0.37 ± 0.05 
Total n-3 PUFA 2.47 ± 0.34ab 2.77 ± 0.33ab 2.91 ± 0.27a 2.33 ± 0.20b 
Total FA (mg/g) 655 ± 116a 602 ± 46ab 867 ± 44c 450 ± 115b,1 
TWD+ Baseline 15d Preg 20d Preg 7d PP 
16:0 23.06 ± 1.42 22.51 ± 0.61 22.44 ± 0.85 22.04 ± 1.34 
18:0 4.44 ± 0.11 4.47 ± 0.23 4.57 ± 0.45 4.52 ± 0.55 
Total SFA 29.87 ± 1.68 29.76 ± 0.69 29.82 ± 0.78 29.50 ± 0.94 
16:1 3.37 ± 0.71 3.64 ± 0.27 3.51 ± 0.46 3.25 ± 0.77 
18:1n-7 2.09 ± 0.21a 2.18 ± 0.20ab 2.37 ± 0.13bc 2.50 ± 0.06c 
18:1n-9 32.43 ± 2.92a 39.33 ± 0.54b 39.58 ± 0.71b 40.63 ± 1.08b 
Total MUFA 38.26 ± 3.53a 45.58 ± 0.35b 45.90 ± 0.84b 46.87 ± 1.09b 
18:2n-6 27.53 ± 4.44a 20.89 ± 0.58b 20.65 ± 1.18b 20.66 ± 1.42b 
20:4n-6 0.62 ± 0.18a 0.34 ± 0.04b 0.35 ± 0.03b 0.30 ± 0.04b 
22:4n-6 0.15 ± 0.06a 0.07 ± 0.01b 0.08 ± 0.01b 0.09 ± 0.02b 
22:5n-6 0.05 ± 0.02a 0.03 ± 0.01b 0.04 ± 0.01ab 0.04 ± 0.01ab 
Total n-6 PUFA 28.78 ± 4.76a 21.65 ± 0.60b 21.43 ± 1.19b 21.42 ± 1.51b 
18:3n-3 1.74 ± 0.26a 1.22 ± 0.07b 1.19 ± 0.08b 1.02 ± 0.10b 
20:5n-3 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
22:5n-3 0.10 ± 0.04 0.07 ± 0.01 0.06 ± 0.01 0.06 ± 0.02 
22:6n-3 0.28 ± 0.08a 0.39 ± 0.07b 0.40 ± 0.03b 0.31 ± 0.05ab 
Total n-3 PUFA 2.17 ± 0.33a 1.72 ± 0.13b 1.69 ± 0.11b 1.44 ± 0.13b 
Total FA (mg/g) 667 ± 108a 666 ± 72a 834 ± 22b 673 ± 44a,2 
TWD- Baseline 15d Preg 20d Preg 7d PP 
16:0 22.03 ± 0.99ab 22.13 ± 0.97ab 23.10 ± 0.61a 20.80 ± 1.23b 
18:0 4.44 ± 0.20ab 4.13 ± 0.16a 4.28 ± 0.16a 4.95 ± 0.51b 
Total SFA 28.92 ± 0.96 28.68 ± 1.08 30.09 ± 0.70 28.60 ± 0.98 
16:1 2.04 ± 1.83a 4.00 ± 0.33b 4.01 ± 0.32b 2.65 ± 0.79ab 
18:1n-7 2.39 ± 0.06ac 1.95 ± 0.11b 2.27 ± 0.14a 2.57 ± 0.12c 
18:1n-9 34.18 ± 0.55a 39.60 ± 0.83b 39.94 ± 0.69b 41.27 ± 0.17c 
Total MUFA 39.01 ± 1.83a 45.99 ± 1.03b 46.68 ± 0.65b 47.01 ± 0.71b 
18:2n-6 26.60 ± 1.45a 21.13 ± 1.59b 19.98 ± 0.79b 21.37 ± 1.45b 
20:4n-6 0.63 ± 0.07a 0.43 ± 0.10b 0.37 ± 0.07b 0.31 ± 0.04b 
22:4n-6 0.18 ± 0.02a 0.11 ± 0.03b 0.10 ± 0.02b 0.11 ± 0.03b 
22:5n-6 0.07 ± 0.02 0.05 ± 0.02 0.06 ± 0.02 0.07 ± 0.01 
Total n-6 PUFA 27.92 ± 1.60a 22.08 ± 1.76b 20.81 ± 0.92b 22.19 ± 1.49b 
18:3n-3 1.64 ± 0.05a 1.25 ± 0.12b 1.14 ± 0.07b 0.91 ± 0.13c 
20:5n-3 0.03 ± 0.01a 0.03 ± 0.01ab 0.02 ± 0.01b 0.02 ± 0.01b 
22:5n-3 0.10 ± 0.01a 0.06 ± 0.02b 0.05 ± 0.01b 0.06 ± 0.01b 
22:6n-3 0.15 ± 0.02a 0.12 ± 0.03ab 0.09 ± 0.02b 0.08 ± 0.01b 
Total n-3 PUFA 1.93 ± 0.08a 1.47 ± 0.17b 1.31 ± 0.10bc 1.08 ± 0.14c 
Total FA (mg/g) 700 ± 47ab 735 ± 33ab 861 ± 83a 589 ± 195b,1,2 
Mean ± SD. Values with different alphabetical superscripts across time and different numerical superscripts across diet are 
significantly different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. SFA, saturated fatty acids; 
MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty acids, TWD total western diet with (+) or 
without (-) docosahexaenoic acid. Tissue collected was white perirenal adipose.  
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Appendix Table 5.5: Fatty acid composition (weight %) of maternal heart during pregnancy and postpartum 
Chow Baseline 15d Preg 20d Preg 7d PP 
16:0 15.72 ± 1.53a 13.03 ± 0.33b 13.27 ± 0.77b 12.59 ± 0.59b 
18:0 17.82 ± 3.53 20.96 ± 0.72 19.45 ± 1.01 19.85 ± 0.88 
Total SFA 38.20 ± 2.87a 37.92 ± 0.70ab 36.19 ± 0.65ab 35.52 ± 0.66b 
16:1 0.94 ± 0.59a 0.28 ± 0.07b 0.34 ± 0.13b 0.33 ± 0.05b 
18:1n-7 2.82 ± 0.12a 2.93 ± 0.08ab 2.77 ± 0.11a 3.01 ± 0.11b 
18:1n-9 9.68 ± 4.66 5.62 ± 0.90 6.68 ± 1.37 6.52 ± 1.321 
Total MUFA 14.21 ± 5.08 9.63 ± 1.04 10.36 ± 1.53 10.57 ± 1.461 
18:2n-6 19.90 ± 3.00 19.52 ± 1.941 19.34 ± 0.791 22.36 ± 1.281 
20:4n-6 13.62 ± 2.97a 16.61 ± 0.88b,1,2 17.67 ± 0.87b,1 15.97 ± 0.83ab 
22:4n-6 0.71 ± 0.10a 0.88 ± 0.10a,1 1.23 ± 0.16b,1 1.07 ± 0.07b,1 
22:5n-6 0.89 ± 0.21ab 0.83 ± 0.17a,1,2 1.31 ± 0.26bc,1 1.75 ± 0.36c,1 
Total n-6 PUFA 35.62 ± 2.22a 38.39 ± 1.17b,1 40.16 ± 0.59bc,1 41.89 ± 0.75c,1 
18:3n-3 0.56 ± 0.35 0.32 ± 0.05 0.38 ± 0.06 0.27 ± 0.06 
22:5n-3 1.32 ± 0.31a 1.48 ± 0.03ab,1 1.63 ± 0.10b,1 1.53 ± 0.05ab,1 
22:6n-3 8.71 ± 2.69 10.45 ± 0.781,2 10.08 ± 1.001 8.51 ± 1.471 
Total n-3 PUFA 10.70 ± 2.48 12.36 ± 0.69 12.19 ± 1.031 10.42 ± 1.381 
Total FA (mg/g) 36.8 ± 8.5a 26.3 ± 1.1b 31.1 ± 5.6ab 27.2 ± 1.2b 
TWD+ Baseline 15d Preg 20d Preg 7d PP 
16:0 15.22 ± 1.10a 14.90 ± 1.53ab 13.20 ± 0.51b 13.24 ± 1.16b 
18:0 20.02 ± 2.37 19.48 ± 1.98 19.89 ± 0.20 19.06 ± 1.55 
Total SFA 38.91 ± 2.03a 37.81 ± 0.86ab 36.59 ± 0.39bc 35.62 ± 0.61c 
16:1 0.69 ± 0.42 0.77 ± 0.56 0.38 ± 0.07 0.56 ± 0.29 
18:1n-7 2.87 ± 0.06a 2.78 ± 0.09a 2.84 ± 0.13a 3.06 ± 0.10b 
18:1n-9 8.61 ± 3.67 11.03 ± 3.51 9.23 ± 0.66 11.07 ± 3.681,2 
Total MUFA 12.85 ± 3.84 15.28 ± 4.02 13.09 ± 0.80 15.47 ± 4.141,2 
18:2n-6 17.48 ± 2.90 15.70 ± 1.022 14.35 ± 0.712 17.15 ± 2.262 
20:4n-6 15.19 ± 1.65ab 13.71 ± 1.95a,1 16.49 ± 0.89b,1 14.21 ± 1.67ab 
22:4n-6 0.67 ± 0.09a 0.45 ± 0.07b,2 0.63 ± 0.11a,2 0.61 ± 0.14ab,2 
22:5n-6 0.80 ± 0.11a 0.33 ± 0.07b,1 0.50 ± 0.07c,2 0.39 ± 0.05bc,2 
Total n-6 PUFA 34.64 ± 1.76a 30.68 ± 2.42b,2 32.51 ± 0.88ab,2 32.97 ± 2.63ab,2 
18:3n-3 0.39 ± 0.22 0.26 ± 0.09 0.20 ± 0.05 0.19 ± 0.05 
22:5n-3 1.16 ± 0.19a 0.74 ± 0.10b,2 0.84 ± 0.05b,2 0.73 ± 0.10b,2 
22:6n-3 11.22 ± 3.49a 13.37 ± 1.95ab,2 15.19 ± 0.83b,2 13.46 ± 1.64ab,2 
Total n-3 PUFA 12.87 ± 3.21 14.48 ± 1.97 16.31 ± 0.902 14.48 ± 1.692 
Total FA (mg/g) 31.9 ± 4.2 29.1 ± 3.1 30.3 ± 2.1 27.7 ± 3.8 
TWD- Baseline 15d Preg 20d Preg 7d PP 
16:0 14.56 ± 1.63 13.35 ± 0.51 12.91 ± 0.46 12.79 ± 1.29 
18:0 20.03 ± 1.28ab 21.22 ± 0.55a 19.68 ± 0.42ab 18.90 ± 1.44b 
Total SFA 38.46 ± 1.79a 38.35 ± 0.78a 35.96 ± 0.61b 35.22 ± 0.73b 
16:1 0.68 ± 0.28 0.41 ± 0.07 0.45 ± 0.08 0.61 ± 0.29 
18:1n-7 2.94 ± 0.15 2.93 ± 0.13 2.86 ± 0.08 3.03 ± 0.18 
18:1n-9 8.53 ± 2.31ab 8.30 ± 0.62a 10.81 ± 0.85ab 12.30 ± 4.05b,2 
Total MUFA 12.93 ± 2.36ab 12.48 ± 0.63a 14.65 ± 1.03ab 16.82 ± 4.13b,2 
18:2n-6 16.92 ± 1.31ab 15.78 ± 0.82ab,2 15.18 ± 1.01a,2 18.09 ± 2.19b,2 
20:4n-6 16.37 ± 1.91a 17.95 ± 0.53ab,2 18.88 ± 0.53b,2 16.36 ± 1.79a 
22:4n-6 0.83 ± 0.19a 0.84 ± 0.11a,1 1.10 ± 0.09b,1 1.02 ± 0.14ab,1 
22:5n-6 1.20 ± 0.46a 1.06 ± 0.35a,2 2.06 ± 0.43b,3 2.06 ± 0.54b,1 
Total n-6 PUFA 35.86 ± 1.80 36.12 ± 0.541 37.71 ± 0.971 38.15 ± 3.101 
18:3n-3 0.36 ± 0.11a 0.22 ± 0.03b 0.20 ± 0.02b 0.21 ± 0.05b 
22:5n-3 1.44 ± 0.22a 1.28 ± 0.09ab,1 1.15 ± 0.10b,3 1.20 ± 0.23ab,3 
22:6n-3 9.85 ± 2.71a 9.48 ± 0.36a,1 8.78 ± 0.66ab,1 6.69 ± 0.77b,1 
Total n-3 PUFA 11.75 ± 2.54a 11.08 ± 0.31a 10.19 ± 0.63ab,1 8.18 ± 0.95b,1 
Total FA (mg/g) 30.7 ± 4.2 26.7 ± 1.7 30.7 ± 2.5 29.7 ± 4.0 
Mean ± SD, n=6 for each group. Values with different alphabetical superscripts across time and different numerical superscripts 
across diet are significantly different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. SFA, 
saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty acids, TWD total western 
diet with (+) or without (-) docosahexaenoic acid.  
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Appendix Table 5.6: Fatty acid composition (weight %) of maternal brain during pregnancy and postpartum 
Chow Baseline 15d Preg 20d Preg 7d PP 
16:0 18.17 ± 0.71a 19.91 ± 1.18b 18.70 ± 0.89ab 19.96 ± 0.39b 
18:0 18.81 ± 0.34 19.22 ± 0.68 19.02 ± 0.33 18.60 ± 0.58 
24:0 1.19 ± 0.17a 0.89 ± 0.14b 0.93 ± 0.13b 0.85 ± 0.07b 
Total SFA 44.93 ± 0.69a 46.03 ± 1.28ab 46.60 ± 0.82b 46.40 ± 0.67b 
18:1n-7 3.52 ± 0.10 3.52 ± 0.19 3.67 ± 0.13 3.59 ± 0.06 
18:1n-9 16.14 ± 0.32 16.06 ± 0.41 16.83 ± 0.75 16.72 ± 0.47 
24:1n-9 1.68 ± 0.25 1.34 ± 0.27 1.48 ± 0.26 1.30 ± 0.15 
Total MUFA 24.80 ± 0.97 23.73 ± 1.15 25.72 ± 1.70 24.78 ± 0.88 
18:2n-6 0.92 ± 0.09 0.82 ± 0.07 0.83 ± 0.07 1.35 ± 1.01 
20:4n-6 8.95 ± 0.30 9.10 ± 0.62 8.87 ± 0.36 8.88 ± 0.40 
22:4n-6 2.96 ± 0.03a 2.73 ± 0.12b 2.65 ± 0.05b 2.74 ± 0.10b 
22:5n-6 0.61 ± 0.05ac 0.50 ± 0.05b 0.54 ± 0.04ab,1 0.63 ± 0.05c,1 
Total n-6 PUFA 14.09 ± 0.36 13.69 ± 0.68 13.42 ± 0.44 14.19 ± 0.701 
20:5n-3 0.01 ± 0.01 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
22:5n-3 0.16 ± 0.01a 0.13 ± 0.01b,1 0.14 ± 0.01b 0.16 ± 0.01a,1 
22:6n-3 12.12 ± 0.79 12.08 ± 0.88 11.82 ± 0.81 12.20 ± 0.56 
Total n-3 PUFA 12.32 ± 0.79 12.25 ± 0.88 12.00 ± 0.82 12.42 ± 0.53 
Total FA (mg/g) 41.8 ± 1.9 41.3 ± 1.8 44.1 ± 1.5 42.2 ± 1.7 
TWD+ Baseline 15d Preg 20d Preg 7d PP 
16:0 18.00 ± 0.18a 19.01 ± 0.64ab 18.91 ± 1.01ab 19.36 ± 0.52b 
18:0 18.88 ± 0.56 19.00 ± 0.27 18.82 ± 0.62 18.44 ± 0.36 
24:0 1.16 ± 0.12a 0.85 ± 0.17b 0.90 ± 0.21ab 0.94 ± 0.13ab 
Total SFA 45.41 ± 0.50 46.18 ± 0.95 46.49 ± 1.42 46.51 ± 0.42 
18:1n-7 3.49 ± 0.08 3.50 ± 0.28 2.95 ± 1.42 3.63 ± 0.18 
18:1n-9 16.13 ± 0.13 16.42 ± 0.96 17.06 ± 1.15 17.04 ± 0.64 
24:1n-9 1.66 ± 0.16 1.28 ± 0.29 1.40 ± 0.35 1.48 ± 0.19 
Total MUFA 24.79 ± 0.39 24.46 ± 2.09 25.18 ± 1.78 25.76 ± 1.42 
18:2n-6 0.86 ± 0.08 0.76 ± 0.06 1.08 ± 0.79 0.93 ± 0.18 
20:4n-6 8.86 ± 0.26 8.96 ± 0.42 8.58 ± 0.50 8.44 ± 0.39 
22:4n-6 2.91 ± 0.14a 2.70 ± 0.03b 2.55 ± 0.10b 2.58 ± 0.07b 
22:5n-6 0.57 ± 0.06a 0.44 ± 0.03b 0.40 ± 0.03bc,2 0.35 ± 0.03c,2 
Total n-6 PUFA 13.83 ± 0.40a 13.40 ± 0.45ab 13.16 ± 0.71ab 12.90 ± 0.45b,2 
20:5n-3 0.01 ± 0.01a 0.01 ± 0.01a 0.02 ± 0.01b 0.02 ± 0.01b 
22:5n-3 0.15 ± 0.01a 0.13 ± 0.01b,1,2 0.14 ± 0.01b 0.14 ± 0.01ab,1,2 
22:6n-3 12.19 ± 0.22 12.02 ± 0.65 12.34 ± 1.05 12.47 ± 0.48 
Total n-3 PUFA 12.37 ± 0.22 12.17 ± 0.65 12.54 ± 1.04 12.66 ± 0.47 
Total FA (mg/g) 41.5 ± 1.8a 41.5 ± 1.0a 44.9 ± 2.1b 40.6 ± 1.4a 
TWD- Baseline 15d Preg 20d Preg 7d PP 
16:0 17.69 ± 0.63a 19.45 ± 0.86b 19.08 ± 0.33ab 19.10 ± 1.38ab 
18:0 18.54 ± 0.30ab 18.92 ± 0.43ab 19.22 ± 0.49a 18.36 ± 0.64b 
24:0 1.28 ± 0.10a 0.92 ± 0.13b 0.90 ± 0.18b 0.95 ± 0.23b 
Total SFA 44.96 ± 0.38a 45.58 ± 1.19ab 46.69 ± 0.74b 46.15 ± 1.29ab 
18:1n-7 3.55 ± 0.04 3.51 ± 0.14 3.59 ± 0.19 3.81 ± 0.31 
18:1n-9 16.24 ± 0.34a 16.45 ± 0.28ab 16.72 ± 0.71ab 17.40 ± 1.12b 
24:1n-9 1.86 ± 0.16 1.42 ± 0.28 1.38 ± 0.32 1.62 ± 0.50 
Total MUFA 25.45 ± 0.80 24.48 ± 0.85 25.19 ± 1.56 26.81 ± 2.82 
18:2n-6 0.82 ± 0.02ab 0.70 ± 0.05a 0.86 ± 0.13b 0.85 ± 0.13b 
20:4n-6 8.75 ± 0.25 8.79 ± 0.40 9.20 ± 0.54 8.32 ± 0.89 
22:4n-6 2.90 ± 0.06a 2.64 ± 0.14b 2.75 ± 0.11ab 2.68 ± 0.22ab 
22:5n-6 0.58 ± 0.04ab 0.47 ± 0.07a 0.63 ± 0.09ab,1 0.64 ± 0.16b,1 
Total n-6 PUFA 13.71 ± 0.26 13.12 ± 0.55 13.96 ± 0.63 13.09 ± 1.082 
20:5n-3 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.04 ± 0.06 
22:5n-3 0.15 ± 0.01a 0.11 ± 0.01b,2 0.13 ± 0.01c 0.12 ± 0.01bc,2 
22:6n-3 11.84 ± 0.58 11.70 ± 0.67 11.84 ± 0.68 11.52 ± 0.98 
Total n-3 PUFA 12.02 ± 0.58 11.84 ± 0.68 12.01 ± 0.68 11.72 ± 0.98 
Total FA (mg/g) 42.8 ± 1.0 43.4 ± 1.5 41.0 ± 5.3 43.7 ± 1.9 
Mean ± SD. Values with different alphabetical superscripts across time and different numerical superscripts across diet are significantly different by Tukey’s HSD 
following a significant F-value (p< 0.05) by two-way ANOVA. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; 
FA, fatty acids, TWD total western diet with (+) or without (-) docosahexaenoic acid.  
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Appendix Table 5.7: Fatty acid composition (weight %) of the placenta during pregnancy 
 Chow TWD+ TWD- 
 15d Preg 20d Preg 15d Preg 20d Preg 15d Preg 20d Preg 
16:0 18.44 ± 0.74a 20.51 ± 0.90b 18.76 ± 0.92a 20.36 ± 0.47b 18.28 ± 0.77a 20.33 ± 0.63b 
18:0 20.32 ± 1.52a 15.42 ± 2.50c 20.21 ± 1.19a 17.44 ± 0.54b 20.64 ± 0.99a 17.20 ± 0.77b 
24:0 0.99 ± 0.16a 1.41 ± 0.44b 0.89 ± 0.10a 1.54 ± 0.23b 0.90 ± 0.13a 1.50 ± 0.17b 
Total SFA 44.43 ± 2.05a 40.86 ± 2.53b 44.68 ± 1.18a 43.88 ± 1.19a 44.44 ± 0.73a 43.21 ± 1.46a 
16:1 0.96 ± 0.27 1.03 ± 0.56 1.06 ± 0.15 0.83 ± 0.07 1.12 ± 0.23 0.88 ± 0.09 
18:1n-7 2.41 ± 0.17a 2.11 ± 0.18b 2.32 ± 0.24ab 2.16 ± 0.09b 2.41 ± 0.22a 2.15 ± 0.11b 
18:1n-9 10.12 ± 2.12a 12.37 ± 5.51ab 12.64 ± 1.76ab 13.88 ± 0.85b 12.48 ± 1.24ab 14.48 ± 1.19b 
Total MUFA 15.24 ± 2.33a 16.70 ± 5.91ab 17.97 ± 1.93ab 18.73 ± 1.03ab 17.96 ± 1.54ab 19.02 ± 1.34b 
18:2n-6 13.00 ± 2.46b 15.54 ± 3.40a 10.75 ± 1.15bc 10.61 ± 0.39c 10.18 ± 0.80c 10.36 ± 0.75c 
20:4n-6 16.23 ± 1.60bc 12.83 ± 2.88a 15.01 ± 1.00bc 14.35 ± 0.68ab 16.29 ± 0.89c 14.79 ± 0.63bc 
22:4n-6 3.21 ± 0.37a 2.28 ± 0.89bc 2.65 ± 0.23b 1.77 ± 0.25c 3.35 ± 0.36a 2.11 ± 0.23bc 
22:5n-6 0.48 ± 0.09a 1.40 ± 0.36b 0.32 ± 0.09a 1.15 ± 0.60b 0.57 ± 0.17a 2.53 ± 0.77c 
Total n-6 PUFA 34.94 ± 1.65a 33.58 ± 2.46ab 30.56 ± 1.36cd 29.37 ± 1.44d 32.23 ± 1.10bc 31.18 ± 1.11cd 
20:5n-3 0.25 ± 0.07ab 0.21 ± 0.06ab 0.28 ± 0.09a 0.21 ± 0.05ab 0.17 ± 0.05b 0.17 ± 0.08b 
22:5n-3 0.61 ± 0.08b 0.77 ± 0.22a 0.54 ± 0.08bc 0.55 ± 0.12bc 0.50 ± 0.11bc 0.43 ± 0.08c 
22:6n-3 2.33 ± 0.44a 3.13 ± 0.84bc 3.26 ± 0.40c 5.15 ± 0.87d 2.11 ± 0.25a 3.10 ± 0.85bc 
Total n-3 PUFA 3.65 ± 0.36ab 4.73 ± 0.85c 4.44 ± 0.46bc 6.22 ± 0.96d 3.13 ± 0.29a 3.98 ± 0.87abc 
Total FA (mg/g) 11.98 ± 1.31a 17.00 ± 5.35c 12.42 ± 0.84ab 16.40 ± 4.59bc 11.73 ± 1.19a 14.97 ± 0.83abc 
Mean ± SD, n=6 for each group. Values with a different superscript are significantly different by Tukey’s HSD following a significant F-
value (p< 0.05) by two-way ANOVA. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; 





Appendix Table 5.8: Fatty acid composition (weight %) of whole body fetuses and pups 
Chow 15d Preg 20d Preg 7d PP 
16:0 26.55 ± 0.72a 26.46 ± 0.79a 21.99 ± 0.83b 
18:0 14.43 ± 0.64a 13.14 ± 0.17a 9.10 ± 1.88b,1 
Total SFA 45.55 ± 0.61a 44.58 ± 0.75a 42.16 ± 1.28b,1 
16:1 2.59 ± 0.14a 2.74 ± 0.26a 0.99 ± 0.12b,1 
18:1n-7 3.51 ± 0.16a 3.44 ± 0.16a 2.02 ± 0.21b 
18:1n-9 15.79 ± 0.88 15.25 ± 0.45 15.75 ± 1.261 
Total MUFA 23.28 ± 0.87a 22.35 ± 0.84a 19.58 ± 1.13b,1 
18:2n-6 3.46 ± 0.29a 7.51 ± 0.70b 18.00 ± 2.25c,1 
20:4n-6 13.79 ± 0.77a 11.57 ± 0.13a 8.57 ± 1.99b,1 
22:4n-6 2.94 ± 0.30a 1.94 ± 0.08b 1.44 ± 0.29b,1 
22:5n-6 1.56 ± 0.23a 1.15 ± 0.13b,1 0.44 ± 0.14c 
Total n-6 PUFA 22.97 ± 0.80a,1 23.55 ± 0.77a,1 30.72 ± 0.89b,1 
20:5n-3 0.12 ± 0.08a 0.16 ± 0.04ab,1,2 0.25 ± 0.04b 
22:5n-3 0.26 ± 0.12a 0.46 ± 0.07a,1 1.02 ± 0.11b,1 
22:6n-3 2.59 ± 0.23a 4.37 ± 0.56b,1 2.56 ± 0.67a,1 
Total n-3 PUFA 3.13 ± 0.29a 5.24 ± 0.72b,1 4.65 ± 0.52b,1 
Total FA (mg/g) 8.24 ± 1.29a 11.37 ± 2.28a 33.57 ± 11.99b,1 
TWD+ 15d Preg 20d Preg 7d PP 
16:0 26.50 ± 0.35a 24.96 ± 0.55b 20.89 ± 0.68c 
18:0 13.91 ± 0.41a 13.17 ± 0.37a 6.87 ± 0.87b,2 
Total SFA 45.61 ± 0.65a 43.76 ± 0.83b 38.35 ± 0.62c,2 
16:1 2.65 ± 0.16a 2.59 ± 0.12a 1.53 ± 0.19b,2 
18:1n-7 3.58 ± 0.11a 3.36 ± 0.15b 2.28 ± 0.14c 
18:1n-9 17.09 ± 1.00a 16.74 ± 1.11a 30.22 ± 1.85b,2 
Total MUFA 24.77 ± 1.07a 24.02 ± 1.28a 34.94 ± 1.82b,2 
18:2n-6 3.18 ± 0.26a 6.33 ± 0.41b 12.64 ± 0.35c,2 
20:4n-6 12.60 ± 0.51a 10.96 ± 0.40b 4.14 ± 1.23c,2 
22:4n-6 2.56 ± 0.16a 1.66 ± 0.13b 0.83 ± 0.21c,2 
22:5n-6 1.21 ± 0.13a 0.69 ± 0.14b,2 0.11 ± 0.05c 
Total n-6 PUFA 20.69 ± 0.792 20.91 ± 0.762 19.56 ± 1.322 
20:5n-3 0.10 ± 0.05a 0.21 ± 0.04b,1 0.19 ± 0.02b 
22:5n-3 0.27 ± 0.07a 0.29 ± 0.09a,1,2 0.48 ± 0.13b,2 
22:6n-3 3.59 ± 0.35a 5.97 ± 0.54b,2 2.64 ± 0.81c,1 
Total n-3 PUFA 4.10 ± 0.30a 6.68 ± 0.61b,2 3.94 ± 0.90a,1 
Total FA (mg/g) 8.90 ± 0.84a 10.03 ± 0.57a 94.35 ± 35.17b,2 
TWD- 15d Preg 20d Preg 7d PP 
16:0 26.41 ± 0.86a 25.87 ± 0.75a 20.86 ± 1.52b 
18:0 13.82 ± 0.84a 12.98 ± 0.37a 6.43 ± 0.81b,2 
Total SFA 45.16 ± 0.94a 43.78 ± 1.12a 38.26 ± 2.41b,2 
16:1 2.68 ± 0.09a 2.70 ± 0.16a 1.55 ± 0.29b,2 
18:1n-7 3.53 ± 0.17a 3.45 ± 0.18a 2.24 ± 0.16b 
18:1n-9 17.01 ± 0.67a 17.62 ± 1.49a 31.36 ± 1.24b,2 
Total MUFA 24.44 ± 0.71a 24.87 ± 1.70a 36.06 ± 1.30b,2 
18:2n-6 3.74 ± 1.33a 6.21 ± 0.52b 12.71 ± 0.39c,2 
20:4n-6 12.92 ± 1.05a 11.73 ± 0.90a 4.34 ± 1.01b,2 
22:4n-6 2.64 ± 0.43a 2.06 ± 0.19a 0.99 ± 0.39b,1,2 
22:5n-6 1.63 ± 0.30a 1.85 ± 0.30a,3 0.30 ± 0.03b 
Total n-6 PUFA 22.04 ± 0.97ab,1,2 23.13 ± 1.19a,1,2 20.16 ± 1.77b,2 
20:5n-3 0.09 ± 0.02a 0.09 ± 0.05a,2 0.16 ± 0.02b 
22:5n-3 0.20 ± 0.10a 0.21 ± 0.12a,2 0.48 ± 0.10b,2 
22:6n-3 2.70 ± 0.60a 3.44 ± 0.41a,1 0.90 ± 0.22b,2 
Total n-3 PUFA 3.22 ± 0.68a 3.92 ± 0.35a,3 2.16 ± 0.26b,2 
Total FA (mg/g) 8.15 ± 1.20a 10.03 ± 0.22a 97.70 ± 19.51b,2 
Mean ± SD, n=6 for each group. Values with different alphabetical superscripts across time and different 
numerical superscripts across diet are significantly different by Tukey’s HSD following a significant F-value 
(p< 0.05) by two-way ANOVA. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 




Appendix Table 5.9: Fatty acid composition (weight %) of 7-day old pup tissues 
 Chow TWD+ TWD- 
Brain    
14:0 1.70 ± 0.22b 2.11 ± 0.37a 2.04 ± 0.30a 
16:0 31.52 ± 0.65a 31.45 ± 0.87a 30.44 ± 0.97b 
18:0 16.30 ± 0.46 16.24 ± 0.30 16.50 ± 0.35 
Total SFA 53.97 ± 1.21b 52.23 ± 1.17a 50.79 ± 1.44a 
16:1 1.47 ± 0.11a 1.45 ± 0.19a 1.29 ± 0.10b 
18:1n-7 2.20 ± 0.06 2.21 ± 0.09 2.21 ± 0.07 
18:1n-9 10.49 ± 0.76 10.59 ± 0.31 10.52 ± 0.39 
Total MUFA 14.77 ± 0.88 15.00 ± 0.96 14.51 ± 0.45 
18:2n-6 1.37 ± 0.88 0.91 ± 0.04 0.90 ± 0.08 
20:4n-6 12.21 ± 0.47a 11.93 ± 0.28a 13.40 ± 0.61b 
22:4n-6 2.40 ± 0.11a 2.44 ± 0.22a 2.89 ± 0.23b 
22:5n-6 1.61 ± 0.11c 1.15 ± 0.12a 2.65 ± 0.15b 
Total n-6 PUFA 18.24 ± 0.60c 17.09 ± 0.56a 20.46 ± 0.99b 
20:5n-3 0.03 ± 0.01ab 0.05 ± 0.02a 0.03 ± 0.01b 
22:5n-3 0.26 ± 0.02c 0.18 ± 0.02a 0.30 ± 0.05b 
22:6n-3 9.33 ± 0.39b 11.27 ± 0.68a 9.37 ± 0.56b 
Total n-3 PUFA 9.64 ± 0.37b 11.52 ± 0.70a 9.72 ± 0.57b 
Total FA (mg/g) 20.47 ± 1.37a 20.41 ± 2.00a 17.08 ± 1.39b 
Heart    
14:0 0.82 ± 0.48 0.95 ± 0.39 1.09 ± 0.23 
16:0 16.19 ± 0.77 16.69 ± 0.77 16.58 ± 0.66 
18:0 18.93 ± 1.32 19.27 ± 1.54 19.22 ± 1.25 
Total SFA 39.89 ± 1.04 40.54 ± 1.12 39.89 ± 2.19 
18:1n-7 3.18 ± 0.38 3.40 ± 0.14 3.37 ± 0.23 
18:1n-9 5.60 ± 1.58b 9.19 ± 3.29a 9.19 ± 2.17a 
Total MUFA 9.91 ± 1.42b 14.08 ± 3.32a 14.92 ± 4.36a 
18:2n-6 7.18 ± 1.09b 5.78 ± 0.76a 5.37 ± 0.42a 
18:3n-6 2.34 ± 0.88b 0.06 ± 0.02a 0.03 ± 0.01a 
20:3n-6 1.07 ± 0.10 1.17 ± 0.10 1.04 ± 0.17 
20:4n-6 23.18 ± 2.03 21.83 ± 2.38 22.89 ± 1.85 
22:4n-6 0.39 ± 0.96c 2.24 ± 0.24a 3.70 ± 0.45b 
22:5n-6 0.18 ± 0.47a 0.29 ± 0.09a 1.33 ± 0.22b 
Total n-6 PUFA 35.35 ± 1.28b 32.13 ± 1.91a 35.24 ± 1.99b 
20:5n-3 0.15 ± 0.28 0.05 ± 0.02 0.04 ± 0.01 
22:5n-3 0.23 ± 0.08b 0.15 ± 0.02a 0.10 ± 0.02a 
22:6n-3 6.68 ± 1.04c 10.09 ± 1.63a 4.67 ± 0.92b 
Total n-3 PUFA 10.30 ± 0.92a 11.83 ± 1.74a 7.44 ± 1.37b 
Total FA (mg/g) 23.98 ± 3.52b 19.17 ± 3.99ab 16.38 ± 4.06a 
Liver    
16:0 20.77 ± 1.05b 19.24 ± 1.46ab 19.06 ± 0.95a 
18:0 15.58 ± 0.87b 13.29 ± 2.26a 12.10 ± 1.78a 
Total SFA 39.05 ± 0.93b 35.20 ± 1.97a 34.21 ± 1.21a 
18:1n-7 1.38 ± 0.06b 1.61 ± 0.13a 1.58 ± 0.10a 
18:1n-9 3.71 ± 0.94b 10.46 ± 2.47a 12.09 ± 2.25a 
Total MUFA 5.83 ± 0.98b 13.11 ± 2.46a 14.76 ± 2.33a 
18:2n-6 9.73 ± 1.16 9.40 ± 1.05 9.87 ± 1.03 
20:4n-6 19.79 ± 0.75c 15.71 ± 2.01a 17.54 ± 0.92b 
22:4n-6 0.92 ± 0.11a 1.24 ± 0.34a 2.08 ± 0.75b 
22:5n-6 0.43 ± 0.07c 0.23 ± 0.11a 1.21 ± 0.23b 
Total n-6 PUFA 32.40 ± 1.30b 28.20 ± 1.44a 32.40 ± 0.94b 
20:5n-3 0.39 ± 0.11b 0.50 ± 0.08a 0.33 ± 0.06b 
22:5n-3 2.47 ± 0.29b 1.52 ± 0.27a 2.52 ± 0.66b 
22:6n-3 13.39 ± 1.50c 15.79 ± 1.13a 9.04 ± 1.57b 
Total n-3 PUFA 16.44 ± 1.39a 18.03 ± 1.17a 12.17 ± 1.66b 
Total FA (mg/g) 25.12 ± 5.06b 33.80 ± 9.05ab 35.39 ± 5.81a 
Mean ± SD, n=6 for each group. Values with a different superscript are significantly different by Tukey’s HSD following a significant F-value 
(p< 0.05) by one-way ANOVA. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty 
acids, TWD total western diet with (+) or without (-) docosahexaenoic acid 
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6 Sex Differences in Fatty Acid Compositions of Plasma, Liver, Brain, and Heart from Birth to 
Adulthood 
6.1 Introduction 
 The effects of estrogen on LCPUFA and long-chain MUFA and SFA synthesis from shorter 
chain precursors has been reported [15,105,112]. Sex differences have been reported to occur 
predominantly when diets are controlled for low DHA intakes [18]. However, recent studies reporting 
sexual dimorphisms in communication skills at 3 years of age following DHA supplementation during 
infancy [20], and the results from chapter 5 showing a sexual dimorphism in the brain DHA 
concentrations of 7-day pups warrant further investigation into when sexual dimorphisms in fatty status 
begin. To my knowledge, the fatty acid compositions of plasma, brain, heart, and liver of female and 
male pups from weeks 1 to 9 have not yet been examined. This study is the first, and provides insight 
into how tissue fatty acid compositions change during development in rats fed a regular chow diet. 
6.2  Methods 
6.2.1: Study Design 
 Five male and five female pups fed Teklad 22/5 Rodent Diet chow were sacrificed each week 
from weeks 1 to 9. Pups were sacrificed after an overnight fast, except for pups 1-3 weeks old who were 
left with their mothers until sacrifice. Plasma, RBC, brain, hearts, and livers were collected and analyzed 
by gas chromatography as described above. 
6.2.2 Diets 
 Rats were fed the chow diets outlined in Table 1 from weeks 4 to 9, and mothers at weeks 1 to 
three were fed chow as well. Since 1 to 3-week-old rats were not fasted, stomach contents were 
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collected, and their compositions at each week are outlined in Appendix Table 6.1 and Appendix Table 
6.2. 
6.2.3 Statistical Analyses 
All statistical analyses were performed using SPSS release 20.0 (IBM, Chicago, IL, USA). The 
effect of sex and time was examined across offspring tissue fatty acid and body weight data using a two-
way ANOVA with interactions. Differences in tissues across time were examined by one-way ANOVA. 
Individual means were compared by Tukey post hoc testing after significant F-value by ANOVA. All 
data are presented as means ± SD with significance accepted when p<0.05. 
6.3  Results 
6.3.1 Body Weights over Time 
 Males were significantly heavier than females from week 6 to week 9 (Figure 8). In both sexes, 
body weights increased each week except between weeks 2 and 3, and weeks 7 and 8, where body 
weights remained equal. 
6.3.2 Changes in the Fatty Acid Composition of Plasma 
Relative levels of DHA and n-3 docosapentaenoic acid (DPAn-3) were significantly affected by 
a sex x time interaction. Both DHA and DPAn-3 decreased below baseline at week 3 and returned to 
baseline levels at week 4. DPAn-3 then decreased below baseline again at week 5 in females and week 6 
in males (Appendix Table 6.3 and 6.4). At week 9, females had higher plasma relative levels of DHA 
than males (Figure 9). Relative levels of ALA were higher in males than females overall, but no sex x 
time interaction occurred in ALA relative levels or concentrations. No effect of sex was detected in 
DHA concentrations, which were highest in both sexes at weeks 2, 4, and 5.  
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Relative levels of ARA increased above baseline at week 5 in females, and week 7 in males and 
were higher in females at week 9 (Appendix Table 6.3 and Appendix Table 6.4 13). Conversely, while 
LA levels increased above baseline at week 3 and returned to baseline levels at week 4 in both sexes, LA 
levels in males increased above baseline again at week 9, and were higher than females at weeks 7, 8, 
and 9 (Figure 9). Concentrations of ARA were not different between sexes. Concentrations of LA were 
higher in males at weeks 7, 8, and 9. 
 In both sexes, total MUFA concentrations increased above baseline at week 5, before returning 
to baseline at week 7. Additionally, the relative composition of saturates were sexually dimorphic. 
Females had higher relative levels of 18:0 acid at weeks 7, 8, and 9, while males had higher levels of 
16:0 acid at weeks 8 and 9 (Appendix Table 6.3 and Appendix Table 6.4).  
 Total fatty acid concentrations in plasma were not significant for sex x time interactions or 
sexual dimorphisms but were affected by time. Fatty acid concentrations increased above baseline at 2, 
5, and 6 weeks of age (Appendix Table 6.3 and Appendix Table 6.4). 
6.3.3 Changes in the Fatty Acid Composition of Liver 
 Female livers had higher relative amounts of DHA than males at week 9, but males had higher 
concentrations at weeks 6 and 9 (Figure 9). In both sexes, relative compositions of DHA and total n-3 
PUFA decreased from weeks 2 to 9, while relative percent compositions of ALA increased from weeks 
1 to 9. In females, relative levels and concentrations of ALA increased and remained above baseline 
levels starting a week 3, whereas in males relative levels and concentrations of ALA increased above 
baseline levels at week 4 (Appendix Table 6.5 and Appendix Table 6.6). Fatty acid composition (weight %) 
of male liver). 
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Males had a higher relative composition of total hepatic n-6 PUFA than females at weeks 6, 8, 
and 9, but differences within individual fatty acids were subtle. There was a significant sex x time 
interaction for relative LA compositions, which increased above baseline at week 2 in females and at 
week 3 in males (Appendix Table 6.5 and Appendix Table 6.6). Relative ARA levels were higher in males 
than females at week 6, but concentrations of LA and ARA were not significant for sex differences or 
sex x time interactions.  
 Relative compositions of total MUFA increased above baseline at week 3 in both sexes, 
suggesting a weaning effect. A sex x time interaction was also shown in 18:1n-7 and 18:1n-9. In 
females, 18:1n-7 started at the same relative percentage as males, and remained at baseline levels at 
week 9, whereas males increased significantly. Relative percentages of 18:1n-9 for females were equal 
to males at baseline, but increased significantly for females while males remained at baseline levels at 
week 9. hepatic total SFAs had a significant time effect, and 16:0 and 18:0 were significant for sex x 
time interactions. Palmitic acid dropped from week 1 to 9, and at week 8, was significantly lower in 
females. Conversely, 18:0 increased from week 1 to 9, and was significantly higher in females at weeks 
8 and 9. Total concentrations were significant for sex differences, and were higher in females (Appendix 
Table 6.5 and Appendix Table 6.6). 
6.3.4 Changes in the Fatty Acid Composition of Heart and Brain 
 DHA concentrations in the brain were significantly higher in females, but there was no sex x 
time interaction, and relative compositions of DHA and ARA, and ARA concentrations showed no 
sexual dimorphisms (Figure 9). Interestingly, brain relative percentages of 18:2n-6 began at the same 
levels in males and females, but were higher in males at week 9 (Appendix Table 6.7 and Appendix 
Table 6.8 ).  
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Relative fatty acid compositions in brain and heart were affected primarily by time. In the brain, 
relative compositions of DHA in both sexes peaked at weeks 3, 4 and 5, while ARA composition was 
highest at week 1 and decreased until week 9. In the heart, DHA relative composition or concentrations 
were not significant for sex x time interactions (Figure 9) but were significantly higher in females 
(Appendix Table 6.9 and Appendix Table 6.10). Total fatty acid concentrations in the brain were affected 
by time, whereas those in the heart were more stable. Total fatty acid concentrations in the brain 
increased above baseline immediately from week 1 to 2, and peaked at weeks 6, 7, and 9, in both sexes. 
6.4 Discussion 
 To my knowledge, this study is the first to demonstrate that in the plasma and liver, 18 carbon 
PUFA increase above baseline levels in males before females, whereas LCPUFA increase above 
baseline in females first. This also appears to be the first study to show that total fatty acid 
concentrations in plasma, liver, brain, and heart peak during adolescence before decreasing entering 
adulthood.  
Higher levels of ARA in the plasma and liver of adult females, and LA in in that of adult males, 
have been reported previously [105,113] and are confirmed in this study. Sexual dimorphisms in 
circulating levels of DHA and ARA have been linked to differences in estrogen  [14,15,17]. In the rat, 
puberty begins in females and males at postnatal days 32-34 and 45-48 respectively [24,114,115]. This 
study goes to further show that these differences also interact with development. The relative percentage 
of plasma ARA increasing above baseline in females prior to males and remaining higher in females at 
adulthood supports the theory of elongation and desaturation being related to estrogen. However, further 




Elongation and desaturation enzymes critical to fatty acid remodelling and synthesis are found in 
the liver [116]. Greater relative percentages of DHA in female livers at week 9 despite similar relative 
percentages of ALA found in female and male livers at that time support previous reports of sexual 
dimorphisms in the expression and activity of elongase and desaturase enzymes [17,63], hepatic export 
and uptake of fatty acids [117–119], and fatty acid metabolism [120]. In particular, higher relative 
percentages of DHA in female livers despite similar ALA amounts supports previous data of females 
having greater expression and activity of delta 5 and delta 6 desaturase [105]. This increase in the 
relative percent of hepatic DHA in females as compared with the higher hepatic relative percentage of 
ARA in males, despite similar levels of LA, suggests females may also have a greater selectivity for 
elongating and desaturating DHA precursors.  
Concentrations and relative percentages of the DHA precursor ALA could be increasing above 
baseline earlier in female as compared with male livers due to a variety of mechanisms. Despite being 
low compared to adolescence and adulthood, estrogen levels are higher in prepubescent females than 
males [23], in rats, females begin adolescence earlier than males [24], and females have a higher 
expression of fatty acid transport proteins [117,118,121]. This, combined with the chow diet being 
composed of more ALA than DHA could explain the greater amounts of LCPUFA precursors in female 
livers, but further research is required to confirm which combination or individual mechanism leads to 
the earlier increase of hepatic ALA in females. 
Sex differences in liver and plasma fatty acids were not limited to PUFA. Sexual dimorphisms in 
relative percent [122] and concentrations of 16:0 and 18:0 of plasma is in agreement with previous 
animal models. Differences in plasma 16:0 concentrations alone has been shown in some animal models 
[112,123], and differences in 18:0 concentrations alone in others [122], but this study shows differences 
in both occurring simultaneously. Females show lower relative percentages of 16:0 starting at week 7, 
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and higher percentages of 18:0 at week 8. Relative percentages of 16:0 decrease from week 7 to week 9 
in both sexes. However, 18:0 increases from week 7 to week 9 in females only. No sex differences in 
MUFA were shown, although higher levels of 16:1 [112] and 18:1n-7 have been reported at later 
timepoints than those observed in this study [122]. This suggests that at a young age, females may have 
a greater ability to convert 16:0 to other fatty acids and are converting it to 18:0 at a greater rate than 
males. 
Hepatic sexual dimorphisms in 18:0, 18:1n-9 and 18:1n-7 concentrations [112,123] were 
confirmed, but differences in 16:0 [112] were not, possibly as a result of not separating PL from TAG 
and other lipid fractions. Higher relative percentages of hepatic 18:1n-7 in males, and nearly 
significantly higher hepatic levels of 18:1n9 in females at week 6 (p =0.059), occurred alongside higher 
relative percentages of 18:0 in females and higher amounts of 16:0 in males. This is in agreement with 
previous studies indicating that estradiol and progesterone increase the protein levels of stearoyl-CoA 
desaturase 1 (SCD1) [110], a delta-9 desaturase that desaturates 18:0 to 18:1n-9 [124]. However, these 
findings are not in agreement with previous findings of 18:1n-7 in the PL fraction being increased in 12 
week old ovariectomized rats given progesterone and estradiol [123]. This could be due to differences 
occurring in older age, an interaction with additional sex hormones affected by ovariectomy models, or 
differences in PL that were not detected in the total lipid extracts of this study.  
In contrast to the plasma and hepatic fatty acid changes, brain and heart tissue were relatively 
stable. There were no sex x time interactions for relative percentages or concentrations of DHA or ARA, 
but there was a sex difference for DHA concentrations being generally higher in female brain. The lack 
of sex differences in the relative percentage of DHA is in agreement with previous data [92,105]. In 
contrast to DHA, brain PUFA and MUFA did show sex x time interactions. The 18:1n-9 spike in 
females at week 6, and the nearly significant (p=0.055) sex differences in total brain fatty acid 
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concentrations were unexpected, but could have implications for sex differences shown in high fat diet 
rodent models [125].  
The heart had fewer significant concentration sex x time interactions than the brain, but relative 
percentage measures were similar, and in both the brain and the heart, LA had a significant sex x time 
interaction. The greater amounts of LA in the male brain is in agreement with previous data [126], but 
the greater amounts of LA in the male heart is not [105]. These sex differences in tissue LA relative 
percentages could be the result of higher levels of plasma LA in males, which are significantly higher 
beginning at week 7, being deposited at a greater rate in male tissues. 
In both sexes, the peaking of total fatty acids in plasma at weeks 2 and 5 suggest high amounts of 
fatty acid turnover during weaning and puberty, and higher circulating fatty acid concentrations at week 
5 appeared to increase the fatty acid concentrations of surrounding tissues. Total fatty acid 
concentrations in liver appeared to be reflected in plasma total fatty acid concentrations, with amounts 
peaking at week 5 before decreasing. This supports studies showing the liver playing a role in fatty acid 
remodelling [116], and the sexual dimorphisms in remodelling could play a role in sexual dimorphisms 
shown in other tissues [105]. Total fatty acid concentrations in the brain peaked at week 6, and were 
maintained at those concentrations for weeks 7 and 9, in agreement with findings that most fatty acid 
accumulation in the brain occurs during early development [3]. However, relative levels of fatty acids 
continued to change in the brain despite the steady total fatty acid concentration. As the brain developed, 
the relative percentage of ARA decreased in both sexes while DHA remained steady, supporting 
previous literature showing a specific need for DHA in the brain [73]. 
The design of this pilot study limited its findings. The fatty acid data is limited to total lipid fatty 
acid analyses, and differences between PL, TAG, and other lipid classes were not determined. Pups were 
chosen out of convenience and from mothers excluded by a previous study as a result of a failure to 
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observe the vaginal plug after breeding. As a result, the block design of the litters were limited to one 
litter per time point when multiple litters should have been used [127]. Pups being weaned abruptly at 3 
weeks of age could be affecting plasma and tissue concentrations at weeks 4 and 5, as free living rats are 
breastfed for longer, and weaned more gradually [128]. Additionally, sex hormones also factor into 
adipose tissue lipolysis [129], and sexual dimorphisms have been shown in intestinal fatty acid uptake 
[130–132]. Collecting adipose tissue and intestines could have provided more insights into how sexual 
dimorphisms in tissues were affecting sexual dimorphisms in the plasma, and vice versa. Finally, these 
findings are limited to rats fed a standard chow diet high in LA, and providing the rats with different 
diets during development could have interacted with changes in tissue fatty acid composition [126]. 
Further research including adipose tissue analysis, and the interaction of different diets and maturity on 
sexual dimorphisms should be conducted.  
6.5 Conclusion 
 This study confirms previous reports of sexual dimorphisms in n-3 and n-6 PUFA, SFA, and 
MUFA, and provides evidence that these dimorphisms interact with development. In chow fed rats, 
females have higher levels of circulating ARA beginning at 8 weeks of age, while males have higher 
levels of plasma LA beginning at weeks 7, which appear to influence brain and heart LA levels. Relative 
percentages of hepatic ALA and LA appear to increase above baseline earlier in females than males, 
potentially playing a role in DHA and ARA levels, which could impact development. Finally, the peak 
in total fatty acid concentrations occurring around puberty in plasma and brain suggest further research 
investigating the influence of diets, developmental stages, and sexual dimorphisms on tissue fatty acid 





Figure 8: Whole Body Weights *Significant sex differences, and letters represent significant time 
differences determined by Tukey’s post hoc following significant two-way ANOVA (p<0.05). Mean ± 






Figure 9: Relative percent (%wt) levels of LA, ARA and DHA in male and female tissues *Significant 
sex difference determined by Tukey’s post hoc following significant two-way ANOVA (p<0.05). Mean 




Appendix Table 6.1: Fatty acid composition (weight %) of female stomach contents 
 Week 1 Week 2 Week 3 




14:0 9.53 ± 0.75a 10.67 ± 0.55b 7.80 ± 0.54c 0.84 0.14 
16:0 22.90 ± 0.99a 23.79 ± 0.68a 17.18 ± 0.21b 0.91 0.09 
18:0 3.20 ± 0.18a 3.26 ± 0.11a 2.98 ± 0.03b 0.41 0.02 
22:0 0.04 ± 0.01a 0.04 ± 0.01a 0.08 ± 0.02b 0.63 0.66 
24:0 0.06 ± 0.01a 0.06 ± 0.01a 0.10 ± 0.02b 0.72 0.75 
Total SFA 53.91 ± 1.94a 57.91 ± 1.43b 50.95 ± 2.90a 0.68 0.67 
16:1 1.24 ± 0.11a 0.86 ± 0.06b 1.00 ± 0.05c 0.20 <0.01 
18:1n-7 1.34 ± 0.15a 0.96 ± 0.06b 1.07 ± 0.05b 0.91 0.04 
18:1n-9 15.26 ± 0.90a 13.77 ± 0.57b 14.35, ± 0.50ab 0.97 0.11 
24:1n-9 0.03 ± 0.01a 0.02, ± 0.01ab 0.02 ± 0.01b 0.71 0.56 
Total MUFA 18.20 ± 1.21a 15.89 ± 0.69b 16.70 ± 0.53b 0.94 0.07 
18:2n-6 20.75 ± 0.41a 21.02 ± 0.57a 27.43 ± 2.29b 0.62 0.97 
18:3n-6 0.52 ± 0.05a 0.32 ± 0.02b 0.13 ± 0.01c 0.14 0.14 
20:2n-6 0.59 ± 0.06a 0.43 ± 0.03b 0.24 ± 0.02c 0.53 0.03 
20:3n-6 0.64 ± 0.04a 0.32 ± 0.02b 0.12 ± 0.01c 0.84 0.37 
20:4n-6 1.40 ± 0.17a 0.80 ± 0.03b 0.50 ± 0.04c 0.59 0.04 
22:4n-6 0.29 ± 0.06a 0.15 ± 0.01b 0.09 ± 0.02b 0.53 0.02 
22:5n-6 0.05 ± 0.01a 0.03 ± 0.01b 0.03 ± 0.01b 0.24 0.03 
Total n-6 PUFA 24.28 ± 0.76a 23.10 ± 0.66a 28.55 ± 2.19b 0.62 0.94 
18:3n-3 1.79 ± 0.06a 2.01 ± 0.03a 2.88 ± 0.26b 0.57 0.58 
20:5n-3 0.45 ± 0.02a 0.35 ± 0.01b 0.28 ± 0.02c 0.36 0.91 
22:5n-3 0.36 ± 0.05a 0.30 ± 0.02b 0.22 ± 0.02c 0.76 0.04 
22:6n-3 0.43 ± 0.04a 0.33 ± 0.01b 0.35 ± 0.01b 0.74 0.58 
Total n-3 PUFA 3.10 ± 0.06a 3.06 ± 0.07a 3.77 ± 0.26b 0.56 0.79 
20:3n-9 0.06 ± 0.01a 0.04 ± 0.01b 0.04 ± 0.01b 0.36 0.03 
Total FA (mg/g) 262 ± 17a 264 ± 37a 115 ± 37b 0.56 0.94 
Mean ± SD, n=5. Different alphabetical superscripts represent differences across time and different numerical 
superscripts represent sex x time interactions significantly different by Tukey’s HSD following a significant F-value 
(p< 0.05) by two-way ANOVA. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 




Appendix Table 6.2: Fatty acid composition (weight %) of male stomach contents 
 Week 1 Week 2 Week 3 




14:0 9.71 ± 0.76ab 11.07 ± 0.15a 8.33 ± 1.13b 0.84 0.14 
16:0 22.88 ± 0.66a 24.18 ± 0.33b 17.52 ± 0.49c 0.91 0.09 
18:0 3.20 ± 0.14a 3.19 ± 0.05a 2.85 ± 0.12b 0.41 0.02 
22:0 0.04 ± 0.01a 0.04 ± 0.01a 0.09 ± 0.03b 0.63 0.66 
24:0 0.06 ± 0.01a 0.06 ± 0.01a 0.09 ± 0.02b 0.72 0.75 
Total SFA 54.65 ± 2.16ab 58.92 ± 0.51a 50.97 ± 4.50b 0.68 0.67 
16:1 1.18 ± 0.14a 0.82 ± 0.03b 0.90 ± 0.06b 0.20 <0.01 
18:1n-7 1.30 ± 0.14a 0.92 ± 0.03b 1.02 ± 0.06b 0.91 0.04 
18:1n-9 15.07 ± 1.01a 13.35 ± 0.24b 13.94 ± 0.82ab 0.97 0.11 
24:1n-9 0.03 ± 0.01a 0.02 ± 0.01a 0.02 ± 0.01a 0.71 0.56 
Total MUFA 17.91 ± 1.30a 15.37 ± 0.30b 16.13 ± 0.89b 0.94 0.07 
18:2n-6 20.54 ± 0.60a 20.62 ± 0.17a 27.91 ± 3.35b 0.62 0.97 
18:3n-6 0.48 ± 0.08a 0.30 ± 0.01b 0.13 ± 0.01c 0.14 0.14 
20:2n-6 0.64 ± 0.07a 0.41 ± 0.02b 0.20 ± 0.02c 0.53 0.03 
20:3n-6 0.64 ± 0.04a 0.31 ± 0.02b 0.11 ± 0.01c 0.84 0.37 
20:4n-6 1.35 ± 0.13a 0.77 ± 0.02b 0.46 ± 0.04c 0.59 0.04 
22:4n-6 0.30 ± 0.04a 0.14 ± 0.01b 0.08 ± 0.01c 0.53 0.02 
22:5n-6 0.05 ± 0.01a 0.03 ± 0.01b 0.02 ± 0.01b 0.24 0.03 
Total n-6 PUFA 24.03 ± 0.86a 22.61 ± 0.22a 28.92 ± 3.26b 0.62 0.94 
18:3n-3 1.78 ± 0.04a 2.01 ± 0.02a 2.99 ± 0.39b 0.57 0.58 
20:5n-3 0.46 ± 0.02a 0.34 ± 0.01b 0.29 ± 0.04b 0.36 0.91 
22:5n-3 0.39 ± 0.04a 0.28 ± 0.01b 0.20 ± 0.03c 0.76 0.04 
22:6n-3 0.43 ± 0.03a 0.33 ± 0.01b 0.35 ± 0.04b 0.74 0.58 
Total n-3 PUFA 3.13 ± 0.09a 3.02 ± 0.03a 3.87 ± 0.45b 0.56 0.79 
20:3n-9 0.06 ± 0.01a 0.04 ± 0.01b 0.03 ± 0.01b 0.36 0.03 
Total FA (mg/g) 271 ± 15a 272 ± 23a 105 ± 31b 0.56 0.94 
Mean ± SD, n=5. Different alphabetical superscripts represent differences across time and different numerical 
superscripts represent sex x time interactions significantly different by Tukey’s HSD following a significant F-value 
(p< 0.05) by two-way ANOVA. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids; FA, fatty acids. 
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Appendix Table 6.3: Fatty acid composition (weight %) of female plasma 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 
14:0 2.44 ± 0.75ab 3.14 ± 0.55a 2.17 ± 0.38b 0.68 ± 0.08c 0.40 ± 0.02c 0.43 ± 0.04c 0.36 ± 0.05c 0.31 ± 0.03c 0.25 ± 0.03c 
16:0 21.44 ± 1.166,7,8 22.99 ± 0.478 19.90 ± 0.274,5,6 18.37 ± 0.332,3,4 17.37 ± 0.482,3,4 19.30 ± 0.973,4,5 19.18 ± 1.463,4,5 16.76 ± 1.321,2 15.13 ± 0.611 
18:0 9.17 ± 0.441 9.57 ± 0.521 10.16 ± 0.621,2 10.30 ± 0.791,2,3 11.80 ± 1.202,3,4 11.89 ± 0.673,4 13.49 ± 0.964,5 15.15 ± 1.255,6 16.28 ± 0.556 
22:0 0.14 ± 0.01a 0.20 ± 0.02bcdf 0.18 ± 0.02abc 0.15 ± 0.03ab 0.22 ± 0.02cdef 0.20 ± 0.02bcdf 0.24 ± 0.02de 0.26 ± 0.06e 0.17 ± 0.02af 
24:0 0.38 ± 0.07ade 0.39 ± 0.03ab 0.42 ± 0.03ac 0.28 ± 0.04d 0.38 ± 0.03ade 0.45 ± 0.03bcefh 0.56 ± 0.04fg 0.59 ± 0.10g 0.39 ± 0.04adh 
Σ SFA 36.29 ± 1.354,5,6,7 38.70 ± 0.947 35.07 ± 0.473,4 31.26 ± 1.321,2 30.99 ± 0.951,2 34.80 ± 1.913,4 37.07 ± 1.424,5,6,7 35.53 ± 1.283,4,5,6 33.50 ± 0.712,3 
16:1 0.57 ± 0.09ad 0.43 ± 0.03a 0.47 ± 0.05ad 0.74 ± 0.11bce 0.75 ± 0.05be 0.89 ± 0.07b 0.76 ± 0.08be 0.57 ± 0.07acf 0.64 ± 0.11def 
18:1n-7 1.11 ± 0.05a 0.86 ± 0.02b 1.14 ± 0.04a 1.53 ± 0.15c 1.50 ± 0.09c 1.40 ± 0.08cd 1.23 ± 0.08ade 1.37 ± 0.11cef 1.19 ± 0.12af 
18:1n-9 7.63 ± 1.34ab 7.23 ± 0.46ab 7.84 ± 0.69ab 8.17 ± 0.87a 8.33 ± 0.83a 7.61 ± 0.33ab 6.48 ± 0.67bd 6.47 ± 0.72bcd 5.57 ± 0.35d 
24:1n-9 0.24 ± 0.04ad 0.17 ± 0.04bcg 0.22 ± 0.03abd 0.14 ± 0.02c 0.19 ± 0.02abc 0.28 ± 0.02dfh 0.36 ± 0.02e 0.35 ± 0.05ef 0.23 ± 0.03agh 
Σ MUFA 9.96 ± 1.432,3,4,5 9.20 ± 0.491,2,3,4 9.94 ± 0.722,3,4,5 10.78 ± 1.003,4,5,6 11.09 ± 0.875,6 10.37 ± 0.352,3,4,5,6 9.04 ± 0.761,2,3 9.02 ± 0.771,2 7.78 ± 0.391 
18:2n-6 21.15 ± 0.951,2,3,4 23.96 ± 0.264,5,6 29.77 ± 0.497 22.10 ± 1.912,3,4 24.12 ± 2.014,5,6 21.40 ± 0.991,2,3,4 18.63 ± 1.311 19.78 ± 2.511,2 18.44 ± 1.151 
18:3n-6 0.45 ± 0.042,3,4,5 0.33 ± 0.011,2 0.33 ± 0.061,2 0.59 ± 0.115,6 0.59 ± 0.064,5,6 0.56 ± 0.033,4,5,6 0.38 ± 0.072 0.37 ± 0.092 0.44 ± 0.042,3,4 
20:2n-6 0.38 ± 0.058,9 0.34 ± 0.027,8,9 0.26 ± 0.033,4,5 0.27 ± 0.024,5,6,7 0.26 ± 0.013,4,5 0.19 ± 0.011,2,3 0.17 ± 0.021 0.20 ± 0.061,2,3,4 0.17 ± 0.031,2 
20:3n-6 0.95 ± 0.038 0.67 ± 0.027 0.41 ± 0.024,5,6 0.28 ± 0.021,2 0.29 ± 0.021,2 0.25 ± 0.021 0.29 ± 0.031,2 0.35 ± 0.082,3,4,5 0.31 ± 0.041,2,3 
20:4n-6 19.78 ± 2.591,2,3,4 18.09 ± 1.321,2 16.30 ± 1.041 23.90 ± 1.814,5,6 24.43 ± 2.295,6,7 25.25 ± 1.265,6,7 27.78 ± 1.916,7 28.21 ± 3.337,8 32.14 ± 1.808 
22:4n-6 0.40 ± 0.04a 0.30 ± 0.02b 0.30 ± 0.06b 0.39 ± 0.04a 0.27 ± 0.02bc 0.22 ± 0.04c 0.23 ± 0.03bc 0.24 ± 0.04bc 0.26 ± 0.04bc 
22:5n-6 0.20 ± 0.032,3,4 0.12 ± 0.021,2,3,4 0.23 ± 0.064,5 0.33 ± 0.065,6 0.20 ± 0.012,3,4 0.22 ± 0.034 0.23 ± 0.144,5 0.15 ± 0.021,2,3,4 0.13 ± 0.031,2,3,4 
Σ n-6 PUFA 43.40 ± 1.74a 43.86 ± 1.51a 47.64 ± 1.02b 47.94 ± 0.85b 50.18 ± 0.68bc 48.20 ± 1.54b 47.85 ± 1.84b 49.42 ± 1.29bc 51.94 ± 1.03c 
18:3n-3* 0.66 ± 0.17ab 0.73 ± 0.10ab 0.97 ± 0.13a 0.92 ± 0.22ab 0.92 ± 0.15ab 0.87 ± 0.06ab 0.70 ± 0.17ab 0.65 ± 0.18ab 0.64 ± 0.10b 
20:5n-3* 1.14 ± 0.13acde 1.10 ± 0.07acdef 0.75 ± 0.04b 1.36 ± 0.23a 1.31 ± 0.13a 0.96 ± 0.11bc 0.87 ± 0.16bd 0.88 ± 0.10be 0.84 ± 0.09bf 
22:5n-3 1.45 ± 0.205,6 1.53 ± 0.096 0.99 ± 0.084 1.27 ± 0.095 0.82 ± 0.063,4 0.54 ± 0.061,2 0.39 ± 0.151 0.51 ± 0.041,2 0.54 ± 0.051,2 
22:6n-3 5.61 ± 0.748 4.44 ± 0.224,5,6 3.29 ± 0.171,2 5.24 ± 0.647,8 4.43 ± 0.114,5,6 3.81 ± 0.372,3,4 3.71 ± 0.301,2,3,4 3.67 ± 0.131,2,3 4.15 ± 0.233,4,5 
Σ n-3 PUFA 8.92 ± 0.85a 7.85 ± 0.27bd 6.05 ± 0.17c 8.84 ± 0.82ab 7.52 ± 0.40d 6.21 ± 0.51c 5.70 ± 0.52c 5.74 ± 0.24c 6.19 ± 0.19c 
20:3n-9 0.13 ± 0.03ab 0.14 ± 0.02a 0.15 ± 0.04a 0.15 ± 0.02a 0.09 ± 0.01bc 0.06 ± 0.01cd 0.04 ± 0.01d 0.04 ± 0.01de 0.05 ± 0.01cdf 
Σ FA (mg/g) 69 ± 13a 144 ± 22b 92 ± 18ac 94 ± 36ac 132 ± 22bcde 112 ± 11ab 97 ± 7ad 98 ± 22ae 82 ± 15a 
Mean ± SD, n=5. Different numerical superscripts represent sex x time interactions and different alphabetical superscripts represent differences across time that are significantly 
different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. *Indicates a significant main effect of sex by two-way ANOVA (p< 0.05). SFA, 




Appendix Table 6.4: Fatty acid composition (weight %) of male plasma 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 
14:0 2.68 ± 0.48a 2.94 ± 0.23a 1.92 ± 0.59b 0.73 ± 0.04c 0.49 ± 0.07c 0.49 ± 0.07c 0.38 ± 0.14c 0.31 ± 0.01c 0.28 ± 0.05c 
16:0 22.06 ± 1.507,8 22.96 ± 0.588 19.82 ± 0.664,5,6 18.90 ± 0.443,4,5 18.42 ± 0.622,3,4 20.58 ± 1.045,6,7 20.76 ± 0.685,6,7 19.83 ± 0.794,5,6 17.79 ± 0.792,3 
18:0 9.33 ± 0.561 9.89 ± 0.361 10.34 ± 0.581,2,3 9.45 ± 0.601 10.58 ± 1.331,2,3 10.17 ± 0.431,2 10.65 ± 0.411,2,3 10.74 ± 0.541,2,3 10.76 ± 0.461,2,3 
22:0 0.17 ± 0.07ab 0.19 ± 0.02abc 0.19 ± 0.02abcd 0.13 ± 0.01a 0.20 ± 0.02bcdf 0.24 ± 0.03cd 0.25 ± 0.01d 0.25 ± 0.02cde 0.15 ± 0.02af 
24:0 0.43 ± 0.05ae 0.39 ± 0.03ace 0.43 ± 0.03ae 0.28 ± 0.04b 0.34 ± 0.04bc 0.45 ± 0.04a 0.55 ± 0.04d 0.56 ± 0.07d 0.36 ± 0.01be 
Σ SFA 37.89 ± 1.565,6,7 38.09 ± 0.756,7 34.62 ± 0.863,4 30.78 ± 1.031 30.82 ± 0.801 34.43 ± 1.863,4 35.42 ± 0.543,4,5 34.96 ± 1.373,4 30.57 ± 0.441 
16:1 0.56 ± 0.03a 0.43 ± 0.01a 0.44 ± 0.02a 0.78 ± 0.11b 0.88 ± 0.09bc 0.96 ± 0.07c 0.76 ± 0.15b 0.55 ± 0.07a 0.55 ± 0.04a 
18:1n-7 1.06 ± 0.04a 0.88 ± 0.03b 1.12 ± 0.02a 1.54 ± 0.12cd 1.64 ± 0.06ce 1.57 ± 0.08cd 1.43 ± 0.05d 1.75 ± 0.08e 1.75 ± 0.08ef 
18:1n-9 7.46 ± 0.67adef 7.10 ± 0.29abf 7.34 ± 0.59acf 8.30 ± 0.76adeg 8.93 ± 0.65d 7.66 ± 0.90adef 7.00 ± 1.00bcef 6.61 ± 0.43f 6.93 ± 0.47bcfg 
24:1n-9 0.25 ± 0.02ad 0.18 ± 0.03bc 0.22 ± 0.02ab 0.14 ± 0.03c 0.17 ± 0.03bc 0.31 ± 0.02d 0.38 ± 0.02e 0.38 ± 0.05e 0.17 ± 0.03bc 
Σ MUFA 9.74 ± 0.682,3,4,5 9.05 ± 0.291,2,3 9.38 ± 0.631,2,3,4,5 10.92 ± 0.914,5,6 12.00 ± 0.686 10.72 ± 0.922,3,4,5,6 9.80 ± 1.182,3,4,5 9.56 ± 0.362,3,4,5 9.61 ± 0.462,3,4,5 
18:2n-6 20.57 ± 0.241,2,3 23.69 ± 0.583,4,5 30.14 ± 0.967 23.32 ± 1.343,4,5 25.85 ± 2.455,6 23.74 ± 1.853,4,5,6 22.08 ± 0.772,3,4 23.78 ± 2.453,4,5,6 27.04 ± 0.746,7 
18:3n-6 0.42 ± 0.032,3 0.34 ± 0.011,2 0.38 ± 0.072 0.64 ± 0.156 0.54 ± 0.103,4,5,6 0.33 ± 0.031,2 0.21 ± 0.031 0.21 ± 0.021 0.20 ± 0.051 
20:2n-6 0.41 ± 0.069 0.34 ± 0.026,7,8,9 0.25 ± 0.042,3,4 0.27 ± 0.044,5,6,7 0.25 ± 0.013,4 0.25 ± 0.043,4 0.23 ± 0.011,2,3,4 0.27 ± 0.023,4,5,6 0.33 ± 0.045,6,7,8 
20:3n-6 0.96 ± 0.088 0.67 ± 0.017 0.44 ± 0.046 0.26 ± 0.021,2 0.29 ± 0.031,2 0.34 ± 0.031,2,3,4,5 0.32 ± 0.031,2,3,4 0.40 ± 0.063,4,5,6 0.43 ± 0.065,6 
20:4n-6 19.36 ± 1.721,2,3 19.24 ± 0.791,2,3 17.19 ± 1.831 23.04 ± 1.853,4,5 21.53 ± 2.522,3,4,5 23.20 ± 1.213,4,5 25.29 ± 1.675,6,7 24.57 ± 1.625,6,7 24.56 ± 1.355,6,7 
22:4n-6 0.36 ± 0.02ac 0.27 ± 0.02bd 0.29 ± 0.04ab 0.37 ± 0.05c 0.27 ± 0.03bd 0.22 ± 0.02d 0.24 ± 0.02bd 0.23 ± 0.04bd 0.29 ± 0.05bd 
22:5n-6 0.13 ± 0.021,2,3,4 0.10 ± 0.011,2 0.23 ± 0.074,5 0.37 ± 0.056 0.21 ± 0.043,4 0.12 ± 0.021,2,3,4 0.11 ± 0.011,2,3 0.10 ± 0.021,2 0.07 ± 0.011 
Σ n-6 PUFA 42.28 ± 1.68a 44.69 ± 0.84a 48.99 ± 1.07b 48.32 ± 0.75b 49.00 ± 0.40b 48.32 ± 1.22b 48.61 ± 1.55b 49.68 ± 1.33b 52.97 ± 0.74c 
18:3n-3* 0.67 ± 0.07a 0.73 ± 0.06ab 0.87 ± 0.18ab 0.99 ± 0.18ab 1.03 ± 0.19b 0.90 ± 0.22ab 0.73 ± 0.12ab 0.76 ± 0.12ab 0.98 ± 0.15ab 
20:5n-3* 1.09 ± 0.07acf 1.07 ± 0.07acf 0.80 ± 0.05a 1.39 ± 0.20bg 1.39 ± 0.19b 1.13 ± 0.17bcdeg 0.97 ± 0.10adh 0.96 ± 0.08aeh 1.10 ± 0.17fgh 
22:5n-3 1.30 ± 0.135 1.45 ± 0.115,6 1.02 ± 0.134 1.32 ± 0.105,6 0.84 ± 0.053,4 0.60 ± 0.061,2 0.58 ± 0.051,2 0.59 ± 0.041,2 0.69 ± 0.132,3 
22:6n-3 5.10 ± 0.496,7,8 4.67 ± 0.175,6,7 3.29 ± 0.291,2 4.94 ± 0.086,7,8 4.63 ± 0.225,6,7 3.43 ± 0.431,2,3 3.39 ± 0.141,2 3.06 ± 0.161,2 3.02 ± 0.221 
Σ n-3 PUFA 8.22 ± 0.42a 7.95 ± 0.30a 6.01 ± 0.31b 8.67 ± 0.38a 7.94 ± 0.37a 6.10 ± 0.71b 5.70 ± 0.16b 5.41 ± 0.14b 5.83 ± 0.49b 
20:3n-9 0.11 ± 0.01ad 0.13 ± 0.01ab 0.16 ± 0.03b 0.15 ± 0.02bc 0.09 ± 0.01de 0.05 ± 0.01ef 0.04 ± 0.01f 0.04 ± 0.01fg 0.04 ± 0.01fh 
Σ FA (mg/g) 88 ± 17a 136 ± 13b 94 ± 25a 114 ± 19ab 131 ± 24b 109 ± 24ab 109 ± 4ab 105 ± 6ab 83 ± 7a 
Mean ± SD, n=5. Different numerical superscripts represent sex x time interactions and different alphabetical superscripts represent differences across time that are significantly 
different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. *Indicates a significant main effect of sex by two-way ANOVA (p< 0.05). SFA, 




Appendix Table 6.5: Fatty acid composition (weight %) of female liver 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 
14:0 0.91 ± 0.17ac 1.26 ± 0.15ab 1.43 ± 0.51b 0.59 ± 0.07cd 0.34 ± 0.02dg 0.28 ± 0.03deg 0.19 ± 0.02dfg 0.16 ± 0.02g 0.18 ± 0.02dgh 
16:0 23.26 ± 0.465 23.17 ± 0.255 20.16 ± 0.504 18.79 ± 0.383 17.49 ± 0.332 16.90 ± 0.312 16.37 ± 0.412 15.02 ± 0.801 16.47 ± 0.372 
18:0 15.94 ± 0.411,2,3 15.09 ± 0.531 15.77 ± 0.951,2 16.48 ± 0.571,2,3,4 17.37 ± 0.642,3,4,5 16.89 ± 1.301,2,3,4 20.03 ± 0.486,7 20.84 ± 1.637 20.19 ± 0.886,7 
22:0 0.17 ± 0.022,3,4 0.12 ± 0.011 0.14 ± 0.011,2 0.17 ± 0.022,3,4 0.19 ± 0.013,4,5 0.15 ± 0.021,2,3 0.19 ± 0.033,4,5 0.21 ± 0.024,5,6 0.14 ± 0.011,2 
24:0 0.53 ± 0.091,2,3,4,5 0.54 ± 0.042,3,4,5,6 0.49 ± 0.061,2,3 0.48 ± 0.051,2 0.52 ± 0.021,2,3,4,5 0.46 ± 0.061,2 0.60 ± 0.023,4,5,6,7 0.74 ± 0.068 0.44 ± 0.051,2 
Σ SFA 42.29 ± 0.51a 41.41 ± 0.39a 39.51 ± 0.28b 37.59 ± 0.86c 37.01 ± 0.47cd 35.76 ± 1.46d 38.55 ± 0.57bc 38.21 ± 1.14bc 38.50 ± 0.93bc 
16:1* 0.23 ± 0.04a 0.18 ± 0.02a 0.34 ± 0.14ab 0.48 ± 0.07b 0.53 ± 0.09bcd 0.70 ± 0.09d 0.52 ± 0.08bde 0.46 ± 0.13bf 0.48 ± 0.08bg 
18:1n-7 1.53 ± 0.033,4 1.31 ± 0.031,2 1.65 ± 0.044,5,6 1.74 ± 0.035,6,7 1.88 ± 0.077,8 1.89 ± 0.107,8,9 1.79 ± 0.165,6,7 1.89 ± 0.157,8,9 1.67 ± 0.094,5,6 
18:1n-9 3.77 ± 0.401 4.96 ± 0.351,2,3,4 7.14 ± 1.376,7 6.53 ± 0.584,5,6,7 6.73 ± 0.505,6,7 7.70 ± 0.797 5.87 ± 0.662,3,4,5,6 6.26 ± 0.954,5,6,7 5.91 ± 0.612,3,4,5,6 
24:1n-9* 0.25 ± 0.03a 0.21 ± 0.02acd 0.15 ± 0.03bef 0.17 ± 0.01bcef 0.20 ± 0.01bdg 0.15 ± 0.02e 0.20 ± 0.02dfg 0.22 ± 0.03ag 0.13 ± 0.02eh 
Σ MUFA 6.08 ± 0.381 6.88 ± 0.341,2,3 9.49 ± 1.554,5,6 9.09 ± 0.654,5,6 9.51 ± 0.625,6 10.61 ± 0.906 8.53 ± 0.573,4,5 9.00 ± 0.874,5,6 8.34 ± 0.613,4,5 
18:2n-6 11.87 ± 0.491 15.17 ± 0.472 19.63 ± 0.933,4,5,6 18.68 ± 0.843 20.77 ± 0.583,4,5,6,7 22.63 ± 1.237 19.75 ± 0.963,4,5,6 19.97 ± 1.593,4,5,6 19.77 ± 1.473,4,5,6 
18:3n-6 0.12 ± 0.011,2 0.04 ± 0.011 0.06 ± 0.011 0.45 ± 0.045,6 0.43 ± 0.084,5,6 0.50 ± 0.066 0.30 ± 0.103,4,5 0.35 ± 0.154,5,6 0.38 ± 0.064,5,6 
20:2n-6 0.48 ± 0.034,5,6 0.56 ± 0.025,6,7 0.56 ± 0.035,6,7 0.47 ± 0.023,4,5 0.46 ± 0.033,4,5 0.37 ± 0.021,2,3 0.34 ± 0.081 0.35 ± 0.091,2 0.34 ± 0.041 
20:3n-6 0.82 ± 0.027,8 0.75 ± 0.047 0.70 ± 0.026,7 0.33 ± 0.021 0.37 ± 0.021,2,3 0.32 ± 0.011 0.38 ± 0.041,2,3 0.47 ± 0.132,3,4,5 0.45 ± 0.061,2,3,4,5 
20:4n-6 19.29 ± 0.683,4,5,6 17.19 ± 0.321,2,3 15.69 ± 1.111 18.17 ± 0.722,3,4 18.54 ± 0.533,4,5 17.62 ± 0.831,2,3 21.39 ± 1.256,7,8 20.45 ± 1.235,6,7 20.97 ± 1.096,7,8 
22:4n-6 0.76 ± 0.036,7 0.67 ± 0.045,6 0.70 ± 0.136 0.55 ± 0.024,5 0.43 ± 0.021,2,3 0.40 ± 0.031,2,3 0.36 ± 0.041,2,3 0.41 ± 0.031,2,3 0.47 ± 0.043,4 
22:5n-6 0.24 ± 0.012,3,4 0.20 ± 0.011,2,3,4 0.50 ± 0.125 0.49 ± 0.085 0.26 ± 0.053,4 0.27 ± 0.053,4 0.16 ± 0.041,2,3,4 0.18 ± 0.071,2,3,4 0.20 ± 0.021,2,3,4 
Σ n-6 PUFA 33.63 ± 0.421 34.59 ± 0.221 37.86 ± 0.482 39.14 ± 0.303,4 41.27 ± 0.186,7 42.14 ± 0.637,8 42.70 ± 1.098,9 42.21 ± 0.457,8 42.60 ± 0.608,9 
18:3n-3 0.21 ± 0.031 0.42 ± 0.041,2,3,4 0.59 ± 0.123,4,5,6 0.69 ± 0.105,6 0.75 ± 0.095,6,7 0.99 ± 0.107 0.71 ± 0.155,6 0.77 ± 0.186,7 0.77 ± 0.155,6,7 
20:5n-3 0.43 ± 0.03acgi 0.52 ± 0.02abd 0.35 ± 0.03c 0.62 ± 0.14d 0.64 ± 0.05de 0.63 ± 0.06df 0.58 ± 0.10bdg 0.61 ± 0.09dh 0.60 ± 0.09bdi 
22:5n-3 2.37 ± 0.185,6 3.39 ± 0.127 2.50 ± 0.306 2.02 ± 0.114 1.44 ± 0.103 1.02 ± 0.051 0.86 ± 0.131 0.98 ± 0.051 0.98 ± 0.071 
22:6n-3 14.33 ± 0.697 12.44 ± 0.566 9.44 ± 1.224,5 10.44 ± 0.535 9.18 ± 0.374,5 8.19 ± 0.433,4 7.53 ± 0.522,3 7.60 ± 0.342,3 7.69 ± 0.552,3 
Σ n-3 PUFA 17.41 ± 0.507 16.85 ± 0.537 12.95 ± 1.375,6 13.82 ± 0.646 12.07 ± 0.334,5 10.87 ± 0.433,4 9.73 ± 0.522,3 10.00 ± 0.152,3 10.07 ± 0.372,3 
20:3n-9 0.08 ± 0.01ad 0.12 ± 0.01bc 0.12 ± 0.02b 0.09 ± 0.01ac 0.06 ± 0.01dgh 0.05 ± 0.01def 0.03 ± 0.01f 0.03 ± 0.01fg 0.03 ± 0.01fh 
Σ FA (mg/g) * 26 ± 4a 35 ± 2b 35 ± 6ab 44 ± 4cde 43 ± 2bc 48 ± 5c 41 ± 3bc 36 ± 5bd 38 ± 5be 
Mean ± SD, n=5. Different numerical superscripts represent sex x time interactions and different alphabetical superscripts represent differences across time that are significantly 
different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. *Indicates a significant main effect of sex by two-way ANOVA (p< 0.05). SFA, 




Appendix Table 6.6: Fatty acid composition (weight %) of male liver 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 
14:0 1.23 ± 0.44a 1.12 ± 0.04a 1.23 ± 0.22a 0.57 ± 0.14b 0.32 ± 0.03bc 0.26 ± 0.04bc 0.16 ± 0.01c 0.14 ± 0.01bd 0.19 ± 0.04bc 
16:0 23.20 ± 0.965 23.02 ± 0.365 20.39 ± 0.454 18.71 ± 0.583 17.52 ± 0.492 17.43 ± 0.612 17.38 ± 0.462 16.68 ± 0.372 17.48 ± 0.642 
18:0 15.07 ± 1.481 15.12 ± 0.241 15.88 ± 1.181,2 15.75 ± 1.131,2 17.65 ± 0.842,3,4,5 17.28 ± 0.632,3,4,5 19.05 ± 0.445,6,7 18.40 ± 0.334,5,6 17.95 ± 0.673,4,5 
22:0 0.17 ± 0.032,3 0.14 ± 0.011,2 0.15 ± 0.021,2 0.19 ± 0.023,4,5 0.19 ± 0.033,4,5 0.19 ± 0.013,4,5 0.24 ± 0.026 0.22 ± 0.015,6 0.14 ± 0.011,2 
24:0 0.62 ± 0.094,5,6,7 0.64 ± 0.025,6,7,8 0.51 ± 0.061,2,3,4 0.48 ± 0.071,2 0.50 ± 0.041,2,3,4,5 0.48 ± 0.031,2 0.65 ± 0.056,7,8 0.68 ± 0.037,8 0.41 ± 0.021 
Σ SFA 41.88 ± 0.27a 41.27 ± 0.35ab 39.56 ± 0.73bd 36.84 ± 1.50c 37.28 ± 1.34ce 36.72 ± 0.90c 38.77 ± 0.46defg 37.43 ± 0.23bf 37.39 ± 0.57cg 
16:1* 0.23 ± 0.02ae 0.17 ± 0.01a 0.31 ± 0.11aceg 0.55 ± 0.09bd 0.51 ± 0.06bd 0.60 ± 0.09b 0.44 ± 0.06cdf 0.34 ± 0.03efg 0.40 ± 0.11dg 
18:1n-7 1.45 ± 0.082,3 1.22 ± 0.011 1.61 ± 0.043,4,5 1.81 ± 0.036,7 1.89 ± 0.067,8,9 2.06 ± 0.089 1.99 ± 0.058,9 2.30 ± 0.1210 2.26 ± 0.1210 
18:1n-9 4.34 ± 0.681,2 4.51 ± 0.211,2,3 6.37 ± 0.744,5,6,7 7.03 ± 1.136,7 6.68 ± 1.215,6,7 6.07 ± 0.493,4,5,6,7 4.92 ± 0.381,2,3,4 5.11 ± 0.151,2,3,4,5 5.35 ± 0.651,2,3,4,5 
24:1n-9* 0.25 ± 0.03a 0.24 ± 0.01ac 0.18 ± 0.02bf 0.18 ± 0.02bde 0.20 ± 0.03bcde 0.17 ± 0.02bf 0.23 ± 0.02ad 0.23 ± 0.01ae 0.14 ± 0.01f 
Σ MUFA 6.57 ± 0.591,2 6.34 ± 0.201 8.66 ± 0.854,5 9.75 ± 1.215,6 9.45 ± 1.224,5,6 9.08 ± 0.504,5,6 7.74 ± 0.391,2,3,4 8.19 ± 0.152,3,4,5 8.36 ± 0.763,4,5 
18:2n-6 12.72 ± 1.321,2 14.42 ± 0.382 19.36 ± 1.463,4 19.67 ± 1.973,4,5,6 19.91 ± 1.533,4,5,6 21.95 ± 0.885,6,7 19.47 ± 0.893,4,5 21.62 ± 0.804,5,6,7 22.03 ± 0.586,7 
18:3n-6 0.14 ± 0.041,2,3 0.06 ± 0.041 0.05 ± 0.011 0.50 ± 0.146 0.41 ± 0.174,5,6 0.27 ± 0.032,3,4 0.14 ± 0.021,2,3 0.16 ± 0.031,2,3 0.16 ± 0.021,2,3 
20:2n-6 0.52 ± 0.034,5,6,7 0.52 ± 0.014,5,6,7 0.59 ± 0.057 0.47 ± 0.024,5 0.45 ± 0.032,3,4 0.50 ± 0.064,5,6,7 0.46 ± 0.033,4,5 0.51 ± 0.064,5,6,7 0.58 ± 0.066,7 
20:3n-6 0.89 ± 0.108 0.73 ± 0.017 0.74 ± 0.077 0.34 ± 0.021,2 0.37 ± 0.041,2,3 0.47 ± 0.053,4,5 0.45 ± 0.061,2,3,4 0.58 ± 0.115,6 0.58 ± 0.064,5,6 
20:4n-6 18.40 ± 1.403,4,5 18.10 ± 0.412,3,4 16.05 ± 1.091,2 17.79 ± 1.231,2,3 18.80 ± 1.353,4,5 19.97 ± 0.654,5,6,7 22.69 ± 0.838 21.30 ± 0.546,7,8 21.64 ± 0.537,8 
22:4n-6 0.82 ± 0.057 0.68 ± 0.026 0.64 ± 0.105,6 0.55 ± 0.044,5 0.44 ± 0.062,3,4 0.31 ± 0.081 0.33 ± 0.031,2 0.33 ± 0.031,2 0.33 ± 0.021,2 
22:5n-6 0.25 ± 0.033,4 0.19 ± 0.011,2,3,4 0.48 ± 0.135 0.50 ± 0.095 0.29 ± 0.104 0.13 ± 0.031,2,3 0.09 ± 0.011 0.10 ± 0.011,2 0.09 ± 0.021 
Σ n-6 PUFA 33.77 ± 0.381 34.72 ± 0.281 37.93 ± 0.402,3 39.84 ± 1.074,5 40.69 ± 0.555,6 43.62 ± 0.389,10 43.66 ± 0.499,10 44.63 ± 0.4510,11 45.44 ± 0.7611 
18:3n-3 0.30 ± 0.101,2 0.39 ± 0.021,2,3 0.51 ± 0.122,3,4,5 0.78 ± 0.176,7 0.67 ± 0.164,5,6 0.77 ± 0.135,6,7 0.53 ± 0.062,3,4,5,6 0.69 ± 0.075,6 0.70 ± 0.085,6 
20:5n-3 0.51 ± 0.07acefhi 0.56 ± 0.03abd 0.36 ± 0.05c 0.69 ± 0.12d 0.58 ± 0.09bdeg 0.62 ± 0.09bdfg 0.51 ± 0.03acghi 0.60 ± 0.03bdh 0.61 ± 0.09bdi 
22:5n-3 2.67 ± 0.326 3.25 ± 0.137 2.69 ± 0.166 2.02 ± 0.244,5 1.40 ± 0.102,3 1.17 ± 0.061,2,3 1.14 ± 0.121,2,3 1.19 ± 0.101,2,3 1.08 ± 0.101,2 
22:6n-3 13.86 ± 1.016,7 13.17 ± 0.356,7 10.05 ± 0.985 9.69 ± 0.985 9.53 ± 0.544,5 7.39 ± 0.162,3 7.20 ± 0.292,3 6.51 ± 0.401,2 5.71 ± 0.291 
Σ n-3 PUFA 17.40 ± 0.537 17.44 ± 0.457 13.69 ± 0.746 13.24 ± 0.895,6 12.24 ± 0.415 10.00 ± 0.292,3 9.43 ± 0.281,2 9.04 ± 0.371,2 8.16 ± 0.201 
20:3n-9 0.07 ± 0.01a 0.11 ± 0.01b 0.12 ± 0.03b 0.10 ± 0.02b 0.06 ± 0.01a 0.04 ± 0.01c 0.03 ± 0.01c 0.03 ± 0.01b 0.03 ± 0.01c 
Σ FA (mg/g) * 30 ± 2a 34 ± 1a 32 ± 2a 46 ± 6b 41 ± 2bcd 42 ± 3bcd 36 ± 3ac 35 ± 2a 36 ± 2ad 
Mean ± SD, n=5. Different numerical superscripts represent sex x time interactions and different alphabetical superscripts represent differences across time that are significantly 
different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. *Indicates a significant main effect of sex by two-way ANOVA (p< 0.05). SFA, 
saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty acids.   
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Appendix Table 6.7: Fatty acid composition (weight %) of female brain 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 
14:0 1.67 ± 0.097 0.95 ± 0.056 0.46 ± 0.062,3,4,5 0.33 ± 0.051,2,3 0.32 ± 0.091,2,3 0.27 ± 0.041,2 0.33 ± 0.101,2,3 0.39 ± 0.031,2,3,4 0.55 ± 0.054,5 
16:0 29.14 ± 0.51a 26.23 ± 0.44b 21.34 ± 1.01c 19.22 ± 1.16cd 18.63 ± 1.58df 17.61 ± 1.97de 20.24 ± 0.65cf 19.59 ± 1.29cd 19.26 ± 0.93cd 
18:0 15.78 ± 0.05a 17.34 ± 0.18b 18.61 ± 0.23c 19.17 ± 0.32cd 19.25 ± 0.22cde 19.56 ± 0.68de 20.09 ± 0.78e 19.38 ± 0.32cde 19.71 ± 0.34def 
22:0 0.06 ± 0.02a 0.18 ± 0.04ab 0.41 ± 0.10bc 0.53 ± 0.13c 0.57 ± 0.15cd 0.64 ± 0.22ce 0.44 ± 0.02bcf 0.48 ± 0.14cg 0.61 ± 0.11ch 
24:0 0.09 ± 0.03a 0.28 ± 0.07a 0.74 ± 0.19b 1.01 ± 0.22b 1.12 ± 0.29b 1.17 ± 0.34b 0.88 ± 0.03b 0.98 ± 0.25b 1.14 ± 0.20b 
Σ SFA 51.02 ± 0.47a 50.39 ± 0.43a 48.07 ± 0.59bc 47.06 ± 0.74bc 46.32 ± 0.87b 47.24 ± 1.47bc 48.22 ± 0.91c 47.34 ± 0.84bc 47.50 ± 0.62bc 
16:1 1.35 ± 0.035 0.82 ± 0.034 0.47 ± 0.032,3 0.36 ± 0.031,2 0.31 ± 0.031 0.37 ± 0.061,2,3 0.38 ± 0.021,2,3 0.38 ± 0.031,2,3 0.37 ± 0.051,2,3 
18:1n-7 2.32 ± 0.09a 2.70 ± 0.08b 3.00 ± 0.14bc 3.16 ± 0.08c 3.37 ± 0.23cdfgh 3.88 ± 0.36e 3.65 ± 0.05ef 3.58 ± 0.16eg 3.74 ± 0.19eh 
18:1n-9 10.36 ± 0.31a 11.19 ± 0.55ab 13.10 ± 0.83bc 14.51 ± 0.72cd 15.57 ± 1.15dfh 18.24 ± 1.78e 16.88 ± 0.29ef 16.24 ± 1.30deg 17.43 ± 1.03eh 
24:1n-9 0.07 ± 0.01a 0.18 ± 0.04a 0.51 ± 0.16ab 0.96 ± 0.25bc 1.15 ± 0.36cg 1.36 ± 0.50cdg 0.92 ± 0.03bce 1.12 ± 0.34cfg 1.56 ± 0.30g 
Σ MUFA 14.62 ± 0.41a 15.75 ± 0.75a 18.73 ± 1.42ab 21.34 ± 1.52bc 23.14 ± 2.42cg 28.09 ± 3.97d 24.69 ± 0.45cde 24.15 ± 2.37cdf 26.56 ± 2.06dg 
18:2n-6 1.22 ± 0.075 1.20 ± 0.055 1.30 ± 0.055 1.04 ± 0.063,4 1.02 ± 0.043,4 0.96 ± 0.072,3,4 0.84 ± 0.041,2 0.79 ± 0.061 0.76 ± 0.031 
18:3n-6 0.07 ± 0.017 0.02 ± 0.014,5,6 0.01 ± 0.011,2,3 0.01 ± 0.011,2,3 0.03 ± 0.016 0.01 ± 0.011,2,3,4 0.01 ± 0.011,2,3 0.01 ± 0.011,2,3 0.01 ± 0.011,2 
20:2n-6 0.16 ± 0.011 0.19 ± 0.011,2,3,4 0.24 ± 0.022,3,4 0.23 ± 0.021,2,3,4 0.24 ± 0.042,3,4 0.25 ± 0.064 0.18 ± 0.021,2,3 0.17 ± 0.021,2 0.18 ± 0.021,2,3,4 
20:3n-6* 0.48 ± 0.02ac 0.54 ± 0.02a 0.62 ± 0.05b 0.56 ± 0.03ab 0.54 ± 0.06ab 0.50 ± 0.07ac 0.43 ± 0.01cd 0.38 ± 0.03d 0.39 ± 0.02de 
20:4n-6 13.52 ± 0.18a 13.20 ± 0.30a 11.50 ± 0.65b 10.25 ± 0.51bc 9.99 ± 0.86c 8.17 ± 0.99d 9.75 ± 0.83ce 9.00 ± 0.69cdf 9.02 ± 0.48cdg 
22:4n-6 3.01 ± 0.073,4,5,6,7 3.07 ± 0.075,6,7 3.14 ± 0.067 3.01 ± 0.103,4,5,6,7 3.13 ± 0.096,7 2.75 ± 0.041,2 2.83 ± 0.171,2,3,4 2.70 ± 0.171 2.80 ± 0.081,2,3 
22:5n-6 1.42 ± 0.07a 1.21 ± 0.06b 0.89 ± 0.07c 0.77 ± 0.10cd 0.70 ± 0.10d 0.38 ± 0.08e 0.51 ± 0.04e 0.47 ± 0.09e 0.41 ± 0.07e 
Σ n-6 PUFA 19.89 ± 0.18a 19.45 ± 0.25a 17.73 ± 0.66b 15.91 ± 0.69c 15.69 ± 0.83c 13.06 ± 0.88d 14.57 ± 0.97cd 13.54 ± 0.83d 13.58 ± 0.57d 
18:3n-3 0.01 ± 0.01a 0.01 ± 0.01a 0.03 ± 0.01abc 0.03 ± 0.01bc 0.02 ± 0.01ab 0.04 ± 0.01c 0.03 ± 0.01cd 0.03 ± 0.01bce 0.04 ± 0.01cf 
20:5n-3 0.04 ± 0.01a 0.03 ± 0.01ab 0.03 ± 0.01abc 0.03 ± 0.01a 0.03 ± 0.01abc 0.02 ± 0.01bce 0.01 ± 0.01ce 0.02 ± 0.01bcde 0.01 ± 0.01e 
22:5n-3* 0.33 ± 0.02ab 0.34 ± 0.01a 0.29 ± 0.02bc 0.26 ± 0.02cd 0.24 ± 0.01d 0.15 ± 0.02e 0.15 ± 0.01e 0.15 ± 0.02e 0.14 ± 0.01e 
22:6n-3 12.19 ± 0.26ab 12.53 ± 0.18ab 13.31 ± 0.63a 13.40 ± 0.82a 13.66 ± 0.82a 11.08 ± 1.56b 12.19 ± 0.41ab 12.75 ± 1.20ab 11.93 ± 1.07ab 
Σ n-3 PUFA 12.58 ± 0.27ab 12.92 ± 0.18ab 13.67 ± 0.63a 13.75 ± 0.84a 13.95 ± 0.83a 11.30 ± 1.56b 12.40 ± 0.42ab 12.96 ± 1.20ab 12.14 ± 1.06ab 
20:3n-9 0.13 ± 0.01ab 0.14 ± 0.01a 0.11 ± 0.02bc 0.09 ± 0.01ceg 0.10 ± 0.02cde 0.08 ± 0.02eg 0.07 ± 0.01efg 0.06 ± 0.01g 0.07 ± 0.01gh 
Σ FA (mg/g) 22 ± 1a 30 ± 1b 34 ± 6b 36 ± 4b 36 ± 2b 56± 6c 48 ± 5cd 45 ± 4d 48 ± 3cd 
Mean ± SD, n=5. Different numerical superscripts represent sex x time interactions and different alphabetical superscripts represent differences across time that are significantly 
different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. *Indicates a significant main effect of sex by two-way ANOVA (p< 0.05). SFA, 
saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty acids.   
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Appendix Table 6.8: Fatty acid composition (weight %) of male brain 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 
14:0 1.82 ± 0.257 1.05 ± 0.046 0.44 ± 0.041,2,3,4,5 0.25 ± 0.111 0.60 ± 0.115 0.35 ± 0.041,2,3 0.42 ± 0.031,2,3,4,5 0.52 ± 0.063,4,5 0.62 ± 0.105 
16:0 29.82 ± 0.56a 26.50 ± 0.36b 21.86 ± 0.78c 18.45 ± 0.60d 19.19 ± 1.48d 19.73 ± 1.76cd 20.07 ± 0.81cd 18.85 ± 0.63d 18.61 ± 1.34d 
18:0 15.75 ± 0.25a 17.06 ± 0.20b 19.06 ± 0.57c 19.07 ± 0.32c 19.33 ± 0.68c 19.52 ± 0.60c 19.60 ± 0.24c 19.70 ± 0.43c 19.40 ± 0.59c 
22:0 0.05 ± 0.01a 0.19 ± 0.05ab 0.40 ± 0.02bc 0.59 ± 0.09c 0.62 ± 0.16cd 0.48 ± 0.17ce 0.44 ± 0.08cf 0.62 ± 0.04cg 0.64 ± 0.18ch 
24:0 0.09 ± 0.01a 0.29 ± 0.08ab 0.70 ± 0.02bde 1.14 ± 0.17c 1.23 ± 0.32c 0.89 ± 0.29cd 0.89 ± 0.15ce 1.28 ± 0.09c 1.16 ± 0.30c 
Σ SFA 51.52 ± 0.39a 50.28 ± 0.26a 47.80 ± 1.19beg 46.23 ± 0.27bc 46.40 ± 1.06bd 48.34 ± 1.23e 48.40 ± 0.53ef 47.61 ± 0.32beg 46.57 ± 1.02cdg 
16:1 1.49 ± 0.186 0.86 ± 0.034 0.49 ± 0.033 0.34 ± 0.011 0.33 ± 0.021 0.40 ± 0.051,2,3 0.36 ± 0.031,2 0.35 ± 0.021 0.32 ± 0.051 
18:1n-7 2.28 ± 0.05a 2.65 ± 0.11ab 2.99 ± 0.09bc 3.20 ± 0.12cfg 3.33 ± 0.28cde 3.65 ± 0.33eh 3.63 ± 0.15efh 3.55 ± 0.16egh 3.83 ± 0.29h 
18:1n-9 10.22 ± 0.36a 11.17 ± 0.52ab 13.14 ± 0.36bc 14.70 ± 0.76cd 15.83 ± 1.21dg 16.44 ± 1.78deg 16.66 ± 0.90dfg 17.29 ± 0.42g 17.77 ± 1.35gh 
24:1n-9 0.12 ± 0.10a 0.18 ± 0.05a 0.50 ± 0.06ab 1.07 ± 0.17bcg 1.22 ± 0.38cg 0.94 ± 0.38bcd 0.98 ± 0.12bce 1.53 ± 0.13cfg 1.59 ± 0.54g 
Σ MUFA 14.61 ± 0.40a 15.70 ± 0.72a 18.54 ± 0.34ab 21.86 ± 1.49bc 23.32 ± 2.53cg 24.71 ± 3.63cdg 24.85 ± 1.50ceg 25.90 ± 0.84cfg 27.21 ± 3.03g 
18:2n-6 1.23 ± 0.115 1.23 ± 0.035 1.23 ± 0.045 1.06 ± 0.054 1.07 ± 0.054 1.04 ± 0.063,4 0.98 ± 0.053,4 0.91 ± 0.052,3 0.98 ± 0.033,4 
18:3n-6 0.07 ± 0.017 0.03 ± 0.015,6 0.02 ± 0.013,4,5 0.02 ± 0.012,3,4,5 0.03 ± 0.015,6 0.01 ± 0.011,2,3 0.01 ± 0.011,2,3 0.01 ± 0.011,2,3 0.01 ± 0.011 
20:2n-6 0.16 ± 0.011 0.19 ± 0.011,2,3,4 0.22 ± 0.021,2,3,4 0.25 ± 0.044 0.24 ± 0.053,4 0.24 ± 0.052,3,4 0.24 ± 0.022,3,4 0.23 ± 0.021,2,3,4 0.24 ± 0.053,4 
20:3n-6* 0.46 ± 0.02a 0.55 ± 0.03b 0.62 ± 0.01b 0.59 ± 0.05b 0.57 ± 0.06b 0.46 ± 0.06a 0.46 ± 0.03a 0.44 ± 0.02a 0.44 ± 0.04a 
20:4n-6 13.34 ± 0.16a 13.21 ± 0.42ab 11.81 ± 0.26bc 10.59 ± 0.76cd 10.17 ± 0.99dg 9.32 ± 1.01deg 9.27 ± 0.63dfg 8.88 ± 0.33g 8.99 ± 0.99gh 
22:4n-6 2.97 ± 0.062,3,4,5,6,7 3.02 ± 0.023,4,5,6,7 3.14 ± 0.137 3.16 ± 0.117 3.06 ± 0.064,5,6,7 2.71 ± 0.121 2.80 ± 0.131,2,3 2.89 ± 0.141,2,3,4,5 2.90 ± 0.071,2,3,4,5,6 
22:5n-6 1.49 ± 0.12a 1.19 ± 0.04b 0.89 ± 0.04c 0.81 ± 0.10cd 0.71 ± 0.12d 0.49 ± 0.11e 0.42 ± 0.06e 0.41 ± 0.03e 0.35 ± 0.05e 
Σ n-6 PUFA 19.76 ± 0.23a 19.43 ± 0.42ab 17.96 ± 0.43bc 16.55 ± 0.84cd 15.90 ± 1.02de 14.31 ± 1.07ef 14.22 ± 0.69f 13.78 ± 0.40fg 13.94 ± 0.97fh 
18:3n-3 0.02 ± 0.01ab 0.01 ± 0.01a 0.03 ± 0.01bcf 0.02 ± 0.01abc 0.01 ± 0.01ab 0.04 ± 0.01cf 0.04 ± 0.01cdf 0.04 ± 0.01cef 0.04 ± 0.01f 
20:5n-3 0.04 ± 0.01a 0.03 ± 0.01abc 0.03 ± 0.01abc 0.04 ± 0.02ab 0.02 ± 0.01bcd 0.02 ± 0.01cd 0.01 ± 0.01d 0.01 ± 0.01de 0.02 ± 0.01cdf 
22:5n-3* 0.34 ± 0.02ab 0.34 ± 0.03a 0.29 ± 0.03b 0.30 ± 0.02ab 0.25 ± 0.01c 0.19 ± 0.02d 0.18 ± 0.02d 0.17 ± 0.01d 0.17 ± 0.01d 
22:6n-3 12.10 ± 0.17ab 12.57 ± 0.22ab 13.50 ± 0.34a 13.56 ± 0.86a 13.11 ± 0.75ab 12.06 ± 1.48ab 11.93 ± 0.74ab 11.61 ± 0.83b 11.98 ± 1.09ab 
Σ n-3 PUFA 12.51 ± 0.17ab 12.98 ± 0.21ab 13.86 ± 0.35a 13.95 ± 0.86a 13.40 ± 0.75ab 12.32 ± 1.48ab 12.18 ± 0.74ab 11.85 ± 0.83b 12.21 ± 1.09ab 
20:3n-9 0.13 ± 0.02a 0.14 ± 0.01a 0.10 ± 0.01bc 0.11 ± 0.02ab 0.10 ± 0.01b 0.07 ± 0.02cf 0.07 ± 0.01cdf 0.07 ± 0.01cef 0.06 ± 0.01f 
Σ FA (mg/g) 22 ± 1a 30 ± 1ab 34 ± 2b 32 ± 3bc 37 ± 3bdf 47 ± 5e 47 ± 2e 46 ± 4ef 47 ± 9e 
Mean ± SD, n=5. Different numerical superscripts represent sex x time interactions and different alphabetical superscripts represent differences across time that are significantly 
different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. *Indicates a significant main effect of sex by two-way ANOVA (p< 0.05). SFA, 
saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty acids.   
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Appendix Table 6.9: Fatty acid composition (weight %) of female heart 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 
14:0 1.23 ± 0.18a 1.39 ± 0.25a 1.61 ± 0.43a 0.65 ± 0.27b 0.39 ± 0.23bc 0.15 ± 0.10c 0.22 ± 0.11bc 0.33 ± 0.09bc 0.24 ± 0.13bc 
16:0 18.62 ± 0.49a 18.53 ± 0.31a 17.69 ± 0.49a 14.41 ± 0.63b 13.74 ± 0.46bc 13.11 ± 0.85bc 12.72 ± 0.93c 13.15 ± 0.49bc 13.17 ± 1.31bc 
18:0 19.01 ± 0.45ab 18.73 ± 0.53ab 17.80 ± 0.71a 19.15 ± 0.89ab 19.72 ± 0.79ab 20.20 ± 1.05ab 20.49 ± 1.23b 20.08 ± 2.25ab 20.16 ± 1.35ab 
22:0 0.17 ± 0.02a 0.19 ± 0.01ad 0.25 ± 0.01be 0.31 ± 0.02c 0.25 ± 0.03be 0.25 ± 0.02b 0.21 ± 0.02def 0.24 ± 0.02bf 0.10 ± 0.01g 
24:0 0.23 ± 0.02acd 0.25 ± 0.01a 0.27 ± 0.01a 0.25 ± 0.02a 0.17 ± 0.02b 0.19 ± 0.02bc 0.17 ± 0.03b 0.20 ± 0.02bd 0.09 ± 0.02e 
Σ SFA 
42.92 ± 
0.273,4,5 43.09 ± 0.203,4,5 41.13 ± 0.443 38.24 ± 0.452 37.22 ± 0.371,2 37.12 ± 0.451,2 37.64 ± 0.501,2 37.63 ± 2.001,2 37.15 ± 0.471,2 
16:1 0.47 ± 0.14 0.22 ± 0.02 0.20 ± 0.05 0.21 ± 0.05 0.35 ± 0.09 0.39 ± 0.18 0.31 ± 0.18 0.38 ± 0.15 0.39 ± 0.19 
18:1n-7 3.42 ± 0.07ac 3.46 ± 0.10ab 3.71 ± 0.17b 3.49 ± 0.13ab 3.40 ± 0.12ac 3.48 ± 0.20ab 3.22 ± 0.15acd 3.14 ± 0.04cd 3.01 ± 0.12d 
18:1n-9 6.48 ± 1.08a 4.43 ± 0.52ab 3.82 ± 0.65b 4.23 ± 1.12ab 5.09 ± 0.92ab 4.95 ± 1.52ab 4.34 ± 1.38ab 5.14 ± 1.22ab 4.83 ± 1.87ab 
24:1n-9 0.16 ± 0.01a 0.12 ± 0.01b 0.11 ± 0.02b 0.10 ± 0.01b 0.06 ± 0.01c 0.06 ± 0.01c 0.07 ± 0.01c 0.07 ± 0.01c 0.05 ± 0.01c 
Σ MUFA 11.27 ± 1.15a 8.95 ± 0.47ab 8.38 ± 0.54b 8.61 ± 1.04ab 9.44 ± 0.89ab 9.47 ± 1.54ab 8.71 ± 1.41ab 9.46 ± 1.34ab 9.02 ± 1.95ab 
18:2n-6 8.88 ± 0.791 10.73 ± 0.671 15.74 ± 0.652 17.05 ± 2.472,3 19.85 ± 1.373,4,5 18.17 ± 1.462,3,4 18.85 ± 1.202,3,4,5 19.87 ± 2.573,4,5 19.53 ± 0.533,4,5 
18:3n-6 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 
20:2n-6* 0.74 ± 0.04a 0.80 ± 0.01b 0.60 ± 0.01c 0.48 ± 0.03d 0.35 ± 0.03e 0.33 ± 0.02ef 0.28 ± 0.01fg 0.27 ± 0.02g 0.26 ± 0.03gh 
20:3n-6 1.03 ± 0.06a 1.10 ± 0.02a 0.82 ± 0.03b 0.51 ± 0.03c 0.39 ± 0.01d 0.36 ± 0.04d 0.34 ± 0.02d 0.33 ± 0.03d 0.32 ± 0.04d 
20:4n-6 21.97 ± 1.02a 20.22 ± 0.84ac 16.00 ± 0.55b 17.28 ± 1.03b 17.32 ± 0.87b 18.26 ± 1.43bc 17.65 ± 1.37b 16.17 ± 1.09b 16.94 ± 0.93b 
22:4n-6 2.09 ± 0.197 1.81 ± 0.026 1.43 ± 0.055 1.26 ± 0.034,5 1.05 ± 0.033,4 1.06 ± 0.173,4 0.92 ± 0.072,3 0.84 ± 0.051,2,3 0.84 ± 0.161,2,3 
22:5n-6 0.51 ± 0.052,3,4 0.56 ± 0.023,4,5 0.75 ± 0.047 0.98 ± 0.108 0.72 ± 0.075,6,7 0.77 ± 0.127 0.67 ± 0.034,5,6,7 0.60 ± 0.104,5,6,7 0.61 ± 0.054,5,6,7 
Σ n-6 PUFA 35.29 ± 0.401,2 35.29 ± 0.201,2 35.41 ± 0.451,2 37.61 ± 1.892,3,4 39.73 ± 0.484,5,6 38.99 ± 0.484,5 38.76 ± 1.284,5 38.14 ± 1.423,4 38.55 ± 0.734 
18:3n-3 0.21 ± 0.04 0.25 ± 0.04 0.34 ± 0.09 0.27 ± 0.17 0.41 ± 0.15 0.39 ± 0.16 0.37 ± 0.18 0.50 ± 0.18 0.41 ± 0.16 
20:5n-3* 0.19 ± 0.02a 0.19 ± 0.01a 0.15 ± 0.02ab 0.15 ± 0.02ab 0.15 ± 0.01ab 0.13 ± 0.01b 0.14 ± 0.01bc 0.15 ± 0.03bd 0.13 ± 0.02be 
22:5n-3 2.54 ± 0.26a 4.40 ± 0.14b 4.70 ± 0.23b 3.25 ± 0.39c 2.32 ± 0.18ad 1.88 ± 0.16de 1.72 ± 0.05e 1.80 ± 0.15ef 1.74 ± 0.08eg 
22:6n-3* 6.93 ± 0.67a 7.33 ± 0.30a 9.33 ± 0.79ab 11.01 ± 2.08be 10.48 ± 0.97bce 11.71 ± 0.97bde 12.26 ± 0.85e 11.91 ± 1.15ef 12.81 ± 1.58eg 
Σ n-3 PUFA* 9.92 ± 0.84a 12.22 ± 0.36ab 14.59 ± 0.89bh 14.73 ± 2.38bch 13.39 ± 0.98bdh 14.12 ± 0.94beh 14.51 ± 0.70bfh 14.38 ± 1.02bgh 15.12 ± 1.46h 
20:3n-9 0.03 ± 0.01a 0.03 ± 0.01ab 0.04 ± 0.01bc 0.05 ± 0.01c 0.03 ± 0.01a 0.02 ± 0.01a 0.02 ± 0.01a 0.02 ± 0.01a 0.02 ± 0.01a 
Σ FA (mg/g) 21 ± 3a 26 ± 2b 27 ± 1b 29 ± 2b 29 ± 2b 26 ± 1b 26 ± 1b 28 ± 1b 27 ± 1b 
Mean ± SD, n=5. Different numerical superscripts represent sex x time interactions and different alphabetical superscripts represent differences across time that are significantly 
different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. *Indicates a significant main effect of sex by two-way ANOVA (p< 0.05). SFA, 
saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty acids.   
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Appendix Table 6.10: Fatty acid composition (weight %) of male heart 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 
14:0 1.39 ± 0.42a 1.50 ± 1.16a 1.71 ± 0.51a 0.75 ± 0.35ab 0.25 ± 0.17b 0.14 ± 0.11bc 0.34 ± 0.29bd 0.16 ± 0.08be 0.21 ± 0.06bf 
16:0 19.45 ± 1.27a 18.91 ± 1.76a 17.64 ± 0.55a 14.34 ± 0.62b 13.44 ± 0.50bc 12.94 ± 1.41bc 13.25 ± 1.41bc 11.88 ± 0.83c 12.12 ± 0.73bc 
18:0 19.64 ± 2.30 18.51 ± 2.00 17.70 ± 0.89 18.75 ± 0.87 20.17 ± 0.68 20.78 ± 1.52 19.80 ± 2.40 20.49 ± 1.10 19.86 ± 0.79 
22:0 0.19 ± 0.02a 0.20 ± 0.04ab 0.25 ± 0.01bcefg 0.30 ± 0.01c 0.26 ± 0.03cdefg 0.23 ± 0.02ae 0.21 ± 0.04af 0.21 ± 0.01ag 0.10 ± 0.01h 
24:0 0.27 ± 0.03a 0.26 ± 0.04a 0.29 ± 0.01a 0.24 ± 0.02a 0.18 ± 0.04b 0.17 ± 0.01b 0.14 ± 0.03b 0.17 ± 0.03b 0.08 ± 0.02c 
Σ SFA 44.52 ± 2.175 43.40 ± 1.414,5 41.41 ± 0.573,4 37.94 ± 0.321,2 37.37 ± 0.381,2 37.41 ± 0.591,2 37.30 ± 1.141,2 36.71 ± 0.581,2 35.88 ± 0.451 
16:1 0.29 ± 0.03 0.23 ± 0.15 0.20 ± 0.07 0.29 ± 0.11 0.29 ± 0.10 0.37 ± 0.33 0.40 ± 0.30 0.20 ± 0.11 0.28 ± 0.11 
18:1n-7 3.27 ± 0.24ab 3.45 ± 0.31ab 3.59 ± 0.15a 3.50 ± 0.18ab 3.61 ± 0.08a 3.40 ± 0.17ab 3.16 ± 0.16b 3.35 ± 0.15ab 3.19 ± 0.10bc 
18:1n-9 5.78 ± 0.91 4.28 ± 2.11 4.05 ± 1.11 4.67 ± 0.79 4.51 ± 1.00 4.21 ± 1.91 5.15 ± 2.91 3.73 ± 1.36 4.67 ± 0.85 
24:1n-9 0.17 ± 0.01a 0.13 ± 0.01b 0.12 ± 0.01bc 0.10 ± 0.01cef 0.06 ± 0.02d 0.07 ± 0.01d 0.08 ± 0.01de 0.07 ± 0.01df 0.05 ± 0.02d 
Σ MUFA 10.25 ± 0.89 8.77 ± 1.89 8.60 ± 1.03 9.18 ± 0.85 9.03 ± 1.09 8.64 ± 2.12 9.52 ± 3.00 8.16 ± 1.39 8.99 ± 0.94 
18:2n-6 8.34 ± 1.361 10.43 ± 1.741 16.00 ± 0.892 17.53 ± 1.052,3 19.55 ± 1.423,4,5 19.90 ± 0.933,4,5 21.63 ± 2.924,5,6 22.07 ± 1.385,6 23.74 ± 1.226 
18:3n-6 0.04 ± 0.01 0.04 ± 0.02 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.02 0.02 ± 0.01 
20:2n-6* 0.80 ± 0.13a 0.83 ± 0.04a 0.59 ± 0.01b 0.46 ± 0.03c 0.37 ± 0.03cd 0.36 ± 0.02cd 0.34 ± 0.02d 0.33 ± 0.01de 0.31 ± 0.03df 
20:3n-6 1.08 ± 0.09a 1.08 ± 0.08a 0.85 ± 0.02b 0.51 ± 0.02c 0.40 ± 0.02d 0.37 ± 0.02d 0.34 ± 0.01d 0.36 ± 0.02d 0.33 ± 0.02d 
20:4n-6 21.68 ± 1.28a 19.75 ± 2.71acdefg 16.04 ± 1.06b 17.16 ± 0.81bc 17.76 ± 0.91bd 17.64 ± 1.54be 16.15 ± 2.46b 17.28 ± 0.97bf 16.44 ± 0.41bg 
22:4n-6 2.26 ± 0.207 1.75 ± 0.196 1.48 ± 0.055 1.25 ± 0.084,5 1.07 ± 0.103,4 0.94 ± 0.062,3, 0.77 ± 0.051,2 0.69 ± 0.021,2 0.66 ± 0.091 
22:5n-6 0.51 ± 0.032,3,4 0.56 ± 0.093,4,5,6 0.72 ± 0.045,6,7 0.97 ± 0.098 0.74 ± 0.166,7 0.54 ± 0.032,3,4 0.42 ± 0.071,2,3 0.39 ± 0.041,2 0.34 ± 0.021 
Σ n-6 PUFA 34.75 ± 2.311 34.48 ± 1.421 35.76 ± 0.471,2,3 37.95 ± 1.254,5 39.93 ± 0.444,5,6 39.78 ± 1.194,5,6 39.71 ± 0.474,5,6 41.16 ± 0.835,6 41.85 ± 1.036 
18:3n-3 0.20 ± 0.06 0.27 ± 0.20 0.36 ± 0.12 0.38 ± 0.11 0.33 ± 0.11 0.33 ± 0.16 0.48 ± 0.37 0.32 ± 0.15 0.45 ± 0.12 
20:5n-3* 0.21 ± 0.03a 0.20 ± 0.01a 0.16 ± 0.01b 0.16 ± 0.01b 0.14 ± 0.01b 0.14 ± 0.01b 0.15 ± 0.01b 0.15 ± 0.01b 0.15 ± 0.01b 
22:5n-3 2.58 ± 0.27ac 4.60 ± 0.75b 4.52 ± 0.50b 3.06 ± 0.24a 2.35 ± 0.22ac 2.10 ± 0.25c 1.94 ± 0.30cd 2.10 ± 0.17ce 1.95 ± 0.19cf 
22:6n-3* 6.28 ± 0.46a 7.98 ± 1.47ab 8.58 ± 1.01abf 10.47 ± 1.15bd 10.59 ± 1.06bcd 11.35 ± 0.97d 10.51 ± 2.17bde 11.03 ± 1.11df 10.46 ± 0.43bdg 
Σ n-3 PUFA* 9.32 ± 0.58a 13.09 ± 2.01b 13.68 ± 1.33b 14.12 ± 1.30b 13.43 ± 1.18b 13.95 ± 1.05b 13.11 ± 2.10b 13.63 ± 1.14b 13.03 ± 0.48b 
20:3n-9 0.02 ± 0.01ad 0.03 ± 0.01a 0.04 ± 0.01b 0.05 ± 0.01c 0.02 ± 0.01ad 0.02 ± 0.01ad 0.02 ± 0.01ad 0.01 ± 0.01d 0.02 ± 0.01de 
Σ FA (mg/g) 21 ± 2 23 ± 2 27 ± 2 27 ± 1 27 ± 3 26 ± 2 26 ± 6 25 ± 1 27 ± 2 
Mean ± SD, n=5. Different numerical superscripts represent sex x time interactions and different alphabetical superscripts represent differences across time that are significantly 
different by Tukey’s HSD following a significant F-value (p< 0.05) by two-way ANOVA. *Indicates a significant main effect of sex by two-way ANOVA (p< 0.05). SFA, 
saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; FA, fatty acids.  
66 
 
7 Examining the Effects of Dietary DHA Supplementation on Spatial Memory and the 
Hippocampus in Female and Male Rats  
7.1 Introduction 
 Interactions between DHA supplementation and biological sex on episodic and working 
memory have been reported in young adults [5], but cognitive sexual dimorphisms may begin 
earlier [20,125]. Modelling these differences in animals could help uncover the mechanisms 
behind the interactions shown in humans. To date, studies reporting the effects of DHA on 
spatial memory in animal models have generally included only adult males and n-3 PUFA 
deficient diets [6,8,9,73]. Additionally, lipidomic analysis on the hippocampus, an area of the 
brain critical to spatial memory [91], has not been performed in both sexes following dietary 
DHA supplementation. An animal model of DHA supplementation including both sexes and 
provided Adequate Fat Western Diets (AFWD), could generate findings more applicable to 
humans. Combining spatial memory analyses with an examination of the hippocampal lipidome 
could provide further insight as to how DHA supplementation affects spatial memory in the rat, 
and examining the erythrocyte lipidome could reveal potential biomarkers for hippocampal DHA 
status [133]. Therefore, the aim of this study was to determine the effect of DHA 
supplementation in a rat model using ALA adequate [134,135] AFWDs [100] to provide insight 
into how sexual dimorphisms affect spatial memory in rats.  
7.2 Methods 
7.2.1 Animals and Study Design 
 Six female rats were bred on campus and placed on AIN-93G based AFWDs with or 
without 2% of total fatty acid mass DHA supplementation (Table 3) after confirmation of 
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pregnancy by vaginal plug. Diets were purchased from Envigo (Mississauga, Ontario, Canada). 
The AFWD used in this study is designed to contain a fatty acid profile typically consumed in 
Western societies, but at an adequate amount of total fat for rodents as outlined in the AIN-93G 
formulation [136]. This reduction in fat compared to the typical Total Western Diet (TWD) [100] 
is important, as a high consumption of SFAs is related to mastitis and inflammation during 
lactation [137]. The 2% DHA supplementation was chosen as this amount has been suggested to 
maximize brain DHA levels [138]. Rats and their pups were kept in a temperature controlled 
room with a 12hr light cycle at 10pm-10am. After weaning, pups were placed on the same diets 
as their mothers, underwent behavioural testing as outlined below at 6 weeks of age, and were 
sacrificed at 7 weeks of age. Plasma, erythrocytes, whole blood, heart, and liver were collected 
whole and snap frozen in liquid nitrogen. Brain was separated into brainstem, cerebellum, cortex, 
hippocampus, striatum, and rest of brain sections over wax sheeting cooled by dry ice, then snap 
frozen in liquid nitrogen. Tissues were then stored at -80°C until analysis. Culling litters to 10 
pups each was considered. However, the reductions in variability from culling on pup weight, 
nutrient availability, and behaviour are still controversial [128,139,140], and mothers may 
already have natural adaptations to adjust milk volume to litter sizes [141]. For these reasons, 
litters were not culled to avoid introducing a confounding factor by reducing perinatal demand 
for maternal DHA between placental transfer and breast milk production. 
7.2.2 Behavioural Testing 
 During testing, rats were placed in clear, polypropylene cages with heating pads 
underneath. At the end of testing, rats were dried and returned to their individual cage. The order 
of testing was chosen at random, and swim patterns were recorded using a Noldus Ethovision XT 
v8.5 video tracking system (Noldus Information Technology, Leesburg, VA, USA). 
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  The testing protocol began with the learning phase, which consisted of 4 trials per day 
for 4 days, starting once at each of the 4 starting positions (NW, N, E, SE) with approximately 10 
min intertrial intervals. Starting positions were approximately equidistant from the platform and 
the order of the starting positions was sorted at random. Timers started as the rats were released 
into the pool facing the wall and stopped when rats touched the platform. Rats had 60s to reach 
the platform and were allowed to remain on it for 30s to orientate themselves. Unsuccessful rats 
were guided to the platform after 60s and allowed to remain on it for 30s. 
 Memory retention was then assessed using a probe test 24h after the last day of the 
learning phase. After the platform was removed, rats were given 30s to search for the platform 
and the time spent in the target quadrant was recorded. Finally, a visual test using a styrofoam 
ball above a platform placed in a different quadrant was performed after the probe test to ensure 
animals could locate visual cues. 
7.2.3 Lipidomic Analyses 
Levels of DHA containing lipid species were determined using ultra high pressure liquid 
chromatography with tandem mass spectrometry (UHPLC-MS/MS). Lipid extracts, spiked with 
500pmol 1,2-diheptadecanoyl-sn-glycero-3-phosphatidylcholine (17:0/17:0 PC) as the internal 
standard, were dried under nitrogen gas and resuspended into 100µL of 65:35:5 acetonitrile-
isopropanol-water + 0.1% formic acid and stored at 4 ºC until analysis. 
 The UHPLC-MS/MS system was a Waters Synapt G2Si QTOF coupled to a Dionex 
UltiMate 3000 UHPLC system (Mississauga, ON) equipped with a Waters ACQUITY CSH C18 
column with dimensions 1.7µm x 2.1mm x 150mm. A reverse-phase, binary multistep HPLC 
protocol using A, 60:40 acetonitrile-water + 0.1% formix acid + 10 mM ammonium formate and 
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B, 90:10 isopropanol-acetonitrile + 0.1% formic acid + 10 mM ammonium formate to separate 
polar and nonpolar lipids.  Column temperature was set at 45 ºC and tray temperature at 4 ºC.  
 The QTOF (quadrupole time of flight) mass spectrometer was operated under positive 
electrospray ionization for PC, PE, and TAG analysis. Data dependent acquisition (DDA) for 
top-5 ions was used with a scan range of m/z 50-1000, a scan frequency of 0.1 sec, and transfer 
cell collision energy ramps of 20-30V at low mass and 30-50V at high mass. All data were lock-
mass corrected using leucine enkephalin (m/z 556.2771) and processed using ProGenesis QI 
software (Nonlinear Dynamics, Newcastle upon Tyne, UK). Data are expressed as relative 
abundancies (ratios of analyte/internal standard) with PC data presented as concentrations as the 
internal standard was 17:0/17:0 PC.   
7.2.4 Fatty Acid Analyses 
RBC and hippocampal tissues were collected for fatty acid analyses. Lipids were 
extracted using the methods described in section 4.2, and fatty acids were analysed by gas 
chromatography as described in section 4.3. 
7.2.5 Statistical Analyses 
Behavioural data were analysed in two ways: 1) with session data analyzed by pup, or 2) 
with session data analyzed by litter. When sessions were analyzed by pup, the four trials of each 
pup in a given session were averaged and analyzed as a function of the overall performance of 
the individual pups. The data of each pup were then divided into a 2x2 factorial for diet and sex 
(n=14-16). When sessions were analyzed by litter, the trials of the males and females of each 
litter were averaged and analyzed as one entity. Groups were then divided into a 2x2 factorial for 
diet and sex (n=3). No adjustments for sex ratio imbalances outlined in Table 5 were made. 
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Mean comparisons for behavioural, fatty acid, and identified lipid species analyses were 
performed using SPSS release 20.0 (IBM, Chicago, IL, USA). The effect of diet, sex, and a diet 
x sex interaction was examined using a two-way ANOVA. Individual means were compared by 
Tukey post hoc testing after significant F-value by ANOVA. Fatty acid and lipidomic data are 
presented as means ± SD with significance accepted when p<0.05, and behavioural data are 
presented as means ± SEM with significance accepted when p<0.05. 
Analyses to determine significantly different compounds detected by UHPLC-MS prior 
to manual identification were performed using ProGenesis QI software (Nonlinear Dynamics, 
Newcastle upon Tyne, UK). Erythrocyte compounds were identified using the ProGenesis q-
value system, which adjusted p-values according to multiple testing by adjusting for each 
individual test, reducing the chances of identifying false positives. Erythrocyte species were 
identified with a q-value of q<0.05, and hippocampal species were identified with a p-value of 
p<0.05. These values were used to reduce the number of detected species into a manageable 
amount that could be manually identified. 
Pearson’s correlations were used to examine the association between hippocampal and 





7.3.1 Body Weight and Food Intake 
 DHA fed rats were significantly heavier than controls from 21 to 47 days of age (Figure 
10). Males were heavier than females from 28 to 47 days of age. DHA fed rats consumed more 
diet at day 21, and males consumed more than females at 28, 35, and 42 days of age (Figure 11).  
7.3.2 Behavioural Testing 
 Statistical analyses for behavioural testing were performed in two ways: with session 
times analyzed 1) by individual pup, or 2) by litter. A priori analyses revealed no differences 
between litters or treatment groups during the first trial (data not shown). Maulchy’s test of 
sphericity also confirmed that within-subject variances for repeated measures were equal (data 
not shown). When session times were analyzed by pup, no significant dietary effects or sexual 
dimorphisms were detected for latency times, distance travelled, or velocity when all learning 
phase sessions were pooled together. The final session of the learning phase was then analyzed 
individually to determine if the learning phase concluded differently between groups. This two-
way ANOVA anlalysis indicated a significant effect of diet on latency time (p=0.048) (Figure 
12), but not distance travelled (p=0.084) (Figure 13) or velocity (p=0.622, data not shown), with 
the supplemented group taking longer to reach the platform, suggesting greater difficulty 
memorizing the platform position. For the probe test, no significant dietary effects or sexual 
dimorphisms were detected for time spent in the correct quadrant, average distance from the 
platform, or velocity (Figure 14). Conversely, when data were analyzed by litter, no significant 
effect of diet or sex was detected on latency time (Figure 15), distance travelled (Figure 16), or 
velocity (p=0.640, data not shown) in either the pooled sessions or during the final day of the 
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learning phase. Similarly, no significant differences were detected during the probe test (Figure 
17). 
7.3.3 Lipidomic Analyses of the Hippocampus 
DHA supplementation reduced ARA-containing lipid species in the hippocampus. Both 
normalized abundance and concentration measures of PC 18:1_20:4 and PC 18:0_20:4 were 
lower in the DHA supplemented group (Figure 18). The normalized abundancies of 22:5 
containing PE, alkenyl-PE, and a PS species were also lower in the DHA supplemented group 
(Figure 18). Of note, the normalized abundancies of the 22:5 containing species PE 16:0_22:5 
and alkenyl-PE 18:0_22:5 were the most affected, being 2.55 and 2.36 fold higher, respectively, 
in the control group hippocampi.  
7.3.4 Lipidomic Analyses of Erythrocytes 
 Erythrocytes in DHA supplemented rats also showed reductions in ARA-containing lipid 
species, and some changes in the hippocampus were mirrored in the erythrocyte fraction (Figure 
19). Of the lipid species affected in the hippocampus, PC 18:0_20:4, PC 18:1_20:4, and PE 
18:0_22:5 we also reduced in the erythrocytes of the supplemented group but showed an 
additional sex effect not shown in the hippocampus. In the erythrocytes, the effects of DHA 
supplementation on fatty acids appeared to have lipid class specificity. Reductions in ARA 
occurred primarily in the PC fraction, while reductions in 18:2 occurred primarily in PE. 
Conversely, both PS changes were due to increases in DHA. 
Both normalized abundance and concentration of PC 18:0_20:4 was lower in the DHA 
supplemented group. The normalized abundance of PC 18:1_20:4 was lower in the DHA group 
73 
 
as well, but concentrations were only nearly significant ( p = 0.076). Interestingly, PC 18:0_20:4 
was also higher in females, while PC 18:1_20:4 was higher in males.  
DHA containing lipid species also differed by diet and sex. PC 18:0_22:6 was higher in 
females, and PS 16:0_22:6 in males. Alkenyl-PE 18:0_22:6 was nearly significantly higher (p = 
0.084) in supplemented females than males, and higher in the DHA group. The normalized 
abundancies of PS were particularly sensitive to DHA supplementation. Both PS 16:0_22:6 and 
18:1_22:6 were higher in the supplemented group. Interestingly, PS 16:0_22:6 was higher in 
males than females. 
Sexual dimorphisms were also present in LA and adrenic acid containing species. In 
alkenyl-PE, 16:0_22:4 was higher in control males than control females, and lowest in DHA 
supplemented rats. The ARA precursor LA was also affected by sexual dimorphisms, and PE 
16:0_18:2 was higher in males.  
7.3.5 Fatty Acid Composition of Hippocampi and Erythrocytes 
 Fatty acid analyses of total lipid extracts indicated that DHA supplementation increased 
the relative percentages of all hippocampal n-3 PUFA except 20:3n-3 (Appendix Table 7.5) 
Interestingly, DHA supplementation also increased hippocampal relative percent and 
concentrations of ARA precursors, though ARA, adrenic acid, DPAn-6, and total n-6 PUFA 
concentrations were lower in the DHA supplemented group. The relative percentage of adrenic 
acid was significant for a sex x diet interaction, being higher in control females than males, and 
both sexes of the control group being higher than rats fed the supplemented diet. Concentrations 
and relative levels of hippocampal LA were higher in males.  
74 
 
 Some of the differences in the relative percentages of hippocampal fatty acids also 
occurred in the erythrocytes. Like the hippocampus, the relative percentages of LA, EPA, DPAn-
3 and DHA were higher in the supplemented group, while the relative percentages of adrenic 
acid, DPAn-6, and total n-6 PUFA were lower in the DHA group (Appendix Table 7.6). Males 
also had higher relative percentages of LA and 18:1n-7 in erythrocytes. The relative percentages 
of erythrocyte fatty acids also had additional differences as compared with the relative 
percentages of the hippocampal fatty acids. Females had higher relative percentages of DHA, 
EPA, and DPAn-6, and males had higher relative percentages of DPAn-3 and total MUFA 
(Appendix Table 7.6) .  
7.3.6 Correlations between Erythrocyte and Hippocampal Fatty acids and Lipid Species 
 Correlations between the concentrations and relative percentages of erythrocyte and 
hippocampal ARA, DPAn-6, and DHA were not significant within male or female dietary 
groups, but relative percentages of adrenic acid was significantly correlated in control males, and 
concentrations of adrenic acid in control females (Appendix Tables 7.7 and 7.8). 
 Correlations between lipid species were performed with sex and dietary groups pooled 
together to compare the results to a previous study[142], and with the groups separated as 
originally proposed. At the lipidomic level, the acyl lipid species of PE 18:0_22:5, PC 18:0_20:4 
and PC 18:1_20:4 in erythrocyets and the hippocampus were correlated. When sex and dietary 
groups were pooled, all species had significant correlations in normalized abundance or 
concentration (). When divided by sex or diet only, only nearly significant correlations were 
observed. In normalized abundance, PC 18:0_20:4 was nearly significantly correlated in the 
DHA group (r=0.74,p=0.060), and in males (r=0.74, p=0.055), and PE 18:0_22:5 was nearly 
significant in males (r=0.72, p=0.070). Some p<0.10 correlations were observed in concentration 
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values as well, with PC 18:1_20:4 in the control group (r=0.65, p=0.082) and in males (r=0.66, 
p=0.088) (Tables 7 and 8). Finally, when divided by sex and diet as originally proposed, these 
correlations were no longer significant except for concentrations of PC 18:1_20:4 in DHA males 
(Table 6). 
7.4 Discussion 
 This study shows that dietary DHA supplementation reduces hippocampal n-6 PUFA 
containing lipid species and increases latency times of the final day of the learning phase in 
adolescent female and male rats. This is the first report of adolescent males and females fed 
AFWDs with dietary DHA supplementation being assessed for spatial memory performance, and 
changes in hippocampal and erythrocyte lipid species at a medio lipidomic level [143]. No sex 
differences in behavioural performance were detected, and the DHA supplemented group 
unexpectedly had significantly longer latency times during the final day of the learning phase. 
Both diets in this study contained sufficient amounts of ALA [134,135]. This study agrees with 
reported increases in total fatty acid levels of DHA, but not with reported increases in DHA 
containing lipid species in the hippocampi of the supplemented group as shown in studies with 
deficient [78] or unreported [93] amounts of dietary ALA. The findings confirm previous reports 
of DHA supplementation reducing normalized abundancies of ARA-containing PC lipid species 
in the hippocampus [78], and also show that these reductions occur in erythrocytes as well. 
Behavioural results did not support the original hypothesis, and supplemented females did not 
perform differently than supplemented males, nor did the supplemented group perform better 
than the unsupplemented group in the MWM. Spatial memory analysis by MWM suggest that 
the reductions of n-6 PUFA in the hippocampus during DHA supplementation in ALA-sufficient 
diets could be increasing latency times in female and male adolescent rats. These observations 
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appear to support recent reports that a balance between ARA and DHA supplementation is most 
effective when supplementing LCPUFA perinatally[144,145].  
 The DHA diet used in this model was composed of 2%wt of total fatty acids as DHA. 
This amount is similar to amounts given to young adults in recent human trials [5] and consumed 
in populations with regular fish consumption [146]. Compared to previous animal trials 
examining DHA and spatial memory, the amount of DHA in the supplemented diet was higher 
than some previously used diets that used 1.1%wt of total fatty acids [6–9,73], but lower than 
others that used 11.2%wt [78]. This study is unique in that both diets provided to the mothers 
and dam reared pups were ALA sufficient [134,135]. While DHA supplementation increased 
normalized abundancies of DHA-containing lipid species in erythrocytes, DHA-containing lipid 
species in the hippocampus did not change, and ARA- containing lipid species were reduced. 
The similar brain DHA composition of the control group compared with the supplemented group 
agrees with previous reports that whole body synthesis rates of ALA are sufficient to supply the 
brain with adequate DHA [86]. The reductions in DPAn-6 but not DPAn-3 fatty acids in the 
hippocampus suggest reductions in 22:5-containing lipid species to be DPAn-6. These reductions 
in the 22:5- and ARA-containing lipid species in the hippocampus agree with previous research 
reporting a preference in the brain for DHA over DPAn-6 and ARA [147,148]. The reductions of 
ARA and DPAn-6 in PC, PE, alkenyl-PE, and PS are in agreement with previously reported data 
[78]. Although no DHA-containing lipid species were significantly increased in the hippocampus 
following supplementation, the relative percent of DHA in total fatty acids was higher in the 
supplemented group. These observations suggest that in rats fed adequate amounts of ALA and 
LA, DHA supplementation does not increase the normalized abundance of specific DHA-
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containing lipid species but does reduce DPAn-6 and ARA-containing lipid species in the 
hippocampus. 
Statistical analyses for the behavioural data were run in two ways to explore how the 
benefits of each would affect the interpretation. The first approach analyzes the data of each rat 
individually and reduces the impact of litter sex ratio imbalances, which was important for the 
interpretation of sex effects in this study. The second approach analyzes the data of each litter as 
a whole, and calls for a balanced subset of multiple litters to be used [125]. The use of a greater 
number of litters reduces the risk of a model with low genetic variability, and provides greater 
power as n=15 litters could be more powerful than n=15 individual rats from genetically similar 
backgrounds. However, the time and financial resources required to perform this method 
properly could be restrictive, and in this study, only 3 litters were used to meet the power 
requirements outlined in an a priori power analysis performed for ethics clearance, in which 
studies using similarly small genetic backgrounds were cited [105]. Unfortunately, this study 
design does not provide the genetic diversity that would provide the additional advantages of 
testing by litter. 
No overall effects of diet or sex were detected in the MWM. However, latency times of 
the DHA supplemented group during the final day of the learning phase were longer than 
controls. This may be due to the imbalance between LCPUFA supplementation, and the 
specificity for DHA over DPAn-6 in the brain [147–149], or due to competition with ARA [150]. 
A previous study has shown that high consumptions of DHA without ARA leads to reduced 
water maze performance that is improved with ARA supplementation, but these DHA 
consumptions were excessive, with DHA composing 5.42-5.45% total energy [150]. However, 
ARA is essential to water maze performance [145], and the reductions in ARA and 22:5-
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containing species in the brain without increases in DHA containing species could be 
detrimental. PL balance is also critical to brain function [151,152]. The observed reduction of all 
quantitatively measured PC species without any observed increases in other PC leaves the 
possibility that the supplementation of DHA without any n-6 LCPUFA supplementation could be 
altering PC/PE balance, but further research would be necessary.  
 The correlations between the concentrations of ARA containing PC species in the 
hippocampus and those in the erythrocytes, and the normalized abundances of 22:5-containing 
PE species in the hippocampus and erythrocytes are in partial agreement with previous reports of 
DHA composition by %wt correlating between PE species in erythrocytes and the hippocampus, 
when animals are not divided by dietary DHA consumption [142]. However, while previous 
reports only correlated total DHA fatty acids within the PE lipid class, this study demonstrates 
that reductions in the concentrations of ARA-containing PC, and the normalized abundancies of 
22:5-containing PE, can be correlated between erythrocytes and the hippocampus as well in both 
males and females. Additionally, this study shows that dividing lipidomic data according to the 
dietary DHA intakes and sex produces some nearly significant correlations, suggesting that 
lipidomic analyses of human trials with more even distributions of dietary intakes could uncover 
potential biomarkers. 
 The lack of a lipidomic and fatty acid analyses of all litters in this study is a limitation. In 
the interest of time, all litters have completed behavioural assessments, but only 4 rats per diet x 
sex group have undergone fatty acid and lipidomic analyses. The inclusion of all rats to meet the 
a priori criteria of a 5% type 1 error rate and 80% test power could change the aforementioned 
results. Future directions should include the addition of a dietary group with a 1:1 ARA:DHA 
supplementation ratio. Providing rats with this diet would provide further insight into whether 
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the reduction in ARA is due to an imbalance in dietary LCPUFA, and has implications related to 
the previously reported hypothesis that in male rats, dietary 18-carbon PUFA consumption plays 
a larger role in LCPUFA synthesis than gene expression [153]. Erythrocyte fatty acid analysis 
seems to provide an additional dimension to this hypothesis, as it appears the DHA group had 
significantly reduced ARA synthesis as compared with controls, which did not have high levels 
of dietary DHA to impede LA elongation. Lipidomic, genomic, and protein analysis of the 
collected hepatic tissues and plasma could provide further insight into how DHA 
supplementation affected ARA synthesis relative to how gene expression affected ARA 
synthesis. Additionally, kinetic analyses could uncover whether in-vivo incorporation rates of 
DHA and ARA into the brain differ between diets and sex. These incorporation rates change 
with availability [148], and data from erythrocytes suggest LCPUFA availability differed 
between sexes and diets. The balance between PE and PC could be investigated as well. With 
current lipidomic data suggesting reductions in hippocampal concentrations of PC, a potential 
imbalance in lipid class homeostasis could be occurring. This could be confirmed by quantitative 
analysis using a Splash Lipidomix mix containing multiple deuterated phospholipid internal 
standards [154]. Finally, the 1:1 ARA:DHA diet could provide rats with the spatial memory 
benefit originally hypothesized. Recent reports in children fed exclusively through infant formula 
with varying levels of DHA and a consistent amount of ARA during infancy found that those fed 
formula with either a lower or equal amount of DHA relative to ARA exhibited greater 
connectivity between frontal and parietal lobes, and greater white matter volume as compared to 




In conclusion, this study demonstrates that dietary DHA supplementation in rats with 
adequate ALA consumption affects spatial memory and increases latency times during the final 
day of the learning phase in the MWM. These results were significant for a diet effect. This 
study also reports that in the hippocampus, DHA supplementation reduced ARA- and 22:5-
containing lipid species, but did not increase DHA containing lipid species. However, increases 
in the relative composition of DHA in total fatty acids of the hippocampus were detected. 
Finally, significant correlations between 22:5- and ARA-containing PE and PC lipid species 
were identified between erythrocytes and the hippocampus, but further research into how these 





Figure 10: Body weights of male and female pups from weaning until adolescence. & indicates 
significant interaction between diet and sex, # indicates significant differences between dietary 
groups, and * indicates significant difference between sexes as determined by two-way ANOVA 
followed by Tukey post hoc (p<0.05). Mean ± SD. DHA females n = 21, DHA males n = 15, 
Control females n = 20, Control males n = 16. 
 
 
Figure 11: Food intakes of male and female pups from weaning until adolescence. # indicates 
intakes are significantly different between dietary groups, and * Intakes are significantly 
different between sexes as determined by two-way ANOVA followed by Tukey post hoc 





































































Figure 12: Effect of DHA-supplementation on escape latency in the Morris water maze. The 
escape latency (time required for a rat to find and climb onto the hidden platform) is presented as 
the mean of four trials ± SEM, n = 14-16. Significant differences between dietary groups 
determined by repeated measures one-way ANOVA followed by Tukey post hoc (p<0.05). 
 
Figure 13: Effect of DHA-supplementation on distance travelled during the Morris water maze 
The escape latency (time required for a rat to find and climb onto the hidden platform) is 
presented as the mean of four trials ± SEM, n = 14-16. Significant differences between dietary 





Figure 14: Performance of DHA and Control males and females during the probe test. (A) time 
in the former platform containing quadrant. (B) average distance from the former platform 
containing quadrant. No significant differences were detected by F test with (p>0.05) two-way 
ANOVA. n = 14-16 per group. 
 
 
Figure 15: Effect of DHA-supplementation on escape latency in the Morris water maze The time 
required (escape latency, mean of four trials) for a rat to find and climb onto a hidden platform is 
presented as the mean ± SEM, n = 3. Significant differences between dietary groups by repeated 





Figure 16: Effect of DHA-supplementation on distance travelled during the Morris water maze 
The time required (escape latency, mean of four trials) for a rat to find and climb onto a hidden 
platform is presented as the mean ± SEM, n = 3. Significant differences between dietary groups 
by repeated measures one-way ANOVA followed by Tukey post hoc (p<0.05). 
 
Figure 17: Performance of DHA and Control males and females during the probe test. (A) time 
in the former platform containing quadrant. (B) average distance from the former platform 
containing quadrant. No significant differences were detected by F test with (p>0.05) two-way 





Figure 18: Significant differences in hippocampal PC (A), PE (B), alkenyl-PE (C) and PS (D) 
concentrations and relative abundancies between DHA and Control groups. Concentrations and 
relative abundancies are significantly different between diets as determined by two-way 




Figure 19: Differences in erythrocyte PC. Relative abundancies between diets (A), sex(B). 
Relative abundancies are significantly different by as determined by two-way ANOVA followed 
by Tukey post hoc at by p<0.05 signified by * or #, or by p<0.01 as signified by ** or ## for sex 
or diet, respectively. Mean ± SD, n=4.  
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Table 3: Macronutrient and fatty acid composition of control and DHA supplemented diets used 
in the behavioural study. 
Diet component Control DHA+ 
Macronutrient mg/g of diet 
Protein 17.70 17.70 
Carbohydrate 60.10 60.10 
Fat 7.20 7.20 
Fatty Acid % composition 
16:0 14.60 ± 0.08 14.58 ± 0.18 
18:0 7.02 ± 0.05 6.46 ± 0.22 
Total SFA 27.95 ± 0.19 24.91 ± 0.16 
16:1 0.72 ± 0.01 0.82 ± 0.01 
18:1n-7 1.51 ± 0.05 1.41 ± 0.09 
18:1n-9 37.13 ± 0.23 38.02 ± 0.14 
Total MUFA 39.77 ± 0.21 40.67 ± 0.10 
18:2n-6 27.95 ± 0.11 27.92 ± 0.06 
20:4n-6 0.05 ± 0.01 0.03 ± 0.01 
Total n-6 PUFA 28.07 ± 0.12 28.02 ± 0.06 
18:3n-3 3.87 ± 0.01 3.86 ± 0.02 
20:3n-3 <0.01 <0.01 
20:5n-3 0.01 ± 0.01 0.01 ± 0.01 
22:5n-3 0.01 ± 0.01 0.04 ± 0.01 
22:6n-3 0.02 ± 0.01 2.10 ± 0.04 
Total n-3 PUFA 3.91 ± 0.01 6.01 ± 0.04 
Data is mean ± SD from triplicate analysis in our laboratory. SFA: saturated fatty acids, MUFA: 




Table 4: Energy composition of control and DHA supplemented diets used in the behavioural 
study. 
Diet component Control DHA+ 
Energy Density (kcal/g) 3.8 3.8 
Macronutrient % of energy 
Protein 18.8 18.8 
Carbohydrate 63.9 63.9 
Fat 17.2 17.2 
Fatty Acid % of energy 
16:0 2.51 ± 0.01 2.51 ± 0.03 
18:0 1.21 ± 0.01 1.11 ± 0.04 
Total SFA 4.81 ± 0.03 4.28 ± 0.03 
16:1 0.12 ± 0.01 0.14 ± 0.01 
18:1n-7 0.26 ± 0.01 0.24 ± 0.01 
18:1n-9 6.39 ± 0.04 6.54 ± 0.02 
Total MUFA 6.84 ± 0.04 6.99 ± 0.02 
18:2n-6 4.81 ± 0.02 4.80 ± 0.01 
20:4n-6 0.01 ± 0.01 0.01 ± 0.01 
Total n-6 PUFA 4.83 ± 0.02 4.82 ± 0.01 
18:3n-3 0.67 ± 0.01 0.66 ± 0.01 
20:3n-3 <0.01 <0.01 
20:5n-3 <0.01 <0.01 
22:5n-3 <0.01 0.01 ± 0.01 
22:6n-3 <0.01 0.36 ± 0.01 
Total n-3 PUFA 0.67 ± 0.01 1.03 ± 0.01 
Data is mean ± SD from triplicate analysis in our laboratory. SFA: saturated fatty acids, MUFA: 




Table 5: Dam and sire pairings and sex ratios of litters and groups used for behavioural analyses 
Each dam was bred once. Each sire was bred with one dam per diet. Total number of pups 
indicates total litter size, broken down by sex. Number of pups used in MWM (Morris Water 




Table 6: Sex Differences in normalized abundance of erythrocyte lipid species 
 Female Male P Sex Effect 
PC 16:0_20:4 40.80 ± 12.77 40.73 ± 12.11 <0.01 
PC 20:4_20:4 2.19 ± 2.00 2.11 ± 1.92 0.90 
PE 18:1_18:2 15.20 ± 4.65 16.22 ± 3.66 0.03 
PE 18:1_22:6 4.83 ± 2.18 4.31 ± 1.85 0.50 
PE 38:6 17.66 ± 7.18 14.17 ± 4.17 0.07 
PE 40:8 5.62 ± 1.07 3.61 ± 0.57 <0.01 
Alkenyl-PE 16:0_22:4 15.44 ± 6.45 17.26 ± 8.71 0.01 
Alkenyl-PE 18:0_22:6 20.58 ± 7.46 19.56 ± 4.35 0.39 
Alkenyl-PE 18:1_22:6 12.01 ± 3.34 12.60 ± 3.74 0.52 
PS 16:0_22:6 1.38 ± 1.05 2.73 ± 1.79 <0.01 
PS 18:1_22:6 6.96 ± 3.74 6.74 ± 3.27 0.80 
Abundance represented as analyte abundance divided by ISTD. Mean ± SD. n=4. P values 
determined by Tukey’s HSD following two-way ANOVA.  
 
 Total Number of Pups 
Number of Pups Used in 
MWM 
Litter # Dam Sire Diet Female Male Female Male 
1 1 1 DHA 9 4 6 4 
2 2 1 Control 6 4 6 4 
3 3 2 Control 7 8 4 6 
4 4 2 DHA 6 6 5 5 
5 5 3 DHA 6 5 4 6 
6 6 3 Control 7 4 6 4 
Total: DHA 21 15 15 15 
  Control 20  16  16 14 
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Table 7: Correlations between hippocampal and erythrocyte lipid species (normalized abundance) 
Correlations of lipid species between hippocampi and erythrocytes. Total group includes all rats analyzed by mass spectrometry. 
Correlations could only be determined for lipid species identified in erythrocytes and the hippocampus. DHA and control groups 
include rats of both sexes from the respective dietary group. Male and female groups include rats that consumed both diets from the 
respective sex. Pearson’s r: Pearson’s correlation coefficient.*p<0.05; **p<0.01 
 
Table 8: Correlations between hippocampal and erythrocyte lipid species (concentrations) 
Group Total DHA Female DHA Male Control Female Control Male 
n 15 4 3 4 4 
Lipid Species Pearson’s r p Pearson’s r p Pearson’s r p Pearson’s r p Pearson’s r p 
PC 18:0_20:4 .55* 0.03 0.19 0.81 0.76 0.45 0.10 0.90 0.52 0.48 
PC 18:1_20:4 .70** <0.001 0.83 0.17 -0.20 0.87 -0.77 0.23 0.59 0.41 
Correlations of lipid species between hippocampi and erythrocytes. Total group includes all rats analyzed by mass spectrometry. 
Correlations could only be determined for lipid species identified in erythrocytes and the hippocampus. DHA and control groups 
include rats of both sexes from the respective dietary group. Male and female groups include rats that consumed both diets from the 
respective sex. Pearson’s r: Pearson’s correlation coefficient;**p<0.01; *p<0.05 
Group Total DHA Female DHA Male Control Female Control Male 
n 15 4 3 4 4 
Lipid Species Pearson’s r p Pearson’s r p Pearson’s r p Pearson’s r p Pearson’s r p 
PC 18:0_20:4 0.39 0.15 -0.90 0.11 0.91 0.27 0.15 0.85 0.69 0.31 
PC 18:1_20:4 0.61* 0.02 0.52 0.48 -1.00** <0.001 -0.03 0.97 -0.25 0.75 




Abundance represented as analyte abundance divided by ISTD. Mean ± SD. n=4. P values determined by Tukey’s 
HSD following two-way ANOVA.  
 
 
Appendix Table 7.2: Normalized abundancies of erythrocyte lipid species in all groups 
 DHA male DHA female Control Male Control Female 






PC 16:0_20:4 30.22 ± 2.36 29.88 ± 5.17 51.24 ± 6.11 51.73 ± 5.98 0.60 <0.01 0.34 
PC 18:0_20:4 1.25 ± 0.66 2.37 ± 0.56 2.69 ± 0.17 4.88 ± 1.18 0.88 0.98 <0.01 
PC 18:0_22:6 8.91 ± 1.00 15.38 ± 2.61 8.39 ± 1.63 13.67 ± 2.54 0.19 <0.01 <0.01 
PC 18:1_20:4 6.29 ± 1.19 3.30 ± 0.49 11.01 ± 1.79 6.70 ± 1.36 0.35 <0.01 <0.01 
PC 20:4_20:4 0.36 ± 0.18 0.79 ± 0.68 3.86 ± 0.64 3.59 ± 1.90 0.56 0.90 <0.01 
PE 18:1_22:6 5.69 ± 1.92 6.56 ± 1.35 2.93 ± 0.25 3.09 ± 1.13 0.60 0.44 <0.01 
PE 16:0_18:2 5.41 ± 0.33 4.09 ± 0.56 8.24 ± 2.00 6.04 ± 0.60 0.47 0.01 <0.01 
PE 18:0_22:5 2.51 ± 0.97 5.61 ± 1.28 7.59 ± 1.60 7.94 ± 1.24 0.07 0.03 <0.01 
PE 18:1_18:2 13.34 ± 1.03 11.88 ± 1.28 19.10 ± 2.67 18.51 ± 4.41 0.77 0.50 <0.01 
PE 38:6 17.61 ± 1.36 23.41 ± 2.59 10.73 ± 2.53 11.92 ± 5.03 0.21 0.07 <0.01 
PE 40:8 3.31 ± 0.37 5.16 ± 0.97 3.91 ± 0.59 6.09 ± 1.08 0.71 <0.01 0.10 
Alkenyl-PE 
16:0_22:4 9.16 ± 0.13 9.52 ± 1.48 25.37 ± 1.22 21.36 ± 1.20 0.01 0.01 <0.01 
Alkenyl-PE 
18:0_22:6 22.96 ± 3.88 27.38 ± 1.97 16.15 ± 1.15 13.79 ± 1.71 0.01 0.39 <0.01 
Alkenyl-PE 
18:1_22:6 15.71 ± 1.75 14.82 ± 0.95 9.49 ± 1.96 9.19 ± 2.01 0.75 0.52 <0.01 
PS 16:0_22:6 4.29 ± 0.76 2.28 ± 0.46 1.18 ± 0.69 0.48 ± 0.47 0.06 <0.01 <0.01 
PS 18:1_22:6 9.21 ± 2.66 10.30 ± 1.14 4.27 ± 1.65 3.62 ± 1.27 0.34 0.80 <0.01 
Abundance represented as analyte abundance divided by ISTD. Mean ± SD. n=4. P values determined by Tukey’s 
HSD following two-way ANOVA.  
  
Appendix Table 7.1: Normalized abundancies of hippocampal lipid species in all groups 













PC 16:0_16:1 5.95 ± 1.84 6.55 ± 1.42 10.40 ± 2.31 8.54 ± 0.77 0.06 0.18 >0.01 
PC 18:0_20:4 15.51 ± 2.89 18.67 ± 0.74 25.33 ± 8.51 22.14 ± 4.14 0.23 1.00 0.02 
PC 18:1_20:4 7.37 ± 1.12 8.18 ± 0.85 14.46 ± 4.21 10.21 ± 1.96 0.62 0.85 0.03 
PC 38:5 0.05 ± 0.06 0.11 ± 0.12 1.03 ± 0.70 1.22 ± 0.50 0.64 0.44 >0.01 
PE 16:0_22:5 1.89 ± 0.60 1.73 ± 0.20 5.53 ± 2.94 3.70 ± 1.65 0.42 0.73 >0.01 
PE 18:0_22:5 10.40 ± 1.28 8.62 ± 1.61 18.35 ± 4.57 19.07 ± 3.18 0.35 0.27 0.01 
Alkenyl-PE 
16:0_22:5 8.18 ± 3.56 7.47 ± 1.51 15.62 ± 4.49 15.34 ± 2.73 0.28 0.94 >0.01 
Alkenyl-PE 
18:0_22:5 2.71 ± 0.73 3.07 ± 1.08 7.14 ± 2.05 6.47 ± 2.16 0.86 0.78 >0.01 
PS 18:0_22:5 15.49 ± 0.89 13.78 ± 3.21 
27.78 ± 
10.63 28.04 ± 9.81 0.80 0.85 >0.01 
PG 18:1_16:0 2.31 ± 0.15 3.82 ± 0.59 5.63 ± 1.59 4.40 ± 1.02 0.01 - - 
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Appendix Table 7.3: Concentrations of hippocampal phosphatidylcholine species in all groups 
 DHA male DHA female Control Male 
Control 
Female 







PC 18:1_20:4  10.19 ± 2.29 10.13 ± 3.01 18.64 ± 6.96 13.69 ± 2.24 0.26 0.25 0.01 
PC 18:0_20:4  21.02 ± 1.11 23.07 ± 5.39 31.53 ± 9.78 29.76 ± 5.11 0.59 0.97 0.03 
PC 16:0_16:1  8.06 ± 2.05 8.25 ± 3.37 13.70 ± 5.36 11.75 ± 3.11 0.57 0.64 0.03 
PC 38:5  0.07 ± 0.08 0.12 ± 0.15 1.16 ± 0.69 1.57 ± 0.37 0.38 0.27 >0.01 
Concentration reported in ng/mg. Mean ± SD. n=4. P values determined by Tukey’s HSD following two-way 
ANOVA.  
 
Appendix Table 7.4: Concentrations of erythrocyte phosphatidylcholine species in all groups 
 DHA male DHA female Control Male 
Control 
Female 






PC 16:0_20:4 5.54 ± 0.81 5.12 ± 2.07 10.08 ± 5.87 7.41 ± 1.45 0.36 0.11 0.44 
PC 18:0_20:4 0.22 ± 0.11 0.41 ± 0.18 0.51 ± 0.23 0.68 ± 0.10 0.53 0.40 0.08 
PC 18:0_22:6 1.63 ± 0.24 2.52 ± 0.46 1.68 ± 1.09 1.93 ± 0.28 0.95 0.07 0.01 
PC 18:1_20:4 1.15 ± 0.24 0.57 ± 0.21 2.18 ± 1.31 0.95 ± 0.21 0.40 0.03 0.08 
PC 20:4_20:4 0.07 ± 0.03 0.13 ± 0.11 0.73 ± 0.35 0.47 ± 0.18 0.17 0.38 <0.01 





Appendix Table 7.5: Fatty acid composition (weight %) of hippocampi 
 DHA Female DHA Male 
Control 
Female Control Male 
P Sex x time 
Interaction 
P Sex Effect 
P Diet Effect 
14:0 0.30 ± 0.01 0.37 ± 0.05 0.29 ± 0.01 0.31 ± 0.03 0.13 <0.01 0.04 
16:0 21.19 ± 1.26 22.15 ± 0.49 20.95 ± 1.42 20.66 ± 1.16 0.29 0.57 0.16 
18:0 20.66 ± 0.23 20.89 ± 0.30 20.99 ± 0.15 20.43 ± 0.42 0.02 - - 
20:0 0.38 ± 0.10 0.41 ± 0.08 0.40 ± 0.05 0.46 ± 0.12 0.75 0.33 0.48 
22:0 0.46 ± 0.15 0.48 ± 0.08 0.48 ± 0.11 0.60 ± 0.19 0.49 0.31 0.32 
24:0 0.69 ± 0.32 0.66 ± 0.02 0.78 ± 0.29 0.94 ± 0.34 0.49 0.63 0.21 
SFAs 48.13 ± 0.61 49.11 ± 0.79 48.11 ± 0.68 47.79 ± 1.15 0.14 0.45 0.13 
16:1 0.38 ± 0.03 0.43 ± 0.02 0.36 ± 0.04 0.36 ± 0.05 0.35 0.18 0.04 
18:1n-7 2.71 ± 0.10 2.56 ± 0.12 2.72 ± 0.11 2.95 ± 0.20 0.02 - - 
18:1n-9 13.56 ± 1.12 12.45 ± 0.86 13.28 ± 1.86 14.35 ± 1.63 0.15 0.98 0.28 
20:1n-9 0.46 ± 0.12 0.40 ± 0.08 0.44 ± 0.15 0.54 ± 0.17 0.25 0.77 0.37 
22:1n-9 0.34 ± 0.09 0.43 ± 0.15 0.28 ± 0.14 0.20 ± 0.09 0.20 0.94 0.03 
24:1n-9 0.47 ± 0.21 0.32 ± 0.13 0.45 ± 0.29 0.63 ± 0.33 0.21 0.95 0.28 
MUFAs 18.84 ± 1.79 17.33 ± 1.39 18.46 ± 2.63 20.14 ± 2.64 0.17 0.94 0.29 
18:2n-6 0.68 ± 0.05 0.78 ± 0.06 0.53 ± 0.04 0.58 ± 0.01 0.27 <0.01 <0.01 
18:3n-6 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 <0.01 0.16 0.68 0.08 
20:2n-6 0.09 ± 0.01 0.11 ± 0.01 0.07 ± 0.02 0.09 ± 0.01 0.69 <0.01 0.03 
20:3n-6 0.49 ± 0.01 0.51 ± 0.04 0.34 ± 0.05 0.35 ± 0.04 0.67 0.44 <0.01 
20:4n-6 11.17 ± 0.81 11.41 ± 0.53 12.31 ± 1.16 11.50 ± 0.59 0.22 0.50 0.16 
22:2n-6 0.03 ± 0.02 0.03 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.67 0.60 0.95 
22:4n-6 2.52 ± 0.03 2.64 ± 0.08 3.06 ± 0.11 2.85 ± 0.14 <0.01 - - 
22:5n-6 0.34 ± 0.04 0.38 ± 0.03 0.95 ± 0.17 0.91 ± 0.13 0.50 0.92 <0.01 
N-6 15.31 ± 0.88 15.88 ± 0.60 17.30 ± 1.34 16.31 ± 0.61 0.11 0.65 0.02 
18:3n-3 0.02 ± 0.01 0.03 ± 0.02 0.01 ± 0.01 0.02 ± 0.01 0.44 0.08 0.03 
20:3n-3 0.01 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 0.02 ± 0.01 0.79 0.11 0.42 
20:5n-3 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.50 0.29 <0.01 
22:5n-3 0.18 ± 0.01 0.19 ± 0.01 0.16 ± 0.02 0.18 ± 0.02 0.49 0.14 0.01 
22:6n-3 14.37 ± 0.68 14.77 ± 1.02 12.93 ± 1.02 12.32 ± 1.08 0.32 0.84 <0.01 
N-3 14.62 ± 0.68 15.05 ± 1.02 13.14 ± 1.00 12.55 ± 1.06 0.31 0.87 <0.01 
20:3n-9 0.10 ± 0.02 0.08 ± 0.01 0.09 ± 0.02 0.10 ± 0.03 0.19 0.68 0.70 
PUFAs 30.03 ± 1.54 31.00 ± 0.98 30.53 ± 2.32 28.96 ± 1.64 0.16 0.73 0.38 
N-6/N-3 1.05 ± 0.02 1.06 ± 0.09 1.32 ± 0.02 1.30 ± 0.06 0.66 0.99 <0.01 
Total 
(mg/g) 38.2 ± 5.1 38.6 ± 3.2 40.4 ± 7.6 41.4 ± 3.4 0.90 0.80 0.35 
Mean ± SD, n=4. P values determined by Tukey’s HSD following two-way ANOVA. SFA, saturated fatty acids; 




Appendix Table 7.6: Fatty acid composition (weight %) of erythrocytes 
 DHA Female DHA Male 
Control 
Female Control Male 






14:0 0.45 ± 0.02 0.48 ± 0.03 0.42 ± 0.02 0.46 ± 0.01 0.41 0.01 0.04 
16:0 24.88 ± 0.30 27.98 ± 1.22 24.37 ± 0.42 26.84 ± 0.58 0.40 <0.01 0.04 
18:0 14.17 ± 0.62 11.11 ± 0.59 15.03 ± 0.55 11.89 ± 0.73 0.91 <0.01 0.02 
20:0 0.17 ± 0.02 0.22 ± 0.10 0.15 ± 0.01 0.16 ± 0.03 0.58 0.33 0.17 
22:0 0.46 ± 0.03 0.48 ± 0.15 0.40 ± 0.03 0.42 ± 0.03 0.93 0.63 0.16 
24:0 1.14 ± 0.08 1.10 ± 0.22 1.18 ± 0.04 1.14 ± 0.06 0.98 0.51 0.58 
SFAs 45.89 ± 1.02 44.79 ± 1.25 45.75 ± 1.35 45.27 ± 0.38 0.57 0.17 0.76 
16:1 0.30 ± 0.05 0.35 ± 0.04 0.31 ± 0.04 0.40 ± 0.04 0.30 <0.01 0.17 
18:1n-7 2.11 ± 0.06 2.39 ± 0.08 2.19 ± 0.02 2.61 ± 0.11 0.09 <0.01 <0.01 
18:1n-9 7.91 ± 0.14 8.25 ± 0.18 8.05 ± 0.15 8.58 ± 0.17 0.27 <0.01 0.01 
20:1n-9 0.12 ± 0.01 0.14 ± 0.01 0.12 ± 0.01 0.14 ± 0.01 0.98 0.01 0.48 
22:1n-9 0.60 ± 0.40 0.78 ± 0.62 0.28 ± 0.31 0.49 ± 0.61 0.95 0.46 0.25 
24:1n-9 0.77 ± 0.51 0.94 ± 0.10 1.02 ± 0.06 1.16 ± 0.11 0.93 0.28 0.10 
MUFAs 13.50 ± 0.84 14.60 ± 0.28 13.68 ± 0.36 15.19 ± 0.57 0.46 <0.01 0.19 
18:2n-6 7.47 ± 0.21 8.92 ± 0.18 6.91 ± 0.38 8.00 ± 0.29 0.22 <0.01 <0.01 
18:3n-6 0.06 ± 0.01 0.04 ± 0.01 0.08 ± 0.01 0.05 ± 0.01 0.59 <0.01 0.01 
20:2n-6 0.25 ± 0.02 0.29 ± 0.01 0.24 ± 0.01 0.30 ± 0.02 0.35 <0.01 0.87 
20:3n-6 0.49 ± 0.01 0.58 ± 0.01 0.40 ± 0.01 0.47 ± 0.03 0.20 <0.01 <0.01 
20:4n-6 21.89 ± 0.71 20.00 ± 0.23 24.92 ± 0.24 23.37 ± 0.50 0.49 <0.01 <0.01 
22:2n-6 0.05 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.02 0.49 0.58 0.62 
22:4n-6 0.77 ± 0.02 0.72 ± 0.05 1.47 ± 0.13 1.47 ± 0.10 0.64 0.62 <0.01 
22:5n-6 0.24 ± 0.02 0.21 ± 0.02 0.60 ± 0.05 0.55 ± 0.03 0.65 0.04 <0.01 
N-6 31.21 ± 0.67 30.81 ± 0.25 34.66 ± 0.16 34.25 ± 0.62 1.00 0.12 <0.01 
18:3n-3 0.32 ± 0.48 0.08 ± 0.01 0.08 ± 0.01 0.09 ± 0.02 0.33 0.36 0.36 
20:3n-3 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.02 0.73 0.72 0.78 
20:5n-3 0.71 ± 0.04 0.65 ± 0.04 0.32 ± 0.02 0.30 ± 0.02 0.16 0.03 <0.01 
22:5n-3 1.64 ± 0.03 1.74 ± 0.04 1.80 ± 0.07 1.84 ± 0.06 0.28 0.03 <0.01 
22:6n-3 6.04 ± 0.21 5.53 ± 0.17 3.01 ± 0.12 2.77 ± 0.12 0.12 <0.01 <0.01 
N-3 8.74 ± 0.55 8.03 ± 0.14 5.24 ± 0.15 5.03 ± 0.19 0.13 0.01 <0.01 
20:3n-9 0.05 ± 0.01 0.05 ± 0.01 0.06 ± 0.01 0.07 ± 0.01 0.25 0.12 <0.01 
PUFAs 40.00 ± 0.91 38.89 ± 0.36 39.96 ± 0.19 39.35 ± 0.57 0.39 0.01 0.48 
N-6/N-3 3.58 ± 0.22 3.84 ± 0.05 6.62 ± 0.20 6.82 ± 0.32 0.81 0.06 <0.01 
Total 
(mg/g) 4.24 ± 0.44 4.26 ± 0.30 4.74 ± 2.11 5.01 ± 0.45 0.82 0.79 0.28 
Mean ± SD, n=4. P values determined by Tukey’s HSD following two-way ANOVA. SFA, saturated fatty acids; 




Appendix Table 7.7: Correlations between hippocampal and erythrocyte fatty acid concentrations (mg/g) 
Group Total DHA Female DHA Male Control Female Control Male 
n 16 4 4 4 4 
Fatty Acid Pearson’s r Pearson’s r Pearson’s r Pearson’s r Pearson’s r 
20:4n-6  0.679
**   -0.089   -0.772   0.841   0.531 
22:4n-6   0.832
**   -0.446   -0.743   0.979*   0.875 
22:5n-6  0.874
**   0.630   -0.720   0.475   -0.822 
22:6n-3  0.484   -0.384   -0.844   0.897   -0.513 
Correlations of fatty acid concentrations (mg/g) between hippocampi and erythrocytes. Total group includes all rats analyzed by GC-
FID. Pearson’s r: Pearson’s correlation coefficient.*p<0.05; **p<0.01 
 
Appendix Table 7.8: Correlations between hippocampal and erythrocyte fatty acid compositions (wt %) 
Group Total DHA Female DHA Male Control Female Control Male 
n 16 4 4 4 4 
Fatty Acid Pearson’s r Pearson’s r Pearson’s r Pearson’s r Pearson’s r 
20:4n-6  0.306 -0.940   0.414   -0.124   -0.374 
22:4n-6   0.849** -0.479   -0.541   0.276   0.967
* 
22:5n-6  0.932** -0.434   -0.075   0.268   -0.249 
22:6n-3  0.714** -0.950   -0.467   -0.166   0.465 
Correlations of fatty acid compositions (wt %)between hippocampi and erythrocytes. Total group includes all rats analyzed by GC-




8 General Discussion 
 The main objectives of this thesis were to assess the effects of DHA supplementation in 
the context of Western diets on maternal tissue stores and the spatial memory of female and male 
pups at adolescence. These objectives were approached through a series of three experiments: the 
first to identify the effect of DHA supplementation on pups and mothers in mothers fed high fat 
TWDs compared to controls; the second to examine when sexual dimorphisms in LCPUFA 
begin in selected tissues of pups fed chow diets; and the third to determine the effect of DHA 
supplementation in AFWDs on spatial memory in adolescent rats. Altogether, these studies 
aimed to address the gap between recommendations and actual intakes of DHA during 
pregnancy, and better understand the effects of dietary supplementation on spatial memory in 
males and females during adolescence. 
 The hypotheses and limitations of individual studies are discussed within their individual 
chapters, however there are general hypotheses and limitations to this thesis. Currently, 
recommendations for omega-3 PUFA intakes, and more specifically DHA intakes during 
pregnancy, are broad and are not tailored to individual dietary habits. For example, Health 
Canada and the IOM recommend 150g of fish per week to women of childbearing age [26], and 
the ISSFAL recommends at least 200mg of DHA/d for pregnant women [25]. However, the 
combined findings of studies 1 and 3 suggest recommendations for dietary n-3 PUFA could be 
more effective if they were provided relative to total fat or caloric intakes, such as the general 
recommendations provided by the Brazilian Dietary Guide [155]. Current ISSFAL 
recommendations to pregnant women suggest that increased DHA consumption is unlikely to 
affect maternal plasma and tissue contents of ARA [25]. However, because fetal ARA accretion 
predominantly occurs postnatally[156], potential changes to maternal ARA status during 
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lactation could affect infant ARA status. Further research on the effect of increased dietary DHA 
consumption on perinatal ARA status should be considered. 
DHA accounted for between 0.3 and 0.5% of total caloric intakes in the supplemented 
diets used in studies 1 and 3. However, 34.5% of total caloric intakes in study 1 were from fat, 
while in study 3 only 17.2% of total caloric intakes were from fat. In these studies, DHA 
appeared to be beneficial to the mothers in study 1, as those on the supplemented diets 
maintained or improved tissue DHA status during pregnancy and postpartum. However, it may 
have been harmful to adolescent pups in study 3, as those from the DHA group had longer 
latency times during the final day of the learning phase during the MWM as compared with 
controls. Providing consumers with the tools necessary to contextualize DHA recommendations 
to their daily fat intakes could improve their DHA status and optimize their health benefits from 
DHA consumption. 
 Although spatial memory outcomes were only measured in study 3, diet significantly 
affected the fatty acid composition of arachidonic acid in both studies 1 and 3. In the pregnancy 
study, mothers fed TWD+ and TWD- had significantly lower ARA in maternal livers and whole 
body fetuses than mothers fed chow. Additionally, ARA was significantly lower in plasma at 
postpartum compared to baseline in all diets, but ARA in maternal liver and adipose was lower 
during the postpartum period in both the TWD groups. These findings of low tissue ARA levels 
despite high LA intakes are in accordance with previous research [157], and suggest that the 
consumption of the high amounts of SFAs and MUFAs in high fat diets could be displacing 




 The TWDs and AFWDs used in the pregnancy and spatial memory studies are worth 
discussing. The fatty acid composition of the diets used in these studies are based on fatty acid 
intakes reported in the 2005 NHANES study [100]. These data, however, are based on USDA 
standard references that have been shown in the past to under-report ARA content, and over-
report n-3 PUFA content in red meat and poultry [158]. Since ARA is predominantly consumed 
in meat, confirming the ARA and n-3 PUFA content in red meat and poultry for recent USDA 
standard references may be important. Regardless, low levels of ARA consumption are also 
reported in studies using a mix of the French food consumption table and USDA standard 
references [159], in pregnant African-Americans[160], and in developing countries [161]. The 
results of the spatial memory study suggest this prevalent low consumption of ARA is 
detrimental when combined with long term DHA supplementation. A 1:1 ratio of ARA:DHA 
appears to be optimal when supplementing the LCPUFA perinatally [144], and further research 
into using this ratio of fatty acids should be conducted. 
  Limitations in this thesis include the differences between puberty in humans and in rats. 
In rats, females begin puberty earlier than males [24,114,115]. This complicates translating 
findings of adolescence in rats studied at a single time point to stages of adolescence in humans 
between both sexes, as female rats may be more developed than males during a single time point, 
whereas humans would be similar. Additionally, the estrous cycle has been reported to affect 
fatty acid status [162] and Morris water maze performance in rats [163]. Measuring estradiol 
levels in females and males could assist in contextualizing the findings between animal and 
human studies, and between stages of the estrous cycle in animal studies.  
The interpretation of this thesis is also limited by differences in lipoproteins and fatty 
acid metabolism between rodents and humans. Although lipoprotein profiles of rats and humans 
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are similar, rats can have higher amounts of circulating TAG and VLDL compared to healthy 
humans [164]. Additionally, the elongation enzyme ELOVL2 which can elongate both 18 and 
20-carbon PUFA to 22-carbon PUFA in rodents, appears to only operate on 20-carbon PUFA in 
humans [165]. The potential interaction of these lipoprotein profiles and enzymes with sex, diet, 
or pregnancy, and the differences they may have between rodents and humans should be taken 
into consideration when interpreting these findings. 
The aim of this thesis was to determine the effects of DHA supplementation in the 
context of western diets on maternal tissue status and spatial memory in female and male pups 
during adolescence. Examination of maternal tissues during pregnancy and the postpartum 
period revealed that maternal adaptations to meet lipid and fatty acid requirements change in the 
transition from pregnancy to lactation with the pup requirement for DHA during lactation being 
particularly detrimental to maternal tissue levels when dietary DHA levels are low. These 
findings can be used to guide examinations of the kinetics of a potential DHA mobilization from 
maternal tissues, or as a guide to examine previously understudied candidates for maternal stores 
of DHA that could be mobilized to meet fetal demand. Furthermore, the examination of DHA 
supplementation from the confirmation of pregnancy to adolescence on spatial memory in males 
and females revealed that DHA supplementation in diets adequate for LA and ALA displaces 
ARA and 22:5n-6 containing lipid species in the hippocampus, and increases latency times in the 
Morris Water Maze. These findings corroborate recent suggestions that a 1:1 ratio of ARA:DHA 
supplementation is optimal for cognitive benefits [144], and could be used to guide future 
recommendations for dietary LCPUFA recommendations. Altogether, these findings show that 
further research is needed in determining appropriate LCPUFA recommendations for the early 
stages of life. Considering the impact of dietary DHA supplementation in the context of Western 
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diets in future study designs could provide valuable insight into its effects on maternal and 
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